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Abstract 
 
The work presented in this Ph.D. thesis is focussed on the synthesis of novel metal complexes 
of α-N-heterocyclic thiosemicarbazones and the effect of metal complexation on the 
antiproliferative activity of this class of organic compounds. α-N-heterocyclic 
thiosemicarbazones are tridentate ligands with a NNS donor set and since several decades are 
known to possess antineoplastic properties. Currently the most promising drug candidate of 
this class of compounds is Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-
AP), which entered several phase I and II clinical trials as an antitumor chemotherapeutic 
agent. α-N-heterocyclic thiosemicarbazones are potent inhibitors of the enzyme ribonucleotide 
reductase, which is a suitable and well established target in cancer chemotherapy, because of 
faster proliferation of tumor cells as compared to healthy cells and therefore higher expression 
of ribonucleotide reductase.  
The influence of gallium(III) and iron(III) on the antiproliferative activity of the metal-free 
ligands was studied in this work by comparison of the cytotoxic activity of five different 
terminally dimethylated thiosemicarbazones and their metal complexes in two human cancer 
cell lines. The strategy behind the combination of gallium(III) and thiosemicarbazones is that 
both are directed to the same molecular target, each in its own way, namely the ribonucleotide 
reductase and therefore potentially provide a synergistic way of action. For selected 
compounds the inhibition potency towards purified ribonucleotide reductase was investigated. 
Subsequently the influence of changing the chalcogen donor atom from sulfur to oxygen or 
selenium in 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazone and their gallium(III) 
and ruthenium(III) complexes on cytotoxic activity was studied.  
Cyclic voltammetry experiments of iron(III) and gallium(III) complexes showed that in 
addition to the metal-centred iron(III)/(II) redox couple several ligand-centred reductions take 
place. These reductions were studied in detail in organic solvents to locate the ligand-centred 
reduction site and the results are supported by quantum chemical studies. 
In addition a novel straightforward synthetic procedure of Triapine was developed, permitting 
for the first time the isolation of metal complexes of this investigational anticancer drug. 
Furthermore it was discovered that Triapine possesses intrinsic fluorescence when light-
irradiated at around λex = 360 nm. This enabled for the first time to monitor the uptake and 
intra-cellular distribution of an α-N-heterocyclic thiosemicarbazone in living human cancer 
cells by fluorescence microscopy.  
  
  
Zusammenfassung 
 
Die vorliegende Dissertation beschäftigt sich mit der Synthese neuartiger Metallkomplexe mit 
α-N-heterozyklischen Thiosemicarbazonen als Liganden und dem Effekt der Komplexierung 
auf die antiproliferative Aktivität dieser Klasse von organischen Verbindungen. α-N-
heterozyklische Thiosemicarbazone sind dreizähnige Liganden mit den Donoratomen NNS 
und seit mehreren Jahrzehnten ist bekannt, dass diese Verbindungen antineoplastische 
Aktivität aufweisen. Derzeit ist die vielversprechendste Verbindung dieser Klasse Triapine (3-
Aminopyridin-2-carboxaldehyd Thiosemicarbazon, 3-AP), welches in mehreren Phase I und II 
klinischen Studien als Krebstherapeutikum untersucht wurde. α-N-heterozyklische 
Thiosemicarbazone sind als starke Inhibitoren des Enzyms Ribonukleotid Reduktase bekannt. 
Dieses Enzym ist ein geeignetes und viel erforschtes Target in der Krebstherapie, weil durch 
die schnellere Proliferation von Tumorzellen im Vergleich zu gesunden Zellen die 
Ribonukleotid Reduktase verstärkt exprimiert wird.  
In dieser Dissertation wurde der Einfluss von Gallium(III) und Eisen(III) auf die 
antiproliferative Aktivität der freien Liganden durch Vergleich der Zytotoxizitäten von fünf 
verschiedenen terminal dimethylierten Thiosemicarbazonen und deren Komplexen in 
humanen Krebszelllinien untersucht. Die zugrundeliegende Idee hinter der Kombination von 
Gallium(III) und Thiosemicarbazonen ist die Tatsache, dass beide auf unterschiedliche Weise 
die Ribonukleotid Reduktase inhibieren und demzufolge potenziell synergistisch wirken. Für 
ausgewählte Verbindungen wurde die Inhibierungsstärke bezüglich isolierter Ribonukleotid 
Reduktase bestimmt. Anschließend wurde der Einfluss des Austausches von Schwefel gegen 
Sauerstoff und Selen in 2-Acetylpyridin N,N-Dimethyl(chalcogen)semicarbazon und deren 
Gallium(III) und Ruthenium(III) Komplexen auf die Zytotoxizität untersucht.   
Untersuchungen von Eisen(III) und Gallium(III) Komplexen mittel zyklischer Voltammetrie 
zeigten neben der erwarteten metall-zentrierten Eisen(III)/(II) Redoxreaktion mehrere 
liganden-zentrierte Reduktionen. Diese wurden im Detail in organischen Lösungsmitteln 
untersucht und der Ort der Reduktion am Liganden bestimmt. Die Ergebnisse wurden von 
quantenchemischen Rechnungen untermauert. 
Des Weiteren wurde in dieser Arbeit eine neue vereinfachte Synthese für Triapine entwickelt, 
was erstmalig die Isolierung von Metallkomplexen von Triapine ermöglichte. Zusätzlich 
wurde entdeckt, dass Triapine intrinsische Fluoreszenz besitzt wenn es bei λex = 360 nm 
angeregt wird. Dies ermöglichte erstmals die Beobachtung der Aufnahme und der zellulären 
Verteilung eines α-N-heterozyklischen Thiosemicarbazons in lebenden humanen Krebszellen 
mittels Fluoreszenzmikroskopie.  
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1 Introduction 
 
1.1 Platinum based anti-cancer drugs – an overview 
 
Cisplatin [cis-diamminedichloridoplatinum(II)] (Fig. 1) was first reported in 1844 by Michele 
Peyrone.1 In 1969, more than one century later, the anticancer properties of cisplatin were 
accidentally discovered by Barnett Rosenberg2,3 during his investigations on the influence of 
an electric field on the growth of Escherichia coli bacteria.4  
 
 
 
Figure 1. Structure of cisplatin. 
 
Today cisplatin is one of the best selling anti-cancer drugs used in nearly 50% of all tumor 
chemotherapies and is one of few anticancer drugs with curative potential (cure rates of more 
than 90% in the case of testicular cancer).5 The clinical success of cisplatin stimulated the 
search for novel even more effective drugs. To date thirty-eight platinum complexes from a 
few thousand prepared, entered phase I clinical trials and only two of them have received 
worldwide clinical approval so far. These are carboplatin6 (cis-diammine-(1,1-
cyclobutanedicarboxylato)platinum(II)) and oxaliplatin7 ((trans-R,R-cyclohexan-1,2-
diamine)oxalatoplatinum(II)) (Fig. 2). Carboplatin shows a tumor inhibiting profile which is 
very similar to that of cisplatin, but is less toxic than cisplatin and can therefore be 
administered at higher doses. Oxaliplatin displays tumor inhibiting properties different from 
those of  cisplatin and carboplatin and is used in a combination therapy against metastatic 
colorectal cancer.8 
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Figure 2. Structures of carboplatin (left) and oxaliplatin (right) 
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In addition to these complexes, other three platinum-based drugs have gained regionally 
limited approval: nedaplatin (Japan), lobaplatin (China) and heptaplatin (South Korea) 
(Fig. 3).  
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Figure 3. Platinum complexes with regionally limited approval: nedaplatin (a), lobaplatin (b) 
and heptaplatin (c). 
 
Although cisplatin was approved for clinical use 30 years ago, the mode of action of cisplatin 
and analogous compounds is not fully understood. Nevertheless it is generally accepted that 
DNA is the critical target of cisplatin (and its analogues)9 and that the active species is the 
aquated form of cisplatin cis-[Pt(NH3)2Cl(OH2)]+.10 The electrophilic Pt(II) binds preferably to 
nitrogen atoms of the DNA bases, mainly the N7 of guanine. Initially, monofunctional DNA 
adducts are formed, but most of them react further to produce intrastrand cross-links of the 
type 1,2-d(GpG) and 1,2-d(ApG).11 These adducts formed lead to serious conformational 
changes in the DNA, eventually resulting in programmed cell death (apoptosis). However, it 
should be mentioned that only about 1% of the intravenously administered cisplatin binds to 
DNA. So the main amount of cisplatin reacts with proteins and low molecular weight 
biomolecules, especially with those containing sulphur.12  
The disadvantages of cisplatin and related compounds are: (a) they can only be used against a 
limited number of tumors, (b) they have severe side effects and (c) the development of drug 
resistance during treatment. 
4
  
In summary cisplatin and closely related platinum antitumor agents show excellent activity in 
some tumors, but there is an increasing demand for novel anti-cancer drugs (Figure 4) which 
show reduced side effects, higher selectivity towards tumor cells, and a broader spectrum of 
responsive tumors, implying the ability to circumvent the problems of resistance to platinum 
compounds. This stimulated investigations in the field of non-platinum metal complexes with 
antitumor properties. 
 
Figure 4. WHO prognosis (2004−2030) of the development of the main causes of death. The 
picture is taken from reference 13. 
 
1.2 Non-platinum based anticancer drugs 
 
Possible advantages of metal ions other than platinum(II) are (a) additional coordination sites, 
(b) changes in the oxidation state, (c) altered ligand affinity and substitution kinetics and 
accordingly a different mode of action.14 The antitumor properties of a number of metal ions 
and complexes are under research, but only a few non-platinum metal based drugs are 
currently in clinical studies, the most promising of which are those containing ruthenium and 
gallium.15  
 
1.2.1 Ruthenium 
 
The two leading ruthenium compounds are (H2ind)[trans-RuCl4(Hind)2] (KP1019, Hind = 
indazole)16, and (H2im)[trans-RuCl4(Him)(DMSO)] (NAMI-A, Him = imidazole, DMSO = S-
5
  
bonded dimethyl sulfoxide)17 which were the first ruthenium-based anticancer drugs in phase I 
clinical studies (Figure 5).  
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Figure 5. Ruthenium antitumor complexes: NAMI-A (left), KP1019 (right) 
 
NAMI-A showed only efficacy against metastases in preclinical models,18 whereas KP1019 
exhibits excellent activity especially in an autochthonous colorectal tumor model that 
resembles human colon tumors in its histological appearance and behavior against 
chemotherapeutics.19 A 70 to 90% average reduction of tumor growth or even complete 
remission was observed by using doses which do not lead to any signs of toxic side effects. 
Furthermore in this model KP1019 showed, higher tumor-inhibiting activity than the standard 
chemotherapeutic agent 5-fluoruracil. Remarkably cisplatin is completely inactive in this 
model which impressively shows the possible advantages of non-platinum based drugs in 
cancer chemotherapy. 
 
1.2.2 Gallium20  
 
Simple gallium salts, such as gallium(III) nitrate and gallium(III) chloride, have been studied 
for their applicability as antineoplastic drugs for more than 30 years, and the therapeutic 
potential of intravenous gallium nitrate has been extensively studied in clinical trials since 
1976.21 But the clinical experience has shown unfavourable pharmacokinetic and toxicological 
properties. Trials to improve the pharmacological effects by changing the mode of 
administration failed because of the low intestinal absorption.22 Hence there were not 
sufficient reasons for the further development of gallium salts as anticancer drugs. (It has to be 
6
  
mentioned that the “simple gallium salts” actually were administered as citrate containing 
solutions to prevent the precipitation of gallium as hydroxides. Citrate can coordinate to the 
gallium ion forming complexes of different stoichiometry, but it has been found that in the 
blood stream, gallium binds very fast to the stronger chelator transferrin23 and model 
calculations suggest that less than 1% exists as citrate complex under equilibrium conditions.24) 
To circumvent the limitations arising when using “simple gallium salts”, and to increase the 
intestinal absorption, gallium complexes with more lipophilic ligands, increased stability 
against hydrolysis and enhanced membrane penetration ability were prepared. Based on 
experience with a ferric maltol complex, which is known to provide iron in a soluble and 
readily absorbable form, an analogous gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-
4-onato)gallium(III) (Figure 6) has been developed.25 This was the first gallium complex 
which entered clinical trials.  
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Figure 6. Structure of gallium maltolate (left) and KP46 (right)  
 
A pharmacokinetic study in healthy humans has demonstrated high bioavailability and minor 
urinary excretion.26 The mean maximum plasma gallium concentration obtained with a single 
administration of gallium maltolate was about five times higher than that from gallium 
chloride. Gallium maltolate was well tolerated in a phase I clinical trial, and the maximally 
tolerated dose was not reached.27    
The second gallium complex that entered clinical phase I studies is tris(8-
quinolinolato)gallium(III) (KP46) developed by Keppler et al.28 (Figure 6). The complex 
shows improved bioavailability as compared to gallium chloride resulting in sufficient plasma 
concentrations in mice. The phase I clinical study included seven patients and the dose of 
KP46 was escalated from 30 mg/m2/day up to 480 mg/m2/day without dose-limiting 
toxicities.29   
7
  
1.2.2.1 (Bio)chemical aspects of gallium30  
 
The solution behavior and coordination chemistry of gallium(III) resemble that of iron(III). 
For example the electronegativity (Ga: 1.81; Fe: 1.83), the ionic radius for octahedral 
complexes (Ga: 0.620 Å; Fe: 0.645 Å) and tetrahedral complexes (Ga: 0.47 Å; Fe: 0.49 Å), as 
well as the electron affinity (Ga: 30.71 eV; Fe: 30.65 eV) are very similar. In contrast the 
electrochemical behavior of gallium(III) and iron(III) is totally different; iron(III) can be easily 
reduced and reoxidized under physiological conditions, whereas gallium(III) cannot change 
the oxidation state under similar conditions. 
Because of the high charge-to-radius ratio gallium(III) is a hard Lewis acid and reacts 
therefore very readily with hard Lewis bases such as OH−. In neutral aqueous solutions the 
hydrated Ga3+ ion hydrolyses nearly completely to highly insoluble, amorphous Ga(OH)3, 
which slowly converts to nearly insoluble GaO(OH), whereas at high pH values the soluble 
[Ga(OH)4]− is formed. At pH 7.4 and 25 °C the total aqueous solubility of gallium is only 
around 1 µM and the dissolved gallium consists of 98.4% [Ga(OH)4]− and 1.6% Ga(OH)3. In 
comparison iron(III) is totally insoluble (~ 10−18 M) under these conditions and forms 
polymers of the form [FeO(OH)]. Thus gallium is slightly soluble in a physiological 
environment whereas iron is not and needs some proteins or chelates as a vehicle for its 
transport. 
 
The biodistribution of gallium, especially the transport in blood and the cellular acquisition 
from blood, is markedly influenced by its similarities to iron. Studies showed that after 
administration of trace amounts of gallium nearly all is bound to the iron transport protein 
transferrin,23 although in the blood there are thousands of other dissolved components. 
Gallium binds to both iron-binding sites of human serum apotransferrin (apotransferrin is the 
metal-free transferrin) with effective stability constants of log K1 = 20.03 and log K2 = 19.3 at 
a serum bicarbonate concentration of 27 mM and pH 7.4, in comparison to log K1 = 22.8 and 
log K2 = 21.5 for iron(III).31 Thus gallium(III) has a lower affinity than iron(III) for binding to 
apotransferrin. However, iron normally occupies only around 30% of the apotransferrin 
binding sites, so there are enough unoccupied binding sites for gallium. The stability of the 
gallium/apotransferrin complex is pH dependent and it is lowered in acidic solution. Therefore 
gallium can be released in the tumor tissues, where the pH is more acidic than in normal 
tissues.32 
8
  
After uptake of gallium into the cell by transferrin, it is able to bind to iron(III) dependent 
enzymes such as ribonucleotide reductase, where it is incorporated instead of iron and inhibits 
the function of the enzyme due to the inability to change the oxidation state, this is also the 
reason why gallium is not able to bind to iron(II) containing proteins like haemoglobin or 
cytochromes.   
 
1.3 Ribonucleotide Reductase 
 
The enzyme ribonucleotide reductase is responsible for the reduction of ribonucleotides to 
deoxyribonucleotides, which is the rate-limiting step in DNA synthesis, and it is the only way 
for the cell to synthesize deoxyribonucleotides. Thus ribonucleotide reductase is highly 
activated in proliferating tumor cells and therefore an excellent target for tumor 
chemotherapy.33  
Ribonucleotide reductase consists of two non-identical dimeric subunits called R1 and R2. The 
R1 subunit harbours the substrate binding site, whereas R2 contains an iron center and a 
tyrosyl radical in both polypeptide chains. The radical in R2 is essential for the reduction of 
ribonucleotides, but it is located far away from the substrate binding site. The radical has to be 
transferred at least 35 Å, where it generates a thiyl radical of a cysteine residue which starts 
the substrate turnover cycle (Figure 7). In the first step the thiyl radical abstracts the 3´-
hydrogen atom from ribose and thereby generates a substrate radical. Subsequently the 2´-OH 
group is protonated and leaves as a water molecule forming a 2´-ketyl radical (state 3). Then 
one hydrogen atom from a cysteine moves to the substrate radical and generates a disulfide 
radical anion, which is transferred to the substrate 3´-position (state 5). In the last step this 
substrate radical abstracts the hydrogen atom from the cysteine residue which started the 
turnover cycle and thereby regenerates the thiyl radical, which is transferred back to the R2 
subunit to form the tyrosyl radical.34 To complete the cycle the generated disulfide bridge has 
to be reduced, and the electron for this reduction is provided from thioredoxin or glutaredoxin, 
which itself is kept in the reduced state by the NADPH dependent protein thioredoxin 
reductase. A possible explanation for the radical transfer back from the cysteine to the R2 
subunit is that the reduction of the disulfide bridge by thioredoxin or glutaredoxin would be 
disturbed.  
 
9
  
 
Figure 7. The postulated reaction mechanism for the reduction of a ribonucleotide (the 
involved amino acid residues are given with the E. coli numbering). The picture is taken from 
reference 34. 
 
Inhibitors of ribonucleotide reductase can be divided into several classes depending on their 
mode of action:35  
 
• Radical scavengers which directly destroy the tyrosyl radical. The most prominent 
representative of this class of compounds is hydroxyurea, which was the first 
ribonucleotide reductase inhibitor in clinical use. 
• Chelating molecules such as pyridoxal isonicotinoyl hydrazone (PIH) or 
desferrioxamine (DFO) that remove iron or prevent the incorporation of iron into the 
metal binding site and thereby inhibit the formation of a stable tyrosyl radical.  
• Nucleoside analogues such as gemcitabine and cytarabine are modified at the 2´-
position of the sugar and are primarily intracellularly converted into the analogous 
nucleotides. In that form, they block the substrate binding site of ribonucleotide 
reductase and/or are incorporated into DNA, which causes a stop of DNA synthesis. 
These substances have received worldwide approval against various tumors, such as 
acute myeloid leukemia, non-small cell lung cancer and pancreatic cancer.  
10
  
• Gallium salts and complexes which inhibit the activity of the R2 subunit by competing 
with iron for its binding site and hence destabilising the tyrosyl radical due to the 
inability to change the oxidation state.36  
• α-N-Heterocyclic thiosemicarbazones, which are the strongest known inhibitors of 
ribonucleotide reductase (for more details see below).    
 
1.4 α-N-Heterocyclic Thiosemicarbazones 
 
The antineoplastic activity of thiosemicarbazones was discovered in 1956, with the 
observation that 2-formylpyridine thiosemicarbazone [Figure 8, (a)] showed antileukemic 
activity in mice.37 In that study it was also reported that the analogous compounds 3-
formylpyridine thiosemicarbazone (b) and 4-formylpyridine thiosemicarbazone (c) as well as 
thiosemicarbazones derived from 2-furandehyde, 2-thiophenaldehyde and 2-pyrrolaldehyde 
show no significant effect on the life span of the mice, (d). Further studies on 
thiosemicarbazones with different formyl heterocycles confirmed the assumption that all 
compounds with other donor set than N,N,S are inactive.38 Hence the minimum requirement 
for biological activity is a heterocyclic nitrogen in α-position to the thiosemicarbazide side 
chain.  
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Figure 8. Structure of thiosemicarbazones which are active/inactive against L1210 leukemia 
in mice 
 
Further structure-activity relationships of a series of 1-formylisoquinoline thiosemicarbazone 
derivatives [Figure 9, (A)] in mice bearing Sarcoma 180 ascites cells showed that replacement 
of the thiosemicarbazide side chain by semicarbazide (D), 2N-methyl thiosemicarbazide (E), 
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S-methylisothiosemicarbazide (F) or 1-(picolinoyl) thiosemicarbazide (G) results in the loss of 
activity (Figure 8).39 1-acetylisoquinoline thiosemicarbazone (B) and 1-formylisoquinoline 
guanylhydrazone (C) are the most active derivatives, but with reduced tumor-inhibiting 
potency as compared to 1-formylisoquinoline thiosemicarbazone.      
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Figure 9. Effect of modifications in the side chain of 1-formylisoquinoline thiosemicarbazone 
on the tumor-inhibiting potency in mice bearing Sarcoma 180 ascites cells 
 
These structure-activity studies led to the development of novel 2-formylpyridine and 1-
isoquinoline thiosemicarbazones. Extensive studies by French et al.40,41,42 showed that the 
most promising candidate is 5-hydroxy-2-formylpyridine thiosemicarbazone (Figure 10), 
which was further evaluated in clinical trials. However because of severe side effects and fast 
inactivation by glucoronidation it has been withdrawn.43,44 To overcome these problems 
Sartorelli et. al. synthesized about 20 years later a panel of 4-methyl, 3-amino, 5-amino and 5-
nitro substituted derivatives.45,46 Compared to 5-hydroxy-2-formylpyridine thiosemicarbazone 
the amino substituted compounds showed higher activity in mice bearing L1210 leukemia, and 
3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine, 3-AP) was selected for 
further evaluation in clinical trials (Figure 10).46  
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Figure 10. Structure of 5-HP (left) and Triapine (right) 
 
The results of phase I and II clinical trials of Triapine as well as active or recruiting trials are 
summarized in Tables 1–3.   
 
 
Table 1. Summary of the phase I clinical trials of Triapine. 
 
Drug(s) Patients/Cancer Results Ref. 
    
Triapine 7 patients  1 patient with stable disease for 18 weeks. 47 
Triapine 27 patients with advanced 
cancer 
8 patients experienced stabilization of their disease for 
2–4 months. No objective tumor responses were 
observed. 
48 
Triapine 24 patients with refractory 
leukemia 
No objective responses occurred. Over 70% of the 
patients had a >50% reduction in white blood cell 
counts. 
48 
Triapine + 
Cisplatin 
24 patients  No partial or complete responses were observed. 4 
patients achieved stable disease for 2-6 treatment 
cycles. 
49 
Triapine 32 patients with advanced 
cancer 
No partial or complete responses were observed. 48 
Triapine + 
Gemcitabine 
26 patients with 
progressive metastatic or 
locally advanced cancer 
1 patient with complete response and 2 patients with 
partial responses. An additional patient had prolonged 
stabilization of a large liver metastasis. 
48 
Triapine 21 patients with advanced 
or metastatic cancer 
No partial or complete responses were observed. 2 
patients remained progression-free for 6 and >10 
months, respectively. 4 other patients achieved stable 
disease for 3-4 months. 
48 
Triapine + 
Cytarabine 
31 patients with refractory 
acute leukemia and high-
risk myelodysplastic 
syndromes  
4 patients achieved a complete response after the first 
cycle. No partial response. 
48 
Triapine + 
Irinotecan 
10 patients with refractory 
tumors 
1 patient achieved partial response. 50 
Triapine + 
Doxorubicin 
14 patients  No objective tumor responses were observed. 2 
patients with stable disease. 
51 
Triapine 25 patients with 
advanced hematologic 
malignancies 
No partial or complete responses were observed. 76% 
of patients had a >50% reduction in white blood cell 
counts. 
52 
Triapine + 
Fludarabine 
33 patients with refractory 
acute leukemias and 
aggressive 
myeloproliferative 
disorders 
2 patients achieved complete responses. 3 patients 
achieved partial responses. 
53 
Triapine + high 
dose Cytarabine 
25 patients with relapsed 
or refractory myeloid 
leukemia 
2 patients with complete responses. 1 patient with 
partial response. 
54 
Triapine + 
Cisplatin + 
Paclitaxel 
Patients with advanced or 
metastatic cancer 
Not reported 55 
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Table 2. Summary of the phase II clinical trials of Triapine. 
 
Drug(s) Patients/Cancer Results Ref. 
    
Triapine 9 patients with metastatic 
breast cancer 
3 patients achieved stable disease. 56 
Triapine + 
Gemcitabine 
60 patients with 
unresectable or metastatic 
pancreatic cancer 
8 patients (15%) achieved partial responses, and 32 
patients (60%) had stable disease. Median survival 
time was 8 months. 13% were alive after 1 year. Thus 
Triapine + Gemcitabine shows activity in pancreatic 
cancer. 
57 
Triapine + 
Gemcitabine 
18 patients as 2nd line 
treatment of  non-small 
cell lung cancer   
No objective responses were observed. 5 patients had 
stable disease (till 135 days). 
58 
Triapine 19 patients with 
recurrent or metastatic 
renal cell carcinoma 
1 patient achieved partial response over 4 months. 
Seven patients had stable disease (3.4–8.2 months). 
The study was stopped after the first stage. 
59 
Triapine + 
Gemcitabine 
26 patients with 
advanced pancreatic 
carcinoma 
No objective responses were observed. 11 patients had 
stable disease. 5 of them had stable disease for more 
than 6 months. The study was stopped after the first 
stage. 
60 
Triapine + 
Gemcitabine 
12 patients with metastatic 
non-small cell lung cancer  
No objective response was seen. 4 patients achieved 
stable disease. The study was stopped after the first 
stage. 
61 
Triapine 14 patients with advanced 
pancreatic cancer 
There were no responses. 2 patients achieved stable 
disease. 
62 
Triapine + 
Cisplatin 
Patients With Recurrent or 
Persistent Platinum-
Resistant Ovarian 
Epithelial or Primary 
Peritoneal Cancer 
Not reported 55 
 
Table 3. Active or recruiting clinical phase I or II trials of Triapine55 
 
Phase Drug(s) Cancer 
   
Phase I Triapine + (Cisplatin) + 
Radiation Therapy 
External-beam radiation therapy with or without 
cisplatin in treating patients with gynecological cancer 
Phase I Triapine + Radiation Therapy Radiation therapy in patients with stage III pancreatic 
cancer that cannot be removed by surgery 
Phase II Triapine + Cisplatin Patients with recurrent or metastatic adenocarcinoma 
of the esophagus or gastroesophageal junction 
Phase II Triapine + Gemcitabine Patients with unresectable or metastatic biliary duct or 
gallbladder cancer 
Phase II Triapine + Fludarabine Patients with myeloproliferative disorders, chronic 
myelomonocytic leukemia, or accelerated phase or 
blastic phase chronic myelogenous leukemia 
 
In conclusion, in six of seven phase II clinical trials containing Triapine only one patient with 
a renal cell carcinoma achieved partial response over 4 months.59 The only clinical trial where 
Triapine in combination with Gemcitabine showed activity was a study in unresectable or 
metastatic pancreatic cancer.57 From 60 patients which were treated 15% achieved partial 
response and 60% had stable disease. The median survival time was 8 months and after one 
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year 13% of the patients were still alive. In comparison, the standard therapy for pancreatic 
cancer is gemcitabine alone, approved in 1997 by the FDA (Food and Drug Administration) 
after a clinical trial63 with a median survival time of 5.7 months and 18% survival rate after 
one year. 
 
1.4.1 Iron Complexes of α-N-Heterocyclic Thiosemicarbazones and the 
Biochemical Mechanism of Action 
 
As already mentioned in chapter 1.3, the principal target of α-N-heterocyclic 
thiosemicarbazones is the enzyme ribonucleotide reductase. In addition, the observation that 
the N,N,S donor set is essential for antitumor activity38 of thiosemicarbazones led to the 
assumption that the activity originates from the capability of these compounds to form stable 
metal complexes. Thus the mechanism of the ribonucleotide reductase inhibition was 
primarily explained by simple chelation of the iron necessary for the activity of the R2 
subunit. But this mechanism was ruled out by studies with 1-formylisoquinoline 
thiosemicarbazone, which demonstrated that the inhibition of the purified enzyme was not 
reversed by addition of iron and that the 50% inhibitory concentration was only about 0.1% of 
the standard iron concentration.64 It was then assumed that the α-N-heterocyclic 
thiosemicarbazones directly bind to the iron in the R2 subunit of ribonucleotide reductase.64 
However, addition of a large excess of iron does not reverse the inhibitory capacity of 1-
formylisoquinoline thiosemicarbazone.65 Thus it was supposed that the active form of the 
inhibitor is the iron complex itself. This was confirmed by Thelander and Gräslund, who 
showed that the preformed iron(III) complex of 1-formylisoquinoline thiosemicarbazone in the 
presence of dithiothreitol is reduced to the iron(II) complex. The latter reacts with molecular 
oxygen, leading to the destruction of the tyrosyl radical (see below).66 That iron is essential for 
effective ribonucleotide reductase inhibition was also reported for Triapine. The inhibition was 
found to be increased for both the iron(II) and iron(III) complex by a factor of 25 and 35, 
respectively as compared to metal free Triapine.67 In addition metal-free Triapine had no 
significant effect on the EPR signal of the tyrosyl radical of the isolated ribonucleotide 
reductase R2 subunit, whereas the iron(II) complex very efficiently quenched the tyrosyl 
radical.68 Furthermore spin trapping experiments showed that the iron(II) complex in contrast 
to Triapine alone or its iron(III) complex is able to produce reactive oxygen species (ROS) by 
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activation of molecular oxygen via a Fenton-like reaction, which are then quenching the 
tyrosyl radical. 
 
Fe(II)–Triapine + O2 → Fe(III)–Triapine + O2− 
Fe(II)–Triapine + O2− + 2H+ → Fe(III)–Triapine + H2O2 
Fe(II)–Triapine + H2O2 → Fe(III)–Triapine + OH· + OH− 
 
That the reactive oxygen species are associated with the antiproliferative activity in cells was 
shown by addition of the antioxidant catalase, resulting in a decrease of the IC50 value of 
Triapine by a factor of 10. The ROS can also explain the formation of DNA strand breaks 
observed with 5-hydroxy-2-formylpyridine thiosemicarbazone,69 1-formylisoquinoline 
thiosemicarbazones70 and Triapine71. In vivo the ROS were linked with severe side effects 
such as methaemoglobinemia and hypoxia frequently observed in clinical phase I/II trials of 
Triapine.52,54,59   
 
The mechanism of action described above is only valid for 4N-unsubstituted α-N-heterocyclic 
thiosemicarbazones such as 5-hydroxy-2-formylpyridine thiosemicarbazones (5-HP) [Figure 
11, (A)]. A study of various 4N-disubstituted analogues of 5-HP [for example: Figure 11, (B, 
C)] showed that they have similar anticancer activity in mice, but a markedly decreased 
inhibitory activity on ribonucleotide reductase compared to 5-HP.72  
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Figure 11. 4N-disubstituted analogues of 5-HP (A)  
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Additionally the concentration required to inhibit 50% of the activity of alkaline phosphatase 
was 250 µM for 5-HP but 17 µM and 4 µM for the 4N-disubstituted compounds B and C, 
respectively. Therefore it was suggested that 4N-disubstituted α-N-heterocyclic 
thiosemicarbazones have additional modes of action. 
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2.1 Novel Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic 
Thiosemicarbazones: Synthesis, Characterization, Cytotoxcicity and 
Interaction with Ribonucleotide Reductase* 
 
Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec, M. A.; Schmidt, P. P.; 
Arion, V. B.; Keppler, B. K.  
J. Med. Chem. 2007, 50, 1254–1265. 
                                                 
*
 Parts of this publication were already presented as a manuscript in my diploma thesis 
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Gallium(III) and Iron(III) Complexes of r-N-Heterocyclic Thiosemicarbazones: Synthesis,
Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase
Christian R. Kowol,† Roland Berger,† Rene Eichinger,† Alexander Roller,† Michael A. Jakupec,† Peter P. Schmidt,#
Vladimir B. Arion,*,† and Bernhard K. Keppler*,†
Institute of Inorganic Chemistry, Faculty of Chemistry, UniVersity of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria, and
Max-Planck Institute for Bioinorganic Chemistry, Stiftstrasse 34-38, Mu¨lheim an der Ruhr, D-45470 Germany
ReceiVed October 28, 2006
A series of gallium(III) and iron(III) complexes with five different 4N-substituted R-N-heterocyclic thiosemi-
carbazones, viz., 2-acetylpyridine N,N-dimethylthiosemicarbazone (1), 2-acetylpyridine N-pyrrolidinylthio-
semicarbazone (2), acetylpyrazine N,N-dimethylthiosemicarbazone (3), acetylpyrazine N-pyrrolidinylthio-
semicarbazone (4), and acetylpyrazine N-piperidinylthiosemicarbazone (5), with the general formula [GaLCl2]
(HL ) 1 and 2) and [ML2][Y] (M ) Ga, HL ) 1-5, Y ) PF6; M ) Fe, HL ) 1-5, Y ) FeCl4 and PF6)
were synthesized and characterized by elemental analysis, a number of spectroscopic methods (NMR, IR,
UV-vis), mass spectrometry, and X-ray crystallography. The in Vitro antitumor potency was studied in
two human cancer cell lines (41M and SK-BR-3). The central metal ions exert pronounced effects in a
divergent manner: gallium(III) enhances, whereas iron(III) weakens the cytotoxicity of the ligands. The
capacity of ligand 1 and its Ga(III) and Fe(III) complexes to destroy the tyrosyl radical of the presumed
target ribonucleotide reductase is reported.
Introduction
R-N-Heterocyclic thiosemicarbazones have been explored for
their applicability as antitumor agents for half a century.1 Their
pharmacological potential has been recognized to include also
antiviral, antimycobacterial, antifungal, and antimalarial proper-
ties,2 and the enzyme ribonucleotide reductase has been identi-
fied as the principal target.3-6 In fact, they are the strongest
known inhibitors of this enzyme, both in cell-free assays and
in intact tumor cells, being several orders of magnitude more
effective than hydroxyurea, the first clinically applied ribo-
nucleotide reductase inhibitor.7,8 The enzyme that catalyzes the
conversion of ribonucleotides to deoxyribonucleotides is pro-
duced at the transition from the G1 to the S phase of the cell
cycle as a prerequisite for DNA replication and is highly
expressed in tumor cells, making it a suitable and well-
established target for cancer chemotherapy. Mammalian (class
Ia) ribonucleotide reductase is composed of an R2 homodimer
(R1 subunit) that contains the catalytically active center consist-
ing of redox-active cysteines that are regenerated by the action
of thioredoxin and a 2 homodimer (R2 subunit) containing a
tyrosyl radical and a diiron center which are essential for
initiation of the nucleotide reduction process at the active site
in R1.9 Inhibitors of this enzyme are classified by their mode
of interference with the enzyme’s functions: (i) radical scav-
engers (e.g., hydroxyurea) that destroy the tyrosyl radical
directly; (ii) chelating molecules (e.g., desferrioxamine) that
remove iron from or prevent incorporation of iron into the metal
binding site thereby quenching the tyrosyl radical indirectly or
inhibiting its formation, and (iii) nucleotide and nucleoside
analogues (e.g., gemcitabine, cladribine, fludarabine, cytarabine)
that interfere with substrate binding.
The ribonucleotide reductase-inhibiting activity of R-N-
heterocyclic thiosemicarbazones has primarily been explained
by their iron-chelating properties, either by coordination of iron
from the R2 subunit or by preformation of an iron chelate which
then inhibits the enzyme, implying that iron complexes might
actually be the active species. The observation that the
preformed iron chelates are more potent inhibitors of ribo-
nucleotide reductase in the absence of additional iron than the
uncomplexed thiosemicarbazones supports the latter hypothesis,
but any interaction restricted to the iron site of the enzyme is
unable to explain the partially protective effects observed with
thioredoxin and small dithiol compounds.6,10,11 It was then
proposed that preformed iron(III) chelates are readily reduced
in blood or in the presence of thiols to the ferrous form11-13
which is able to destroy the tyrosyl radical of the enzyme by a
one-electron reduction in an oxygen-requiring reaction.14 The
assumption that the activity of R-N-heterocyclic thiosemi-
carbazones is not solely based on their iron-chelating properties
has recently found support in the observation that 3-amino-
pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP, triapine)
induces iron-dependent free radical damage, thereby behaving
distinctly different from classic iron-chelating drugs such as
desferrioxamine.15
Apart from the well-established inhibition of ribonucleotide
reductase, additional targets and modes of action have also been
discussed. In particular, radical reactions similar to those induced
by bleomycin may explain the formation of DNA strand breaks
observed with 5-hydroxy-2-formylpyridine-thiosemicarbazone
(5-HP)16 and 1-formylisoquinoline-thiosemicarbazone,17 sug-
gesting the induction of direct DNA damage that might be
reinforced by the inhibitory effects on ribonucleotide reductase.7
Besides, inhibition of topoisomerase II by a mechanism
distinctly different from that of etoposide has been suggested
for a variety of 4N-substituted thiosemicarbazones and, in
particular, their copper(II) complexes.18-20
The major problem encountered in the development of R-N-
heterocyclic thiosemicarbazones is the high general toxicity and,
consequently, the low therapeutic index of many representatives
of this class of compounds. Apart from its rapid inactivation
by glucoronidation, 5-hydroxy-2-formylpyridine-thiosemicar-
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bazone, the first clinically evaluated representative, had been
withdrawn because of severe hematological and gastrointestinal
side effects.21,22 More recently, however, triapine has entered
the clinical stage of development.23-26 This compound shows
therapeutic activity over a certain range of dosages in preclinical
tumor models without imposing intolerable host toxicity27 and
has led to a renewed interest in this class of compounds.
The rationale for preparing gallium(III) complexes of R-N-
heterocyclic thiosemicarbazones is based on the fact that
gallium(III) also inhibits the activity of ribonucleotide reduc-
tase28 and is endowed with clinically useful antiproliferative
properties.29-31 Due to similarity in ligand binding affinity with
iron(III), gallium(III) affects intracellular iron availability, but
also interacts directly with ribonucleotide reductase, by compet-
ing with iron for its binding site in the R2 subunit of the
enzyme.32,33 Combining a central metal and a ligand that are
directed at the same molecular target in different ways is being
pursued as a strategy to produce highly potent ribonucleotide
reductase inhibitors expected to benefit from a synergistic action
of the two components.
A prototypic, highly cytotoxic gallium complex with
2-acetylpyridine N,N-dimethylthiosemicarbazone has been re-
ported recently.34 The concentration-effect curves of this
complex closely parallel those of the uncomplexed thiosemi-
carbazone, indicating that the cytotoxic properties of the
complex are largely governed by the ligand. However, an
increase in cytotoxic potency gained by complexation with
gallium has been observed. This seemed to be explainable by
the metal-to-ligand stoichiometry of 1:2, raising the question
whether gallium(III) specifically contributes to the biological
activity or whether similar effects might be achieved by
complexation to iron. Furthermore, structural rearrangements
in solution have been recognized in the case of this complex,
resulting in a mixture of species with 1:2 and 1:1 metal-to-
ligand stoichiometry, complicating the interpretation of the
biological results obtained with this compound.
The aim of the present study was the synthesis of a series of
related R-N-heterocyclic thiosemicarbazone complexes allowing
the exploration of structure-activity relationships with regard
to the role of the central metal (gallium vs iron), the metal-to-
ligand stoichiometry, and the impact of structural modifications
of the thiosemicarbazone ligand.
Results and Discussion
Syntheses. Complex 6 (Figure 1) with metal-to-ligand
stoichiometry 1:1 ([GaLCl2]) has been obtained from 1 and
GaCl3 in a 2:1 molar ratio in boiling dry ethanol in 68% yield,
whereas the synthesis of 7 has been performed starting from 2
and GaCl3 in 1:2 molar ratio with 82% yield. The formation of
6 and 7 has been corroborated by elemental analyses and
electron impact (EI) mass spectra. The latter showed the
presence of intense molecular ion peaks at m/z 360 with relative
intensity (r.i.) 53.7% for 6 and 386 (r.i. 98.4%) for 7. Other
signals observed (see Supporting Information) could easily be
related to structural fragments emerging from molecular ions
M+. It should also be noted that electrospray ionization (ESI)
did not provide ions that could be related to the structures of 6
and 7. Starting from Ga(NO3)3 and the corresponding ligands
1-5 in 1:2 molar ratio in ethanol by subsequent addition of
NH4PF6, complexes [GaL2]+ (8-12) have been isolated as
hexafluorophosphates in 56-91% yield. Complexes 13-15 have
been produced by reacting FeCl3 with the corresponding ligand
in 1:1 molar ratio in boiling dry ethanol, and complexes 16 and
17 in 3:2 molar ratio, respectively. The reaction of Fe(NO3)3‚
9H2O with the ligands 1-5 in 1:2 molar ratio, followed by
addition of an excess of hexafluorophosphate, produced com-
plexes 18-22 in 72-92% yield. The positive ion ESI mass
spectra of 8-12 and 13-22 showed strong peaks (see Sup-
porting Information) due to [GaL2]+ (L ) L1-L5) and [FeL2]+
(L ) L1-L5), correspondingly. The presence of counterions
PF6- or [FeCl4]- has been proved by ESI mass spectra recorded
in the negative ion mode. The electronic spectra of both
gallium(III) and iron(III) complexes are dominated by intra-
ligand transitions associated with pyridine or pyrazine ring,
azomethine, and thione portions of the thiosemicarbazone moiety
(see Supporting Information). Of note is the large increase in
the magnitude of the band at ∼400 nm, which is assumed to
originate from the thioamide portion of the thiosemicarbazone
HL, upon complexation (Figure S1). The high intensity of this
band of the ligand in the complexed form is expected on the
basis of reduced symmetry and in addition due to the increased
lengths of the chromophore along the axis of the molecule in
the complex (trans-configuration) when compared to the metal-
free ligand, which usually adopts cis-configuration. The d-d
band with the maximum at 894 nm (18) and 957 nm (15),
respectively, in the case of iron complexes is presumably due
to 2T2g f 2T1g transition of the d5 low-spin system.35 Selected
complexes 6, 8, 14, and 18 were shown to be stable for at least
15 h when dissolved in a mixture of DMSO/H2O 1:100 (v/v)
(see Figures S1-S4). We also observed that more concentrated
solution of 8 in DMSO/H2O 1:1 (v/v) produced X-ray diffraction
quality single crystals of the same composition as the starting
material after 48 h (in line with UV/vis data).
All gallium and iron complexes were found to crystallize very
well from chloroform or chloroform-ethanol mixtures saturated
with hexane or diethyl ether. This enabled their characterization
in the solid state by X-ray crystallography.
Crystal Structures. ORTEP drawings of [Ga(L1)Cl2] (HL1
) 2-acetylpyridine N,N-dimethylthiosemicarbazone) (6), the
complex cation [Ga(L3)2]+ (10), and [Fe(L3)2]+ (15) (HL3 )
acetylpyrazine N,N-dimethylthiosemicarbazone) with the atom
labeling schemes are shown in Figures 2 and 3, whereas those
of complexes 11, 13, 16-18, and 21 are quoted as Supporting
Information (Figures S5-S10).
The geometry of the gallium ion in 6 is distorted square-
pyramidal. The calculated τ value for the degree of trigonality
is 0.28.36 All compounds with metal-to-ligand stoichiometry
Figure 1. The library of thiosemicarbazones and their metal complexes.
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1:2 crystallize in centrosymmetric space groups as racemic
mixtures of the two enantiomers of chiral octahedral gallium(III)
or iron(III) complexes.
Cytotoxicity. The cytotoxic potencies of five 4N-substituted
R-N-heterocyclic thiosemicarbazones, seven gallium complexes,
and ten iron complexes were investigated in the human tumor
cell lines 41M (ovarian carcinoma) and SK-BR-3 (mammary
carcinoma) by means of the colorimetric MTT assay. Generally,
SK-BR-3 cells are less sensitive to the compounds investigated
in this study, giving up to 38 times higher IC50 values than 41M
cells. All the complexes and the ligands have very high cytotoxic
potencies, with IC50 values ranging from picomolar to nanomolar
concentrations (Table 1), and their concentration-effect curves
are rather flat, gently declining over a range of 3 orders of
magnitude (Figures 4-6), which contrasts with the steep
concentration-effect curves usually observed with tumor-inhibit-
ing metal compounds. This suggests that the cytotoxicity is
mainly governed by the thiosemicarbazone ligands, which are
highly cytotoxic themselves, while complexation to metal ions
rather serves to modulate their mode of action and activity.
In order to give direction to the future development of this
class of compounds, structure-activity relationships have been
explored in following respects: (i) impact of complexation to
gallium(III) or iron(III) as compared to the uncomplexed
thiosemicarbazone; (ii) influence of the ligand-to-metal stoi-
chiometry; (iii) structural modifications of the thiosemicarbazone
and (iv) influence of the counterion in the iron(III) complex
salts.
The effects of the central metal on the activity of ligands
1-5 are very pronounced, and notably they are divergent (Figure
4). Complexation to iron(III) weakens the cytotoxic properties
to a remarkable extent. The IC50 values of the iron complexes
range from 13 to 172 nM in the cell line 41M and from 29 to
930 nM in SK-BR-3 cells, indicating roughly 12- to 2400-fold
(41M) and 9- to 660-fold (SK-BR-3) lower cytotoxicities than
those of the corresponding metal-free ligands, respectively. In
contrast, 1:2 gallium(III) complexes (8-12) show an increase
in cytotoxicity compared to the corresponding metal-free ligands
by a factor of 1.5 to 17 for 41M cells and 3 to 11 for SK-BR-3
cells, respectively. This results in IC50 values in the low
nanomolar or even in the picomolar range (0.0045-0.27 nM
for 41M and 0.17-1.8 nM for SK-BR-3 cells). A pairwise
comparison of the direct analogues [Ga(L1-5)2][PF6] and
[Fe(L1-5)2][PF6] reveals that the gallium complexes are by a
factor of 210 to 33000 (41M) and 150 to 4000 (SK-BR-3) more
cytotoxic than the iron compounds, respectively.
Since structural rearrangements in solution, resulting in a
mixture of species with 1:2 and 1:1 metal-to-ligand stoichiom-
etry (eq 1), had been recognized in the case of [bis(2-
acetylpyridine N,N-dimethylthiosemicarbazone)gallium(III)]
tetrachlorogallate(III) and analogous compounds with tetrachloro-
gallate(III) as counteranion,37 the complex salts with hexafluoro-
phosphate have been prepared.
In order to examine the influence of the ligand-to-metal
stoichiometry, the gallium(III) complexes of the general formula
[GaLCl2], i.e., 6 and 7, were hence compared with their
[GaL2][PF6] congeners 8 and 9, respectively (Figure 5). The
cytotoxicity of complexes with metal-to-ligand stoichiometry
1:1 is either similar (6 in 41M cells and 7 in both cell lines) or
up to 4.6 times higher (6 in SK-BR-3 cells) than those of the
corresponding uncomplexed thiosemicarbazones. Although the
former compounds contain two more easily replaceable chloro
ligands, when compared to tridentate thiosemicarbazones, which
Figure 2. ORTEP drawing of [GaL1Cl2] (HL1 ) 2-acetylpyridine N,N-
dimethylthiosemicarbazone) (6) with thermal ellipsoids depicted at 50%
probability level.
Figure 3. ORTEP drawing of the complex cations [Ga(L3)2]+ (10)
(left) and [Fe(L3)2]+ (15) (right) (HL3 ) acetylpyrazine N,N-dimethyl-
thiosemicarbazone) with thermal ellipsoids depicted at 50% probability
level.
Table 1. Cytotoxicity of R-N-Heterocyclic Thiosemicarbazones (1-5),
Their Gallium(III) Complexes (6-12), Iron(III) Complexes (13-22),
Cisplatin, Ga(NO3)3, Fe(NO3)3, and NH4PF6 in Two Human Cancer Cell
Linesa
IC50 (nM)
compd 41M SK-BR-3
Ligands
1 0.22 ( 0.14 2.7 ( 1.4
2 0.36 ( 0.07 3.1 ( 1.1
3 0.073 ( 0.005 1.4 ( 0.1
4 1.1 ( 0.4 5.0 ( 2.3
5 0.41 ( 0.03 2.2 ( 0.3
Ga(III) Complexes
6 0.19 ( 0.15 0.59 ( 0.27b
7 0.16 ( 0.07b 1.8 ( 0.2
8 0.053 ( 0.018b 0.56 ( 0.47b
9 0.18 ( 0.03b 0.52 ( 0.05b
10 0.0045 ( 0.0006b 0.17 ( 0.01b
11 0.065 ( 0.042b 0.47 ( 0.22b
12 0.27 ( 0.08b 0.79 ( 0.05b
Fe(III) Complexes
13 154 ( 10b 447 ( 63b
14 26 ( 7b 29 ( 12b
15 172 ( 24b 930 ( 206b
16 13 ( 9b 104 ( 37b
17 27 ( 6b 64 ( 24b
18 126 ( 32b 452 ( 36b
19 54 ( 25b 87 ( 11b
20 149 ( 20b 682 ( 267b
21 17 ( 8b 76 ( 11b
22 57 ( 22b 120 ( 22b
cisplatin 0.39 ( 0.07 μM
Ga(NO3)3 70 ( 4 μM >100 μM
Fe(NO3)3 >100 μM >100 μM
NH4PF6 >100 μM >100 μM
a 50% inhibitory concentrations in 41M and SK-BR-3 cells after exposure
for 96 h in the MTT assay. Values are means ( standard deviations obtained
from at least three independent experiments. b Different from corresponding
uncomplexed thiosemicarbazone (compounds 1-5) (pe 0.1; Wilcoxon rank
sum test).
[GaL2][GaCl4]T 2[GaLCl2] (1)
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Figure 4. Concentration-effect curves of thiosemicarbazones HL (white symbols), their gallium(III) complexes [GaL2][PF6] (black symbols), and
iron(III) complexes [FeL2][PF6] (gray symbols), obtained by the MTT assay in 41M cells (left panels: A, C, E, G, J) and SK-BR-3 cells (right
panels: B, D, F, H, K). In each case, the thiosemicarbazone is less cytotoxic than the gallium complex, but more cytotoxic than the iron complex.
A, B. Compounds 1 (white), 8 (black), and 18 (gray). C, D. Compounds 2 (white), 9 (black), and 19 (gray). E, F. Compounds 3 (white), 10 (black),
and 20 (gray). G, H. Compounds 4 (white), 11 (black), and 21 (gray). J, K. Compounds 5 (white), 12 (black), and 22 (gray). Values are means (
standard deviations from at least three independent experiments.
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should allow covalent binding to biomolecules more readily,
neither the shapes of their concentration-effect curves nor their
cytotoxic potencies suggest any substantial differences in their
pharmacological behavior as compared to the congeners with
stoichiometry 1:2.
Structural modifications of two moieties of the thiosemicar-
bazone ligands (aromatic N-heterocycle: pyridine vs pyrazine;
terminal amine group: dimethylamine vs pyrrolidine vs piperi-
dine) have been explored for their effect on the cytotoxicity of
the complexes with 1:2 metal-to-ligand stoichiometry. For
comparison, the concentration-effect curves of the uncomplexed
thiosemicarbazones HL, i.e., 1-5, the gallium(III) complexes
[GaL2][PF6] 8-12, and the iron(III) complexes [FeL2][PF6] 18-
22 are depicted in Figure 6. In general, cytotoxic potencies
mostly range within 1 order of magnitude for each class of
compounds, and the effects exerted by the structural modifica-
tions of the thiosemicarbazone moieties are quite small in
comparison to the impact of the central metal described above.
Within the uncomplexed thiosemicarbazones, cytotoxicity de-
creases in the following rank order in both cell lines based on
IC50 values: 3 > 1 ≈ 5 ≈ 2 > 4.
Strikingly, the cytotoxicity-weakening effects of complexation
with iron(III) become more pronounced with increasing cyto-
toxic potency of the thiosemicarbazone, resulting in an inverse
rank order of the corresponding iron(III) complexes in 41M
cells: 21 (ligand 4)> 19 (ligand 2) ≈ 22 (ligand 5)> 18 (ligand
1) g 20 (ligand 3). A similar tendency, though with a slightly
deviating rank order, is discernible in SK-BR-3 cells. However,
no structure-activity relationships with validity for both cell
lines can be deduced from the concentration-effect curves of
the gallium(III) complexes, and the rank orders with regard to
cytoxic potency neither correspond to that of the uncomplexed
thiosemicarbazones nor to that of the iron(III) analogues.
Accordingly, there is no correlation between the cytotoxicity-
enhancing effects of complexation with gallium(III) and the
cytotoxic potency of the uncomplexed thiosemicarbazones.
The counterions of the cationic iron(III) complexes seem to
have a marginal, if any, impact on cytotoxicity, as the differences
between the IC50 values obtained with the complex salts
containing either tetrachloroferrate(III) or hexafluorophosphate
are mostly within the same range of variation.
Clarifying the question left open by a previous publication
on the gallium(III) complex of 2-acetylpyridine N,N-dimethyl-
thiosemicarbazone,34 the work presented here clearly indicates
that gallium(III) is able to enhance the cytotoxicity of R-N-
heterocyclic thiosemicarbazones to an extent largely exceeding
that of mere stoichiometric effects, whereas complexation to
iron(III) is not only disadvantageous in comparison to gal-
lium(III) but even results in a marked attenuation of the activity
by 1 to 3 orders of magnitude. The latter observation deviates
from findings reported in the literature for other R-N-
heterocyclic thiosemicarbazones. On the one hand, it sharply
contrasts with the enhancing effects of complexation with
iron(III) on the cytotoxicity and the ribonucleotide reductase-
inhibitory potency of 2-formylpyridine- and 1-formylisoquino-
line-thiosemicarbazone10 but also with the in ViVo antileukemic
behavior of a 2-acetylpyridine thiosemicarbazone analogue
carrying a terminal hexahydroazepine group, which has been
reported to be inactive unless complexed with iron(III).38 On
the other hand, the attenuating effects are much more pro-
nounced than those reported for the complexation of 4N-
azabicyclononane-substituted thiosemicarbazones derived from
3-acetylpyridazine, 4-acetylpyrimidine, and acetylpyrazine with
iron(II).39 In consideration of the converse effects of iron(III)
observed with the thiosemicarbazones studied here, the favorable
properties obtained by complexation to gallium(III) can un-
equivocally and specifically be ascribed to this particular metal
ion and are not the result of complexation in general or the
Figure 5. Concentration-effect curves of thiosemicarbazones HL (white symbols) and their gallium(III) complexes [GaLCl2] (black symbols,
dashed line) and [GaL2][PF6] (black symbols, solid line), obtained by the MTT assay in 41M cells (left panels: A, C) and SK-BR-3 cells (right
panels: B, D). The complexes with metal-to-ligand stoichiometry 1:1 are at least as cytotoxic as the uncomplexed thiosemicarbazones but do not
exceed their congeners with stoichiometry 1:2. A, B. Compounds 1 (white), 6 (black; dashed lines), and 8 (black; solid lines). C, D. Compounds
2 (white), 7 (black; dashed lines), and 9 (black; solid lines). Values are means ( standard deviations from at least three independent experiments.
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geometry of the complex, which is essentially the same for both
central metals (Figure 3).
These findings do not necessarily exclude the possibility that
preformed iron chelates are the species actually exerting the
biological effects in ViVo, given the high affinity of the
thiosemicarbazones for iron and the low concentrations of iron
in cell culture media as compared to those encountered in ViVo,
but they clearly indicate that all thiosemicarbazones under
investigation display their full antiproliferative potency when
the metal-binding site is not occupied by iron. Whether the
beneficial effects of coordination to gallium result from the
pharmacological properties of this metal or from the fact that it
prevents premature coordination to iron remains to be elucidated
by further studies.
All five ligands used for synthesis of the complexes presented
here are derived from a basic structure. As compared to the
impact of complexation, the structural modifications of the
thiosemicarbazones have comparatively little impact on their
biological activity in Vitro, suggesting that all thiosemicarbazone
structures under investigation are capable of interacting with
their common biological target in a comparable manner. The
generally high cytotoxic potencies of compounds 1-5 are in
accordance with literature data that report inhibition of lym-
phoma cell growth by compounds 1, 3, 4 and related 4N-
disubstituted R-N-heterocyclic thiosemicarbazones with IC50
values in the low nanomolar range.40 When starting from the
2-acetylpyridine- or acetylpyrazine thiosemicarbazone structure,
the dimethylation of the terminal nitrogen atom (4N) of the
thiosemicarbazone chain has been recognized as the crucial
modification in order to obtain this exceptionally high cytotox-
icity.40 This tremendous cytotoxicity has been found to be
preserved when the dimethylamino group is replaced by
cycloamine functions (pyrrolidine or piperidine), which is also
confirmed by the results presented here.
Whether the conclusions drawn from our in Vitro findings,
in particular the favorable effects of complexation with gal-
lium(III), can be transferred to the in ViVo setting is subject to
ongoing studies in animal tumor models. As to the antitumor
activity of the uncomplexed thiosemicarbazones, results reported
in the literature are fragmentary and rather conflicting: In
contrast to 2-formylpyridine-thiosemicarbazone,1,5,41 3-amino-
pyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine)42
and other representatives lacking substituents at the terminal
amine nitrogen, 2-acetylpyridine N,N-dimethylthiosemicarba-
Figure 6. Concentration-effect curves of thiosemicarbazones HL (white symbols), their gallium(III) complexes [GaL2][PF6] (black symbols) and
iron(III) complexes [FeL2][PF6] (gray symbols), obtained by the MTT assay in 41M cells (left panels: A, C, E) and SK-BR-3 cells (right panels:
B, D, F). Within each class of compounds, cytotoxic potencies mostly range within 1 order of magnitude, and the structural modifications of the
thiosemicarbazone moieties exert rather small effects in comparison to the impact of the central metal. A, B. Compounds 1 (-4-), 2 (-]-), 3
(-O-), 4 (-0-) and 5 (-×-). C, D. Compounds 8 (-2-), 9 (-[-), 10 (-b-), 11 (-9-) and 12 (-×-). E, F. Compounds 18 (-2-), 19
(-[-), 20 (-b-), 21 (-9-) and 22 (-×-). Values are means ( standard deviations from at least three independent experiments.
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zone is completely devoid of antileukemic activity in nontoxic
doses in mice, whereas replacement of dimethylamine either
by longer alkylamines or by bulky cycloamines results in
restored activity, though at higher optimal doses,43 suggesting
that the introduction of a sterically more demanding substituent
might be beneficial from a therapeutic point of view.
Interaction with Ribonucleotide Reductase. The sensitivity
of the R2 specific tyrosine free radical in mouse ribonucleotide
reductase R2 protein to 2-acetylpyridine N,N-dimethylthiosemi-
carbazone (1), its gallium(III) and iron(III) complexes [Ga(L1)2]-
[PF6] (8) and [Fe(L1)2][PF6] (18), Ga(NO3)3, and Fe(NO3)3 was
tested. A highly purified ribonucleotide reductase R2 protein
(30 μM R2 monomer) in buffer containing 1% DMSO was
incubated with 30-33 μM of the above-mentioned compounds
along with the control sample (blank) for 10 min at 298 K. The
frozen samples were analyzed by EPR spectroscopy, and the
EPR spectra of the tyrosyl radical (Y*) were measured at 40
K. As the reaction time was short and the results after 10 min
incubation time were not conclusive, the samples were thawed,
and the compounds were allowed to react with ribonucleotide
reductase R2 protein for further 30 min at 298 K. Measurement
of the EPR spectra of the samples refrozen in liquid nitrogen
showed no change of the EPR signal (Figure 7). The results
obtained prompted us to investigate the same reaction in the
presence of dithiothreitol (DTT) as a reductant. All six samples
were thawed, and to each of them 1 mM (final concentration)
of DTT was added. After incubation for 15 min, the samples
were refrozen in liquid nitrogen and EPR spectra measured. As
seen in Table 2 and Figure 7, the R2 specific EPR signal
decreased significantly for HL1, [Ga(L1)2][PF6], and [Fe(L1)2]-
[PF6] but remained almost unchanged for Ga(NO3)3, Fe(NO3)3,
and control experiment. The samples were thawed again,
allowed to react for further 16 h at 298 K, and refrozen and the
EPR spectra remeasured. All thiosemicarbazone-containing
samples (1, 8, and 18) showed relatively fast kinetics for the
destruction of the tyrosyl radical Y* (Figure 7). In comparison,
Y* is slowly destroyed in the blank on the long time scale (>16
h), which is known from stability measurements. This decay is
accounted for in Figure 8 by relating the Y* concentration of
the samples to that of the blank in %, whereas in Figure 9 it is
shown that 1% DMSO has no effect on the natural decay. Figure
8 shows clearly that Ga(NO3)3 does not enhance the decay of
Y* in DTT-containing buffer under the experimental conditions
and that Fe(NO3)3 displays a lag time in the destruction kinetics
of Y* compared to the ligand-containing samples. These samples
already exhibited after 15 min incubation time a quenching of
Y* by more than 50%, whereas the Fe(NO3)3 sample still
contained the same amount of Y* as the blank but shows a
similar quenching of more than 80% after 16.5 h.
Under anaerobic conditions, the quenching of Y* by 1, 8,
and 18 is much faster than in the presence of oxygen (Table 2
and Figure 9). In addition, the three species show very different
reactivity with [Fe(L1)2][PF6]. ligand. [Ga(L1)2][PF6] under
anaerobic conditions, whereas their aerobic reactivity displays
only moderate differences, nevertheless, in the same order.
However, quenching of Y* seems to be an insufficient explana-
tion for antitumor potency because of the reversed order of the
Table 2. Mouse R2 Tyrosyl Radical Concentration [Y*] in μM Measured under Aerobic and Anaerobic Conditions for Samples Containing 30 μM
Reconstituted R2 Monomer and 30-33 μM Tested Compound after 1, 15, and 1005 min Total Incubation Time at 298 K
tyrosyl radical concentration [Y*] in μM
time[min] blank blank + DMSO blank + DMSO + DTT Ga(NO3)3 Fe(NO3)3 1 8 18
Aerobic
1 17.7 16.5 16.6 17.2 17.4 16.8
15 17.4 16.9 18.2 7.0 9.3 5.1
1005 5.9 5.4 0.9 0.5 0.3 0.6
Anaerobic
1 19.8 19.1 20.9 17.3 18.3 8.5 15.9 3.2
15 18 18.4 22.4 18.2 19.8 0 0 0
1005 2.6 3.2 0 0 0 0 0 0
Figure 7. Mouse R2 tyrosyl radical concentration [Y*] in μM for
samples containing 30 μM reconstituted R2 monomer and 33 μM tested
compound after 10 and 40 min total incubation time at 298 K (left).
Radical concentration [Y*] after addition of 1 mM DTT, measured
after 1, 15, and 1005 min (right). Inset: X-band EPR spectrum of [Y*]
of the blank at 40 K. Further EPR measuring conditions: 9.64 GHz,
100 kHz modulation frequency, 3 G modulation amplitude, 41 ms time
constant, and 82 s recording time. *blank + DMSO (left) and blank +
DMSO + DTT (right).
Figure 8. Percentage of the [Y*] concentrations in the samples from
Figure 7 relating their Y* concentration to that of the blank, therefore
accounting for the natural decay of the [Y*] concentration in mouse
R2. Sample composition, incubation time, and conditions as in Figure
7.
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latter. This might suggest the existence of additional molecular
targets less considered so far.
As for aerobic conditions, under anaerobic conditions the
presence of DTT alone or with one of the metal nitrates shows
no significant effect after 15 min incubation. However, the lack
of oxygen in presence of DTT increases the instability of Y*
also in the blank, so that it is decayed completely after 16.6 h
incubation, preventing any conclusion on an additional reactivity
of the two metal nitrates. This accelerated decay indicates that
DTT acts as a slow radical quencher in the absence of oxygen.
Surprisingly, Y* decays faster in the absence of DTT under
anaerobic conditions than in presence of both oxygen and DTT,
as can be seen from the Y* concentration of these blanks after
16.6 h in Figures 7 and 9. This together with the unexpected
results from the anaerobic DTT containing blank and the aerobic
Fe(NO3)3/DTT containing sample might be explained by reduc-
tion of Fe(III) to Fe(II) in the presence of DTT. Here, Fe(III) is
available in mouse R2 solutions as R2 is isolated as Y*- and
iron-free apoprotein and reconstituted with four Fe(II)/mono-
mer44 resulting in an optimal Y* yield of 0.7 ( 0.1 Y*/
monomer. Although only two Fe(III) are bound tightly at the
diiron binding site of each monomer, not more than 15% of
the excess iron can be removed from the mouse R2 protein by,
e.g., size exclusion chromatography.45 Nevertheless, this excess
Fe(III) most likely bound to the protein surface and the iron
bound at the diiron binding site of R2 monomers, where no Y*
has been formed, are available in solution46 and might react
with the DTT. During reconstitution, an Fe(II) is delivering an
electron to the diiron-center-radical site from the surface of the
R2 protein,9,44 and in a similar way the delivery of an electron
from bound Fe(II) to Y* in reconstituted R2 might quench the
radical. This directly explains the faster radical decay in the
anaerobic DTT containing blank. In the aerobic samples,
formation of Fe(II) by DTT would initiate two counter-working
reactions as the combination of Fe(II) and oxygen reconstitutes
the tyrosyl radical again. The slower Y* decay in the DTT and
oxygen containing blank (Figure 7) compared to the blank
containing neither oxygen nor DTT (Figure 9) indicates that
the reconstitution is more efficient. This in turn explains the
result from the aerobic Fe(NO3)3/DTT-containing sample (Figure
7), in which the oxygen compensates the tyrosyl radical
destruction in the first 15 min but is used up on the long time
scale, where the quenching by Fe(II) prevails.
Conclusions
The combination of 4N-substituted R-N-heterocyclic thio-
semicarbazone moieties with a central gallium(III) ion, both
well-known inhibitors of the enzyme ribonucleotide reductase,
yielded a series of highly potent antiproliferative coordination
compounds that are being explored for their applicability as
anticancer agents. Although the pharmacological properties of
these complexes must be primarily attributed to the thiosemi-
carbazone ligands, gallium(III) unequivocally and specifically
modulates their cytotoxic potency in a beneficial way. In
contrast, coordination to iron(III), which is most likely the
principal biotransformation process undergone by R-N-hetero-
cyclic thiosemicarbazones in ViVo, actually impairs the biological
activity of all representatives of this class of compounds
investigated in this study. Although slow Y* quenching on the
hour time scale has been found in DTT-containing mouse R2
solution without the thiosemicarbazone ligand, the much faster
reaction on the minute time scale in presence of the ligand
clearly shows that the Y* in mammalian R2 protein is a direct
and preferred target of R-N-heterocyclic thiosemicarbazones
under slightly reducing conditions, which also prevail in cancer
cells. The reversed order of cytotoxic activity [Ga(L1)2][PF6]
> HL1 > [Fe(L1)2][PF6] and Y* quenching kinetics [Fe(L1)2]-
[PF6] > HL1 > [Ga(L1)2][PF6] nicely displays the difference
between a complex whole cell and a purified protein solution.
A number of explanations, starting from the uptake kinetics to
additional reactions with target(s) other than ribonucleotide
reductase, are imaginable for this solely quantitative difference.
Experimental Section
All solvents and reagents were obtained from commercial
suppliers and used without further purification. 2-Acetylpyridine
N,N-dimethylthiosemicarbazone (1), 2-acetylpyridine N-pyrroli-
dinylthiosemicarbazone (2), acetylpyrazine N,N-dimethylthiosemi-
carbazone (3), acetylpyrazine N-pyrrolidinylthiosemicarbazone (4),
and acetylpyrazine N-piperidinylthiosemicarbazone (5) have been
prepared as described in the literature.40,47 Elemental analyses were
carried out on a Carlo Erba microanalyzer at the Microanalytical
Laboratory of the University of Vienna and were within (0.4% of
the theoretical values. Electrospray ionization mass spectrometry
was carried out with a Bruker Esquire 3000 instrument (Bruker
Daltonic, Bremen, Germany). Electron impact mass spectrometry
was carried out at 70 eV with a Finnigan MAT 8230 (Bremen,
Germany). Expected and experimental isotope distributions were
compared. Infrared spectra were obtained from KBr or CsI pellets
with a Perkin-Elmer FT-IR 2000 instrument (4000-200 cm-1).
UV-vis spectra were recorded on a Perkin-Elmer Lambda 650
UV-vis-spectrophotometer using samples dissolved in methanol
(900-200 nm). 15 and 18 were also measured on a Hewlett-Packard
8453 UV-vis spectrophotometer (1100-200 nm). 1H NMR spectra
were recorded on a Bruker DPX400 spectrometer at 298 K. The
residual 1H present in DMSO-d6 was used as internal reference.
The assignment was proven by 2D NMR (13C,1H; 1H,1H, and 13C,1H
via long-range couplings) spectra. Abbreviations for NMR data
are: py ) pyridine, pz ) pyrazine, Cq,py ) quaternary carbon of
pyridine, Cq,pz ) quaternary carbon of pyrazine. EPR measurements
were performed on a Bruker ElexSys E500 EPR-spectrometer
equipped with an EPR-910 Oxford Instruments helium-flow cryostat
or on a Bruker ESP300E spectrometer in a quartz-Dewar filled with
liquid nitrogen. An average spin concentration was calculated by
comparison with a mouse R2 standard with a well-known radical
content calibrated earlier against the copper standard.
Figure 9. Mouse R2 tyrosyl radical concentration [Y*] in μM under
anaerobic conditions for samples containing 30 μM reconstituted R2
monomer and 30 μM tested compound after 1, 15, and 1005 min total
incubation time at 298 K. To underline that all samples had a similar
starting concentration of [Y*] a virtual (not measured) starting data
point at time 0 was included at the average [Y*] concentration of the
other samples for the three ligand-containing samples displaying a fast
Y* decay. EPR measuring conditions: 9.42 GHz and 77 K, all other
settings as in Figure 7.
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Syntheses of Complexes. 2-Acetylpyridine N,N-Dimethylthio-
semicarbazonato-N,N,S-dichlorogallium(III), Ga(L1)Cl2 (6). To
2-acetylpyridine N,N-dimethylthiosemicarbazone (1) (0.60 g, 2.70
mmol) in boiling dry ethanol (22 mL) was added an ethanolic
gallium(III) chloride solution (2.29 mmol/mL) (0.59 mL, 1.35
mmol). After a few minutes, a yellow precipitate was formed. The
reaction mixture was heated at 90 °C for 1 h. The product was
separated from the hot solution by filtration, washed with dry
ethanol, and dried in Vacuo. Yield: 0.33 g (68%). Anal. (C10H13-
Cl2GaN4S): C, H, N. 1H and 13C NMR, mass spectrometry, IR
and UV-vis spectroscopy data for 6 and all following complexes
can be found in Supporting Information. Crystals suitable for X-ray
data collection were obtained from chloroform saturated with
n-hexane.
2-Acetylpyridine N-Pyrrolidinylthiosemicarbazonato-N,N,S-
dichlorogallium(III), Ga(L2)Cl2 (7). To 2-acetylpyridine N-
pyrrolidinylthiosemicarbazone (2) (0.30 g, 1.21 mmol) in dry
ethanol (24 mL) at 75 °C was added an ethanolic gallium(III)
chloride solution (3.13 mmol/mL) (0.77 mL, 2.42 mmol) dropwise
within 3 min. The reaction mixture was cooled down to room
temperature and stirred overnight. The reaction mixture was allowed
to stand at 4 °C for 1 h, and the yellow precipitate was filtered off,
washed with dry ethanol, and dried in Vacuo. Yield: 0.38 g (82%).
Anal. (C12H15Cl2GaN4S): C, H, N, S. Crystals suitable for X-ray
data collection were obtained from ethanol/chloroform 1:2 solution
saturated with diethyl ether.
[Bis(2-acetylpyridine N,N-dimethylthiosemicarbazonato)-
N,N,S-gallium(III)] Hexafluorophosphate, [Ga(L1)2]PF6 (8). To
2-acetylpyridine N,N-dimethylthiosemicarbazone (1) (0.20 g, 0.90
mmol) in dry ethanol (20 mL) was added gallium(III) nitrate
nonahydrate (0.19 g, 0.45 mmol) in ethanol (5 mL), and the mixture
was stirred for 15 min at room temperature until all ligand had
dissolved. Addition of ammonium hexafluorophosphate (0.29 g,
1.80 mmol) produced a yellow precipitate. The reaction mixture
was stirred further for 30 min at room temperature. The precipitate
was filtered off, washed with ethanol, and dried in Vacuo. Yield:
0.27 g (91%). Anal. (C20H26F6GaN8PS2): C, H, N.
[Bis(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-
N,N,S-gallium(III)] Hexafluorophosphate, [Ga(L2)2]PF6 (9). To
2-acetylpyridine N-pyrrolidinylthiosemicarbazone (2) (0.70 g, 2.82
mmol) in dry ethanol (70 mL) was added gallium(III) nitrate
nonahydrate (0.59 g, 1.41 mmol) in dry ethanol (14 mL) at 50 °C.
The reaction mixture was stirred for 1 h and then cooled down to
room temperature with an ice bath. To the clear yellow solution
was added ammonium hexafluorophosphate (0.23 g, 1.40 mmol)
in dry ethanol (14 mL) in one portion. The reaction mixture was
stirred for 30 min at room temperature and then cooled below 5
°C with an ice bath. The yellow precipitate formed was filtered off
and washed with dry ethanol. The crude product was recrystallized
from methanol (100 mL) and dried in Vacuo at 50 °C. Yield: 0.77
g (77%). Anal. (C24H30F6GaN8PS2): C, H, N, S.
[Bis(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-
gallium(III)] Hexafluorophosphate, [Ga(L3)2]PF6 (10). To
acetylpyrazine N,N-dimethylthiosemicarbazone (3) (0.30 g, 1.34
mmol) in ethanol (30 mL) at room-temperature was added gal-
lium(III) nitrate nonahydrate (0.28 g, 0.67 mmol) in ethanol (9 mL)
and stirred for 15 min until all ligand had dissolved. After the
addition of ammonium hexafluorophosphate (0.44 g, 2.68 mmol),
an orange solid formed. The precipitate was filtered off, washed
with ethanol, and dried in Vacuo. Yield: 0.40 g (90%). Anal.
(C18H24F6GaN10PS2): C, H, N. Crystals suitable for X-ray data
collection were obtained from chloroform saturated with n-hexane.
[Bis(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-
gallium(III)] Hexafluorophosphate, [Ga(L4)2]PF6 (11). To
acetylpyrazine N-pyrrolidinylthiosemicarbazone (4) (0.50 g, 2.00
mmol) in dry ethanol (50 mL) at 50 °C was added gallium(III)
nitrate nonahydrate (0.42 g, 1.00 mmol) in ethanol (10 mL). The
reaction mixture was stirred for 30 min and then cooled down to
room temperature with an ice bath. To the clear yellow solution
was added ammonium hexafluorophosphate (0.16 g, 1.00 mmol)
in dry ethanol (10 mL). The reaction mixture was stirred for 2 h at
room temperature and then allowed to stand at 4 °C overnight. The
orange precipitate formed was filtered off, washed with dry ethanol,
and dried in Vacuo. Yield: 0.40 g (56%). Anal. (C22H28F6GaN10-
PS2): C, H, N, S. Crystals suitable for X-ray data collection were
obtained from chloroform saturated with n-hexane.
[Bis(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-
gallium(III)] Hexafluorophosphate, [Ga(L5)2]PF6 (12). To
acetylpyrazine N-piperidinylthiosemicarbazone (5) (0.32 g, 1.16
mmol) in dry ethanol (30 mL) at 50 °C was added gallium(III)
nitrate nonahydrate (0.24 g, 0.58 mmol) in ethanol (6 mL). The
reaction mixture was stirred for 40 min and then cooled down to
room temperature with an ice bath. To the clear orange solution
was added ammonium hexafluorophosphate (0.10 g, 0.61 mmol)
in dry ethanol (6 mL). The reaction mixture was allowed to stand
at 4 °C for 1.5 h. The orange precipitate was filtered off, washed
with dry ethanol, and dried in Vacuo. Yield: 0.25 g (57%). Anal.
(C24H32F6GaN10PS2): C, H, N, S.
[Bis(2-acetylpyridine N,N-dimethylthiosemicarbazonato)-
N,N,S-iron(III)] Tetrachloroferrate(III), [Fe(L1)2][FeCl4] (13).
The complex has been prepared following the literature protocol.35
Crystals suitable for X-ray data collection were obtained from
chloroform saturated with n-hexane.
[Bis(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-
N,N,S-iron(III)] Tetrachloroferrate(III), [Fe(L2)2][FeCl4] (14).
To 2-acetylpyridine N-pyrrolidinylthiosemicarbazone (2) (0.20 g,
0.80 mmol) in dry ethanol (24 mL) at 70 °C was added an ethanolic
iron(III) chloride solution (0.26 mmol/mL) (3.1 mL, 0.80 mmol).
The reaction mixture was stirred for 30 min, cooled down to room
temperature, and then allowed to stand at 4 °C overnight. The black
precipitate was filtered off, washed with dry ethanol, and dried in
Vacuo. Yield: 0.13 g (43%). Anal. (C24H30Cl4Fe2N8S2): C, H, N,
S.
[Bis(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-
iron(III)] Tetrachloroferrate(III), [Fe(L3)2][FeCl4] (15). To
acetylpyrazine N,N-dimethylthiosemicarbazone (3) (0.23 g, 1.03
mmol) in boiling dry ethanol (15 mL) was added an ethanolic
iron(III) chloride solution (0.17 mmol/mL) (6 mL, 1.03 mmol). The
reaction mixture was refluxed for 30 min and cooled down to room
temperature. The black precipitate was filtered off, washed with
absolute ethanol, and dried in Vacuo. Yield: 0.21 g (57%). Anal.
(C18H24Cl4Fe2N10S2): C, H, N. Crystals suitable for X-ray data
collection were obtained from chloroform saturated with n-hexane.
[Bis(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-
iron(III)] Tetrachloroferrate(III), [Fe(L4)2][FeCl4] (16). To
acetylpyrazine N-pyrrolidinylthiosemicarbazone (4) (0.30 g, 1.20
mmol) in dry ethanol (30 mL) at 70 °C was added an ethanolic
iron(III) chloride solution (0.12 mmol/mL) (10 mL, 1.20 mmol).
The reaction mixture was stirred for 30 min and cooled down to
room temperature, and a second portion of an ethanolic iron(III)
chloride solution (0.12 mmol/mL) (5 mL, 0.60 mmol) was added.
The reaction mixture was allowed to stand at 4 °C for 45 min. The
black precipitate formed was filtered off, washed with dry ethanol,
and dried in Vacuo. Yield: 0.41 g (90%). Anal. (C22H28Cl4-
Fe2N10S2): C, H, N, S. Crystals suitable for X-ray data collection
were obtained from chloroform saturated with n-hexane.
[Bis(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-
iron(III)] Tetrachloroferrate(III), [Fe(L5)2][FeCl4] (17). To
acetylpyrazine N-piperidinylthiosemicarbazone (5) (0.32 g, 1.16
mmol) in dry ethanol (30 mL) at 70 °C was added an ethanolic
iron(III) chloride solution (0.12 mmol/mL) (5 mL, 0.60 mmol). The
reaction mixture was stirred for 40 min and then cooled down to
room temperature. An ethanolic iron(III) chloride solution (0.12
mmol/mL) (10 mL, 1.20 mmol) was added again in one portion,
leading to the precipitation of the product. The reaction mixture
was allowed to stand at 4 °C for 1 h. The black precipitate was
filtered off, washed with dry ethanol, and dried in Vacuo. Yield:
0.41 g (88%). Anal. (C24H32Cl4Fe2N10S2): C, H, N, S. Crystals
suitable for X-ray data collection were obtained from chloroform
saturated with n-hexane.
[Bis(2-acetylpyridine N,N-dimethylthiosemicarbazonato)-
N,N,S-iron(III)] Hexafluorophosphate, [Fe(L1)2]PF6 (18). To
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2-acetylpyridine N,N-dimethylthiosemicarbazone (1) (0.30 g, 1.35
mmol) in ethanol (15 mL), iron(III) nitrate nonahydrate (0.27 g,
0.67 mmol) in ethanol (5 mL) was added at room temperature. To
the black solution formed was added ammonium hexafluorophos-
phate (0.44 g, 2.70 mmol) in ethanol (5 mL), and the mixture was
stirred at room temperature for 1.5 h and subsequently refluxed
for 1 h. After the reaction mixture cooled down to room temper-
ature, the black precipitate was filtered off, washed with ethanol,
and dried in Vacuo. Yield: 0.32 g (72%). Anal. (C20H26F6FeN8-
PS2): C, H, N. Crystals suitable for X-ray data collection were
obtained from chloroform saturated with n-hexane.
[Bis(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-
N,N,S-iron(III)] Hexafluorophosphate, [Fe(L2)2]PF6 (19). To
2-acetylpyridine N-pyrrolidinylthiosemicarbazone (2) (0.70 g, 2.82
mmol) in dry ethanol (70 mL) at 70 °C was added iron(III) nitrate
nonahydrate (0.57 g, 1.41 mmol) in dry ethanol (15 mL). The
reaction mixture was stirred for 30 min and cooled down to room
temperature with an ice bath. To the clear dark solution was added
ammonium hexafluorophosphate (0.23 g, 1.41 mmol) in dry ethanol
(14 mL). The reaction mixture was stirred for 30 min at room
temperature and then allowed to stand at 4 °C overnight. The black
precipitate was filtered off, recrystallized from methanol (100 mL),
and dried in Vacuo at 50 °C. Yield: 0.88 g (91%). Anal. (C24H30F6-
FeN8PS2): C, H, N, S.
[Bis(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-
iron(III)] Hexafluorophosphate, [Fe(L3)2]PF6 (20). To acetylpyr-
azine N,N-dimethylthiosemicarbazone (3) (0.30 g, 1.34 mmol) in
ethanol (40 mL) was added iron(III) nitrate nonahydrate (0.27 g,
0.67 mmol) in ethanol (5 mL). The reaction mixture was stirred at
room temperature for 30 min and filtered. The black precipitate
formed after the addition of ammonium hexafluorophosphate (0.44
g, 2.70 mmol) was stirred at room temperature for 1 h, filtered off,
washed with ethanol, and dried in Vacuo. Yield: 0.40 g (92%).
Anal. (C18H24F6FeN10PS2): C, H, N.
[Bis(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-
iron(III)] Hexafluorophosphate, [Fe(L4)2]PF6 (21). To acetylpyr-
azine N-pyrrolidinylthiosemicarbazone (4) (0.30 g, 1.20 mmol) in
dry ethanol (30 mL) at 70 °C was added iron(III) nitrate nonahydrate
(0.24 g, 0.60 mmol) in ethanol (6 mL). The reaction mixture was
stirred for 30 min and then cooled down to room temperature with
an ice bath. To the clear dark solution was added ammonium
hexafluorophosphate (0.10 g, 0.61 mmol) in dry ethanol (6 mL).
The reaction mixture was stirred for 1.5 h at room temperature
and then allowed to stand at 4 °C overnight. The black precipitate
was filtered off, washed with dry ethanol, and dried in Vacuo.
Yield: 0.37 g (89%). Anal. (C22H28F6FeN10PS2): C, H, N, S.
Crystals suitable for X-ray data collection were obtained from
chloroform saturated with n-hexane.
[Bis(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-
iron(III)] Hexafluorophosphate, [Fe(L5)2]PF6 (22). To acetylpyr-
azine N-piperidinylthiosemicarbazone (5) (0.32 g, 1.16 mmol) in
dry ethanol (30 mL) at 70 °C was added iron(III) nitrate nonahydrate
(0.24 g, 0.60 mmol) in ethanol (6 mL). The reaction mixture was
stirred for 30 min and then cooled down to room temperature with
an ice bath. To the clear dark solution was added ammonium hexa-
fluorophosphate (0.10 g, 0.61 mmol) in dry ethanol (6 mL). The
reaction mixture was stirred at room temperature for 3 h. The black
precipitate was filtered off, washed with dry ethanol, and dried in
Vacuo. Yield: 0.39 g (90%). Anal. (C24H32F6FeN10PS2): C, H, N,
S.
Crystallographic Structure Determination. X-ray diffraction
measurements were performed on a Nonius Kappa CCD and a
Bruker X8APEX II CCD-diffractometer. Details of the structure
determination are given in Table S2.
Crystal data, data collection parameters, and structure refinement
details for 6, 10, 11, 13, 15-18, and 21 are given in Tables S2-
S4. The structures were solved by direct methods and refined by
full-matrix least-squares techniques. Non-hydrogen atoms were
refined with anisotropic displacement parameters. H atoms were
placed at calculated positions and refined as riding atoms in the
subsequent least-squares model refinements. The isotropic thermal
parameters were estimated to be 1.2 times the values of the
equivalent isotropic thermal parameters of the atoms to which
hydrogens were bonded. The following computer programs were
used: structure solution, SHELXS-97;48 refinement, SHELXL-97;49
molecular diagrams, ORTEP;50 computer: Pentium IV; scattering
factors.51 Crystallographic data have been deposited with the
Cambridge Crystallographic Data Center with numbers
CCDC603767-603775. Copies of data can be obtained, free of
charge, on application to CCDC, 12 Union Road, Cambridge CB2
1EZ, U.K. (deposit@ccdc.com.ac.uk).
Cell Lines and Culture Conditions. Human 41M (ovarian
carcinoma) and SK-BR-3 (mammary carcinoma) cells were kindly
provided by Lloyd R. Kelland (CRC Centre for Cancer Therapeu-
tics, Institute of Cancer Research, Sutton, UK) and Evelyn Dittrich
(General Hospital, Medical University of Vienna, Austria), respec-
tively. Cells were grown in 75 cm2 culture flasks (Iwaki) as adherent
monolayer cultures in complete culture medium, i.e., Minimal
Essential Medium (MEM) supplemented with 10% heat-inactivated
fetal bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine,
and 1% nonessential amino acids (100×) (all purchased from Gibco/
Invitrogen). Cultures were maintained at 37 °C in a humidified
atmosphere containing 5% CO2.
Cytotoxicity Tests in Cancer Cell Lines. Cytotoxicity was
determined by means of a colorimetric microculture assay (MTT
assay, MTT ) 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide). 41M and SK-BR-3 cells were harvested from
culture flasks by trypsinization and seeded into 96-well microculture
plates (Iwaki). A cell density of 4 × 103 cells/well was chosen in
order to ensure exponential growth throughout drug exposure. After
a 24 h preincubation, cells were exposed to solutions of the test
compounds in 200 μL/well complete culture medium for 96 h. For
this purpose, the compounds were dissolved in DMSO and then
serially diluted in complete culture medium such that the effective
DMSO content did not exceed 0.5%. At the end of exposure, drug
solutions were replaced by 100 μL/well RPMI1640 culture medium
(supplemented with 10% heat-inactivated fetal bovine serum) plus
20 μL/well MTT solution in phosphate-buffered saline (5 mg/mL
PBS). After incubation for 4 h, the medium/MTT mixtures were
removed, and the formazan crystals formed by the mitochondrial
dehydrogenase activity of vital cells were dissolved in 150 μL
DMSO per well. Optical densities at 550 nm were measured with
a microplate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm in order to correct for unspecific absorption.
The quantity of vital cells was expressed in terms of T/C values
by comparison to untreated control microcultures, and IC50 values
were calculated from concentration-effect curves by interpolation.
Evaluation is based on means from at least three independent
experiments, each comprising six microcultures per concentration
level. Differences between cytotoxic potencies of the uncomplexed
ligands and their gallium(III) and iron(III) complexes were analyzed
using the Wilcoxon rank sum test.52
Quenching of the Tyrosyl Radical of Mouse Ribonucleotide
Reductase R2 Protein. Highly purified mouse ribonucleotide
reductase R2 protein44 was used for incubation with ligand 1 and
its gallium(III) and iron(III) complexes 8 and 18, correspondingly,
as well as Ga(NO3)3 and Fe(NO3)3.
Ligand 1 and complexes 8 and 18 are well soluble in DMSO
but only sparingly soluble in water. The final DMSO concentration
in the protein solution was kept at 1.1%. The solubility of Ga(NO3)3
and Fe(NO3)3 in DMSO was tested and found to be below the mM
range. Thus, Ga(NO3)3 and Fe(NO3)3 were dissolved in water. A
concentrated solution of reconstituted mouse ribonucleotide reduc-
tase R2 protein was diluted to 30 μM R2 monomer in buffer (50
mM Tris/HCl, pH 7.6, and 100 mM KCl in H2O). This solution
should contain 12-21 μM tyrosyl radical (Y*) depending on the
yield of the reconstitution. Solutions each containing 3 mM
2-acetylpyridine N,N-dimethylthiosemicarbazone (1), [Ga(L1)2][PF6]
(8), or [Fe(L1)2][PF6] (18) in DMSO and Ga(NO3)3 or Fe(NO3)3 in
water were prepared. Six samples were prepared by mixing 180
μL of 30 μM R2 monomer (15 μM R2) solution with each of the
following: 2 μL of DMSO, 2 μL of 3 mM 1 in DMSO, 2 μL of 3
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mM 8 in DMSO, 2 μL of 3 mM 18 in DMSO, 2 μL of 3 mM
Ga(NO3)3 in water and 2 μL of DMSO, and 2 μL of 3 mM Fe(NO3)3
in water and 2 μL of DMSO in Eppendorf reaction vials and
transferring them into 4 mm outer diameter quartz-glass EPR tubes.
After a total incubation time of 10 and 40 min at 298 K, they were
frozen slowly in liquid nitrogen, and EPR spectra were measured
at 40 K. As dilution was negligible here, this yielded a 1:1 molar
ratio of R2 monomer and the tested compound (30-33 μM each).
The same operations were repeated twice in the presence of 1 mM
dithiothreitol with 15 min and >16 h incubation time at 298 K.
A second series of samples were prepared in an anaerobic tent.
The buffer solution as well as the other stable solutions (3 mM
each of 1, 8, and 18 in DMSO and Ga(NO3)3 and Fe(NO3)3 in H2O)
were bubbled with argon for 30 min. They were degassed by the
vacuum applied in the lock of the anaerobic tent and left standing
open for equilibration inside the tent for more then 16 h. The
concentrated protein solution was degassed with great care in the
lock and diluted 40-fold with the anaerobic buffer. The 20 mM
DTT solution was prepared freshly inside the tent from preweighed
powder and anaerobic buffer. Solutions were mixed in Eppendorf
reaction vials and transferred to the bottom of an EPR tube by a
Hamilton syringe with a long needle. EPR tubes were sealed with
stoppers made from butyl-rubber and frozen immediately in liquid
nitrogen. As indicated by the aerobic results, DTT is starting the
reaction, so all other compounds were mixed with the 30 μM R2
monomer solution in advance. The time for addition of DTT,
transfer to the EPR tube, and freezing it was estimated to take about
1 min; thus, the first time point is set to 1 min. The EPR spectra
were measured at 77 K. Three types of blanks were prepared: (i)
30 μM R2 monomer; (ii) 30 μM R2 monomer in 1% DMSO; (iii)
30 μM R2 monomer in 1% DMSO and 1 mM DTT. For the other
five samples, final concentrations were 30 μM R2 monomer, 1%
DMSO, 30 μM reactive species, and 1 mM DTT.
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Spectroscopic data 
 
2-Acetylpyridine N,N-dimethylthiosemicarbazonato-N,N,S-dichlorogallium(III), 
Ga(L1)Cl2 (6). EI-MS, m/z (r. i.): 360 (53.7), [M]+·; 345 (100), [M-CH3]+; 325 (32.6), 
[M-Cl]+.  IR spectrum in KBr (CsI), cm-1: 1524 s, 1392 s, 1376 s, 1297 s, 1247 s, 356 s 
and 341 s (Ga-Cl). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 255 (5540), 303 (8980), 
405 (23410). 1H NMR (400.13 MHz, dmso-d6): δ = 8.91 (d, 1H, py), 8.33 (t, 1H, py),  
8.11 (d, 1H, py), 7.83 (t, 1H, py), 3.28 (br. s, 6H, N(CH3)2), 2.59 (s, 3H, CCH3). 13C 
NMR (100.63 MHz, dmso-d6): δ = 176.1 (C-S), 146.7 (Cpy), 146.3 (Cq, py), 143.5 (Cpy), 
143.1 (C=N), 127.0 (Cpy), 123.9 (Cpy), 41.0 and 38.7 (N(CH3)2), 14.1 (CH3).   
 
2-Acetylpyridine N-pyrrolidinylthiosemicarbazonato-N,N,S-dichlorogallium(III), 
Ga(L2)Cl2 (7). EI-MS, m/z (r. i.): 386 (98.4), [M]+·; 371 (76.0), [M-CH3]+; 351 (72.5), 
[M-Cl]+. IR spectrum in KBr, cm-1: 1500 s, 1452 s, 1372 s, 1282 s. UV/vis (MeOH), 
λmax, nm (ε, M−1 cm−1): 256 (4950), 306 (8750), 407 (24310). 1H NMR (400.13 MHz, 
dmso-d6): δ = 8.92 (d, 1H, py), 8.33 (t, 1H, py), 8.10 (d, 1H, py), 7.83 (t, 1H, py), 3.68-
3.66 (br. m, 4H, N(C4H8)), 2.58 (s, 3H, CCH3), 1.96-1.92 (br. m, 4H, N(C4H8)). 13C 
NMR (100.63 MHz, dmso-d6): δ = 173.1 (C-S), 146.7 (Cpy), 146.5 (Cq, py), 143.6 (Cpy), 
142.5 (C=N), 126.9 (Cpy), 123.9 (Cpy), 50.4,  49.0 and 25.1 (N(C4H8)), 14.0 (CH3).   
 
[Bis-(2-acetylpyridine N,N-dimethylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(L1)2]PF6 (8). ESI-MS in EtOH (positive): m/z 511, 
[GaL2]+. IR spectrum in KBr, cm-1: 1519 s, 1389 s, 1302 s, 1252 s, 843 s and 559 m (P-
F). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 252 (11730), 303 (18770), 406 (44000). 1H 
NMR (400.13 MHz, dmso-d6): δ = 8.25-8.20 (m, 4H, py), 7.92 (d, 2H, py), 7.60-7.54 
(m, 2H, py), 3.25 (br. s, 12H, N(CH3)2), 2.83 (s, 6H, CCH3). 13C NMR (100.63 MHz, 
dmso-d6): δ = 176.1 (C-S), 147.4 (C=N), 146.3 (Cq, py), 145.3 (Cpy), 143.2 (Cpy), 127.8 
(Cpy), 124.7 (Cpy), 41.3 and 38.9 (N(CH3)2), 14.9 (CH3). 
 
[Bis-(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-N,N,S-
gallium(III)]hexafluorophosphate, [Ga(L2)2]PF6 (9). ESI-MS in MeOH (positive), 
m/z 563, [GaL2]+; ESI-MS in MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr,  
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cm-1: 1496 s, 1449 s, 1375 s, 1283 s, 841 s and 558 m (P-F). UV/vis (MeOH), λmax, nm 
(ε, M−1 cm−1): 254 (10220) 305 (17110), 409 (43160). 1H NMR (400.13 MHz, dmso-
d6): δ = 8.25-8.19 (m, 4H, py), 7.92 (d, 2H, py), 7.60-7.54 (m, 2H, py), 3.74-3.71 (br. m, 
4H, N(C4H8)), 3.62-3.58 (br. m, 2H, N(C4H8)), 3.50-3.44 (br. m, 2H, N(C4H8)), 2.82 (s, 
6H, CCH3), 1.94-1.88 (br. m, 8H, N(C4H8)). 13C NMR (100.63 MHz, dmso-d6): δ = 
172.9 (C-S), 147.0 (C=N), 146.0 (Cq, py), 145.1 (Cpy), 143.1 (Cpy), 127.7 (Cpy), 124.6 
(Cpy), 50.8, 49.2 and 25.2 (N(C4H8)), 15.0 (CH3). 
 
[Bis-(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(L3)2]PF6 (10). ESI-MS in H2O (positive): m/z 513, [GaL2]+. 
IR spectrum in KBr, cm-1: 1537 s, 1509 s, 1397 s, 1298 s, 1257 s, 836 s and 558 m (P-
F). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 242sh (12150), 266 (13350), 323 (27730), 
434 (37210). 1H NMR (400.13 MHz, dmso-d6): δ = 9.53 (d, 2H, pz), 8.86 (d, 2H, pz) 
7.91 (dd, 2H, pz), 3.33 and 3.22 (br. s, 12H, N(CH3)2), 2.88 (s, 6H, CCH3). 13C NMR 
(100.63 MHz, dmso-d6): δ = 175.7 (C-S), 149.0 (Cpz), 146.5 (Cpz), 145.9 (C=N), 140.4 
(Cq, pz), 138,4 (Cpz), 41.4 and 39.3 (N(CH3)2), 15.0 (CH3). 
 
[Bis-(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(L4)2]PF6 (11). ESI-MS in MeOH (positive): m/z 565, 
[GaL2]+; ESI-MS in MeOH (negative), m/z 145, [PF6]−. IR spectrum in KBr, cm-1: 1497 
s, 1448 s, 1374 s, 1280 s, 834 s and 557 m (P-F). UV/vis (MeOH), λmax, nm (ε, M−1 
cm−1): 245sh (10860), 268 (12370), 324 (26980), 437 (37300). 1H NMR (400.13 MHz, 
dmso-d6): δ = 9.52 (s, 2H, pz), 8.86 (d, 2H, pz), 7.91 (dd, 2H, pz), 3.77-3.74 (br. m, 4H, 
N(C4H8)), 3.64-3.58 (br. m, 2H, N(C4H8)), 3.52-3.45 (br. m, 2H, N(C4H8)), 2.86 (s, 6H, 
CCH3), 1.96-1.91 (br. m, 8H, N(C4H8)). 13C NMR (100.63 MHz, dmso-d6): δ = 172.3 
(C-S), 149.0 (Cpz), 146.6 (Cpz), 145.5 (C=N), 140.5 (Cq, pz), 138,4 (Cpz), 51.0, 49.6 and 
25.2 (N(C4H8)) 15.0 (CH3). 
 
[Bis-(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(L5)2]PF6 (12). ESI-MS in MeOH (positive): m/z 593, 
[GaL2]+; ESI-MS in MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr, cm-1: 1440 
s; 1294 s; 1252 s; 841 s and 558 m (P-F). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 268  
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(12440), 324 (26530), 437 (37080). 1H NMR (400.13 MHz, dmso-d6): δ = 9.53 (d, 2H, 
pz), 8.88 (d, 2H, pz), 7.91 (dd, 2H, pz), 3.88 (br. s, 8H, N(C5H10)), 2.87 (s, 6H, CCH3), 
1.66-1.57 (br. m, 12H, N(C5H10)). 13C NMR (100.63 MHz, dmso-d6): δ = 174.7 (C-S), 
149.2 (Cpz), 146.7 (Cpz), 146.2 (C=N), 140.3 (Cq, pz), 138,4 (Cpz), 51.0, 47.8, 26.3 and 
24.8 (N(C5H10)), 15.2 (CH3). 
 
[Bis-(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-N,N,S-iron(III)] 
tetrachloroferrate(III), [Fe(L2)2][FeCl4] (14). ESI-MS in MeOH (positive): m/z 550, 
[FeL2]+. IR spectrum in KBr, cm-1: 1540 s, 1503 s, 1450 s, 1285 s, 1195 s. UV/vis 
(MeOH), λmax, nm (ε, M−1 cm−1): 216sh (48640), 248 (33550), 300 (22370), 331 
(23380), 381 (29720), 466sh (9170), 617 (800).   
 
[Bis-(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] 
tetrachloroferrate(III), [Fe(L3)2][FeCl4] (15). ESI-MS (positive): m/z 500, [FeL2]+; 
ESI-MS (negative): m/z 196, [FeCl4]−. IR spectrum in KBr (CsI), cm-1: 1554 s, 1524 s, 
1400 s, 1307 s, 1258 s, 384
 
s (Fe-Cl). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 222sh 
(39810), 255sh (31310), 303sh (23600), 325 (24790), 402 (23470), 503sh (7910), 636 
(690), 957 (500). 
 
[Bis-(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-iron(III)] 
tetrachloroferrate(III), [Fe(L4)2][FeCl4] (16). ESI-MS in MeOH (positive): m/z 552, 
[FeL2]+. IR spectrum in KBr, cm-1: 1546 s, 1519 s, 1449 s, 1282 s. UV/vis (MeOH), 
λmax, nm (ε, M−1 cm−1): 221sh (46410), 257sh (35740), 301sh (26760), 330 (28410), 
407 (27740), 502sh (9810), 654 (870). 
 
[Bis-(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-iron(III)] 
tetrachloroferrate(III), [Fe(L5)2][FeCl4] (17). ESI-MS in MeOH (positive): m/z 580, 
[FeL2]+; ESI-MS in MeOH (negative): m/z 196, [FeCl4]−. IR spectrum in KBr, cm-1: 
1517 s, 1440 s, 1302 s, 1249 s, 1150 s. UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 227 
(43060), 257sh (34460), 302sh (26160), 324 (27280), 408 (27510), 503sh (8820), 660 
(860). 
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[Bis-(2-acetylpyridine N,N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] 
hexafluorophosphate, [Fe(L1)2]PF6 (18). ESI-MS in H2O (positive): m/z 498, [FeL2]+. 
IR spectrum in KBr, cm-1: 1554 s, 1400 s, 1315 s, 1250 s, 840 s and 558 m (P-F). 
UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 217sh (46680), 248 (30710), 300 (20570), 330 
(20910), 378 (26770), 464sh (9410), 612 (850), 894 (540). 
 
[Bis-(2-acetylpyridine N-pyrrolidinylthiosemicarbazonato)-N,N,S-iron(III)] 
hexafluorophosphate, [Fe(L2)2]PF6 (19). ESI-MS in MeOH (positive): m/z 550, 
[FeL2]+; ESI-MS in MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr, cm-1: 1503 
s, 1452 s, 1291 s, 839 s and 558 m (P-F). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 
217sh (43770), 249 (28800), 299 (18820), 330 (19230), 383 (26280), 465sh (9000), 617 
(800). 
 
[Bis-(acetylpyrazine N,N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] 
hexafluorophosphate), [Fe(L3)2]PF6 (20). ESI-MS (positive): m/z 500, [FeL2]+. IR 
spectrum in KBr, cm-1: 1558 s, 1527 s, 1403 s, 1309 s, 1259 s, 843 s and 558 m (P-F). 
UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 222sh (32780), 255sh (25090), 303sh (19040), 
324 (19660), 404 (20280), 501sh (7210), 636 (770).  
 
[Bis-(acetylpyrazine N-pyrrolidinylthiosemicarbazonato)-N,N,S-iron(III)] 
hexafluorophosphate, [Fe(L4)2]PF6 (21). ESI-MS in MeOH (positive): m/z 552, 
[FeL2]+. IR spectrum in KBr, cm-1: 1552 s, 1449 s, 1285 s, 848 s and 557 m (P-F). 
UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 223sh (36240), 256sh (26950), 301sh (20280), 
328 (21240), 411 (22540), 502sh (8400), 659 (790). 
 
[Bis-(acetylpyrazine N-piperidinylthiosemicarbazonato)-N,N,S-iron(III)] 
hexafluorophosphate, [Fe(L5)2]PF6 (22). . ESI-MS (positive): m/z 580, [FeL2]+; ESI-
MS in MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr, cm-1: 1520 s, 1437 s, 
1307 s, 1249 s, 845 s and 558 m (P-F). UV/vis (MeOH), λmax, nm (ε, M−1 cm−1): 227 
(38630), 257sh (30120), 301sh (22750), 324 (23690), 410 (25980), 503sh (8690), 642 
(870). 
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Table S1. Microanalytical data. 
 
Substance 
number 
Theory Found 
6 C: 33.19, H: 3.62, N: 15.48. C: 33.33, H: 3.38, N: 15.24 
7 C: 37.15, H: 3.90, N: 14.44, S: 8.26. C: 36.88, H: 3.80, N: 14.44, S: 8.17.. 
8 C: 36.55, H: 3.99, N: 17.05. C: 36.28, H: 3.86, N: 16.80.. 
9 C: 40.64, H: 4.26, N: 15.80, S: 9.04. C: 40.62, H: 4.13, N: 15.82, S: 8.91.. 
10 C: 32.79, H: 3.67, N: 21.25. C: 32.77, H: 3.45, N: 20.98.. 
11 C: 37.15, H: 3.97, N: 19.69, S: 9.02. C: 37.26, H: 3.86, N: 19.48, S: 8.90.. 
12 C: 38.99, H: 4.36, N: 18.94, S: 8.67. C: 39.31, H: 4.40, N: 18.60, S: 8.48.. 
14 C: 38.53, H: 4.04, N: 14.98, S: 8.57. C: 38.59, H: 4.04, N: 14.95, S: 8.45.. 
15 C: 30.97, H: 3.47, N: 20.06 C: 31.25, H: 3.43, N: 19.99.. 
16 C: 35.22, H: 3.76, N: 18.67, S: 8.55. C: 35.41, H: 3.76, N: 18.40, S: 8.51.. 
17 C: 37.04, H: 4.14, N: 18.00, S: 8.24. C: 36.86, H: 3.96, N: 17.69, S: 8.44.. 
18 C: 37.33, H: 4.07, N: 17.42. C: 37.03, H: 3.86, N: 17.20.. 
19 C: 41.45, H: 4.35, N: 16.11, S: 9.22. C: 41.22, H: 4.50, N: 15.68, S: 8.96.. 
20 C: 33.50, H: 3.75, N: 21.70 C: 33.43, H: 3.48, N: 21.42.. 
21 C: 37.88, H: 4.05, N: 20.08, S: 9.19. C: 38.18, H: 4.02, N: 19.83, S: 9.13.. 
22 C: 39.73, H: 4.45, N: 19.31, S: 8.84. C: 39.70, H: 4.55, N: 19.10, S: 8.93.. 
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Figure S1. UV/vis spectroscopy data of 1 (black) and 6 in DMSO/H2O 1 : 100.                                
First measurement of 6 (red), after 30 minutes (green), after 15 hours (blue). 
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Figure S2. UV/vis spectroscopy data of 8 in DMSO/H2O 1 : 100.                                
First measurement (red), after 15 hours (blue). 
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Figure S3. UV/vis spectroscopy data of 14 in DMSO/H2O 1 : 100.                                                    
First measurement (red), after 15 hours (blue). 
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Figure S4. UV/vis spectroscopy data of 18 in DMSO/H2O 1 : 100.                                  
First measurement (red), after 15 hours (blue). 
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X-Ray crystallographic data 
Table S2. Details of data collection for 6, 10, 11, 13, 15-18, 21. 
 
Complex 6 10 11 13 15 16 17 18 21 
Number of 
frames 
265 389 502 344 216 379 379 1213 379 
Seconds/frame 250 65 60 70 200 15 95 40 50 
Scan width 2 2 1.5 2 2 2 2 1 2 
Distance from 
the detector 
30 30 30 30 30 30 30 37.5 30 
 
Table S3. Crystal Data for 6, 10, 11, 13, 15. 
Complex 6 10 11·CHCl3 13 15 
empirical 
formula 
C10H13Cl2GaN4S  C18H24F6GaN10PS2 C23H29Cl3F6GaN10PS2 C20H26Cl4Fe2N8S2  C18H24Cl4Fe2N10S2  
Fw 361.93 659.27 830.72 696.11 698.08 
space 
group 
Pna21 1P  P21/n P21/n P21/n 
a, Å 12.922(3) 8.699(2) 19.105(4) 14.831(3) 14.824(3) 
b, Å 14.760(3) 11.906(2) 8.833(2) 13.259(3) 13.113(3) 
c, Å 7.4060(10) 12.967(3) 19.865(4) 15.009(3) 15.004(3) 
α, deg  79.31(3)    
β, deg  78.05(3) 102.00(3) 107.82(3) 109.27(3) 
γ, deg  82.03(3)    
V, Å3 1412.5(5) 1284.1(5) 3279.1(12) 2809.8(10) 2753.2(10) 
Z 4 2 4 4 4 
λ, Å 0.71073 0.71073 0.71073 0.71073 0.71073 
ρcalcd, g 
cm-3 
1.702 1.705 1.683 1.646 1.684 
crystal 
size, mm3 
0.08 × 0.08 × 0.01 0.37 × 0.17 × 0.06 0.29 × 0.20 × 0.06 0.10 × 0.10 × 0.04 0.20 × 0.20 × 0.04 
T, K 200 120 120 120 120 
µ, mm-1 2.461 1.371 1.329 1.589 1.623 
R1a 0.0313 0.0315 0.0347 0.0256 0.0362 
wR2b 0.0648 0.0790 0.0891 0.0706 0.0890 
GOFc 1.031 1.041 1.043 1.057 1.040 
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Table S4. Crystal Data and Details of Data Collection for 16, 17, 18, 21. 
Complex 16·CHCl3 17·CHCl3 18 21 
empirical formula C23H29Cl7Fe2N10S2 C25H33Cl7Fe2N10S2 C20H26F6FeN8PS2 C22H28F6FeN10PS2  
Fw 869.53 897.59 643.42 697.47 
space group 1P  1P  P21/c P21/n 
a, Å 8.880(2) 10.956(2) 8.4265(2) 12.609(3) 
b, Å 13.369(3) 11.464(2) 17.9472(5) 12.979(3) 
c, Å 15.996(3) 16.644(3) 18.4968(5) 18.280(4) 
α, deg 79.39(3) 101.45(3)   
β, deg 76.45(3) 102.72(3) 100.4230(10) 106.05(3) 
γ, deg 73.03(39 110.98(3)   
V, Å3 1752.0(6) 1813.6(6) 2751.15(13) 2875.0(11) 
Z 2 2 4 4 
λ, Å 0.71073 0.71073 0.71073 0.71073 
ρcalcd, g cm-3 1.648 1.644 1.553 1.611 
crystal size, mm3 0.20 × 0.17 × 0.14 0.20 × 0.09 × 0.06 0.22 × 0.14 × 0.04 0.26 × 0.17 × 0.11 
T, K 120 120 100 120 
µ, mm-1 1.515 1.466 0.825 0.799 
R1a 0.0416 0.0373 0.0358 0.0375 
wR2b 0.1068 0.0915 0.0860 0.0986 
GOFc 1.041 1.031 1.006 1.068 
 
a
 R1 = Σ||Fo| - |Fc||/Σ|Fo|, b wR2 = {Σ[w (Fo2 - Fc2)2] /Σ[w(Fo2)2 ]}1/2. c GOF = {Σ[w(Fo2 - 
Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total number of 
parameters refined. 
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Details of crystal structures of 6, 10, 11·CHCl3, 13, 15, 16·CHCl3, 
17·CHCl3, 18 and 21 
 
The structure of 15 consists of the complex cations [Fe(L3)2]+ and anions [FeCl4]-. An 
ORTEP drawing of [Fe(L3)2]+ is shown in Figure 3. The iron atom is coordinated by the 
two approximately planar tridentate ligands. The coordination polyhedron approaches 
an octahedron, where the two ligands are bound to Fe(1) atom through a nitrogen atom 
of the pyrazine ring, and a nitrogen and sulphur atom of the thiosemicarbazide group in 
a meridional arrangement. The pattern of coordination is similar to that observed in 
[FeL2][FeCl4] (LH = 2-acetylpyridine N-pyrrolidinylthiosemicarbazone)1. The two 
sulphur atoms are located in cis-positions because of the planarity of the tridentate 
ligand. On coordination of two L- to iron(III) four five-membered chelate rings are 
formed: two C2N2Fe and two N2CSFe (Fe1-N1-C4-C5-N3, Fe1-N3-N4-C7-S1, Fe1-N6-
C13-C14-N8 and Fe1-N78-N9-C16-S2). The formation of four five membered chelate 
rings is presumably the reason for some distortion of the coordination geometry from an 
ideal octahedron2. Note that the angles ∠N1-Fe-S1 at 164.46(9)° and ∠N6-Fe-S2 at 
165.74(10)° deviate markedly from the ideal value of 180°. The reason might be some 
repulsion between S1 and S2. The angle ∠N3-Fe-N8 is at 178.79(13)°. 
There is a slight shortening of the bond distance between iron and the nitrogen of the 
pyridine ring (1.910(3) and 1.918(3) Å) compared to the distance between iron and the 
nitrogen in the thiosemicarbazide chain (1.979(3) and 1.988(3) Å).  
The C-S bond distances C7-S1 at 1.760(4) Å and C16-S2 at 1.761(4) Å are longer 
compared to those reported in metal-free thiosemicarbazones (1.678(2) Å in 4-
formylpyridine thiosemicarbazone, 1.692(4) in 2-acetylpyridine-N-pyrrolidinyl 
thiosemicarbazone or 1.707 Å in thiosemicarbazide)1,3 indicating an increase of single-
bond character for C-S bond in [Fe(L3)2][FeCl4]. 
 
The geometric parameters of the cations of 13, 16 – 18 and 21 are very similar to those 
of 15. 
 
The structure of 10 consists of the complex cations [Ga(L3)2]+ and the complex anions 
[PF6]-. The structure of the cation is shown in Figure 3. Like iron in complexes 13-22 
the gallium atom is coordinated by two tridentate ligands in octahedral manner. 
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The angles ∠N1-Ga1-S1 and ∠N6-Ga1-S2 at 160.02(5)° and 159.77(5)° deviate 
markedly from the ideal value of 180° (the deviation is about 5° larger in comparison to 
the iron complexes). The angle ∠N3-Ga1-N8 is at 162.37(6)°, which differs by ca. 20° 
from the corresponding angles in the iron complexes. 
There is also a slight shortening of the bond distance between gallium and the nitrogen 
of the pyridine ring (2.0361(17) and 2.0372(17) Å) compared to the distance between 
gallium and the nitrogen in the thiosemicarbazide fragment (2.1407(17) and 2.1639(16) 
Å). The Ga-N lengths are longer than the corresponding Fe-N distances. 
The C-S bonds distances C7-S1 at 1.754(2) and C16-S2 at 1.745(2) Å are slightly 
shorter than in the analogous iron complexes, but there is also an increase of single-
bond character for C-S bond in [Ga(L3)2]+ in comparison to metal free 
thiosemicarbazones. 
In conclusion the coordination polyhedron of this gallium(III) complex is different from 
that for the corresponding iron(III) complexes. The deviation from the ideal octahedron 
is more evident. 
 
Complex 11 shows very similar geometric parameters to those of complex 10.  
 
The structure of the 1 : 1-complex 6 is shown in Figure 2. The gallium atom is 
coordinated by one approximately planar tridentate thiosemicarbazone and two chloro 
ligands. The thiosemicarbazone ligand is bound to the gallium atom in the same manner 
as in the 1 : 2-complexes (N,N,S - coordination).  
The angle ∠N1-Ga1-S1 at 155.27(11)° shows the strongest deviation from the ideal 
value of 180° of all complexes. There is also a marked difference between Ga1-N1 at  
2.049(3) Å and Ga1-N2 at 2.100(3) Å. The same picture as observed for complexes of  
1 : 2 stoichiometry. 
The C8-S1 at 1.740(4) Å is in the range of the bond length in the gallium 1 : 2-
complexes. The angles ∠N2-Ga1-Cl1 and ∠N2-Ga1-Cl2 are different at 110.44(14)° 
and 138.14(14)°, respectively. The Ga1-Cl1 is at 2.1958(13) Å and Ga1-Cl2 at 
2.2244(13) Å.  
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Figure S5. ORTEP drawing of  [GaL2]+  (HL = acetylpyrazine N-pyrrolidinyl 
thiosemicarbazone) (11) with thermal ellipsoids depicted at 50% probability. 
 
 
 
 
 
 
 
 
Figure S6. ORTEP drawing of  [FeL2]+  (HL = 2-acetylpyridine N,N-dimethyl 
thiosemicarbazone) (13) with thermal ellipsoids depicted at 50% probability. 
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Figure S7. ORTEP drawing of  [FeL2]+  (HL = acetylpyrazine N-pyrrolidinyl 
thiosemicarbazone) (16) with thermal ellipsoids depicted at 50% probability. 
 
 
 
Figure S8. ORTEP drawing of  [FeL2]+  (HL = acetylpyrazine N-piperidinyl 
thiosemicarbazone) (17) with thermal ellipsoids depicted at 50% probability. 
 
 
 
 
53
S16 
 
 
Figure S9. ORTEP drawing of  [FeL2]+  (HL = 2-acetylpyridine N,N-dimethyl 
thiosemicarbazone) (18) with thermal ellipsoids depicted at 50% probability. 
 
 
 
 
Figure S10. ORTEP drawing of  [FeL2][PF6]  (HL = acetylpyrazine N-pyrrolidinyl 
thiosemicarbazone) (21) with thermal ellipsoids depicted at 50% probability. 
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Abstract
Three chalcogensemicarbazones, viz., 2-acetylpyridine N,N-dimethylsemicarbazone (HL1), 2-acetylpyridine N,N-dimethylthiosemi-
carbazone (HL2) and 2-acetylpyridine N,N-dimethylselenosemicarbazone (HL3), their corresponding gallium(III) complexes
[Ga(L1–3)2]PF6 and the ruthenium(III) compound [Ru(L
2)2]PF6 have been prepared and characterised by X-ray crystallography and
spectroscopic techniques (IR, UV/vis, 1H, 13C, 15N, 77Se NMR) in order to elucidate the eﬀect of metal ion complexation and chalcogen
donor identity on the cytotoxicity of chalcogensemicarbazones in two human tumour cell lines 41M (ovarian carcinoma) and SK-BR-3
(mammary carcinoma).
 2007 Elsevier Inc. All rights reserved.
Keywords: Antitumour agents; Gallium; Ruthenium; Thiosemicarbazone; X-ray diﬀraction
1. Introduction
a-N-Heterocyclic thiosemicarbazones possess a wide
range of pharmacological properties, including antitumour,
antimalarial, antibacterial, antifungal and antiviral activity
[1]. Pyridine-2-carbaldehyde thiosemicarbazone, the ﬁrst a-
N-heterocyclic thiosemicarbazone with antitumour proper-
ties, has been reported half a century ago [2]. The enzyme
ribonucleotide reductase (RR) has been identiﬁed as the
principal target for this class of compounds [3,4]. The para-
mount role of the ribonucleotide reductase in DNA synthe-
sis and the high expression in tumour cells, has made it a
suitable and well established target in cancer chemotherapy
[5]. The ribonucleotide reductase-inhibiting activity of a-N-
heterocyclic thiosemicarbazones was supposed to be due to
their pronounced iron-chelating properties, which enable
sequestering of iron from the R2 subunit of the enzyme or
prior formation of an iron complex, which then inhibits
the enzyme [6]. In addition, iron-dependent free radical
damage of RR in the case of 3-amino-pyridine-2-carboxal-
dehyde-thiosemicarbazone (3-AP, triapine) has also been
suggested to be responsible for the observed inhibiting activ-
ity [7].
Thiosemicarbazones and their derivatives are versatile
ligands as they exhibit various binding modes with transi-
tion and some main group metals. They can act as mono-
or bidentate ligands binding to metal ions via diﬀerent
donor atoms. The coordination capacity of thiosemicar-
bazones can be further increased, if aldehydes or ketones,
which contain additional functional group(s) in position(s)
suitable for chelation, are used for their preparation [8].
0162-0134/$ - see front matter  2007 Elsevier Inc. All rights reserved.
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We recently synthesised a series of gallium(III) and
iron(III) complexes of the general formula [ML2][PF6] with
ﬁve diﬀerent a-N-heterocyclic N,N-disubstituted thiosemi-
carbazones (HL), which use for coordination the NNS
donor atom set, and found that the central metal ion has
a pronounced but diﬀerent eﬀect on the cytotoxicity of
the ligands [9]. Gallium(III) acts in a synergistic way with
the thiosemicarbazones and enhances the cytotoxicity,
whereas complexation to iron(III) results in a marked
attenuation of the antiproliferative activity. Remarkably,
we observed a reversed order of mouse R2 tyrosyl radical
(Y*) quenching kinetics by gallium(III) and iron(III) thi-
osemicarbazonates in the presence of dithiothreitol. Struc-
tural modiﬁcations of the thiosemicarbazone (replacement
of pyridine ring by pyrazine, and variation of substituents
at the terminal N4-atom of the thiosemicarbazide moiety)
have little impact on their antiproliferative activity
in vitro, indicating a comparable manner of their interac-
tion with a biological target. Extending this work on struc-
ture–activity relationships, we decided to study the eﬀect of
the chalcogen donor on the antiproliferative activity of
both metal-free 2-acetylpyridine (chalcogen)semicarbaz-
ones and their gallium(III) complexes of 2:1 stoichiometry.
In addition, the focus has been set on the elucidation of the
eﬀect of thiosemicarbazone coordination to metal ions
other than gallium(III) and iron(III), and speciﬁcally to
ruthenium(III), on cytotoxicity.
In order to carry out these investigations, we prepared
the required 2-acetylpyridine (chalcogen)semicarbazones
and their gallium(III) and ruthenium(III) complexes
(Scheme 1), providing a detailed spectroscopic (IR, UV/
vis, 1H, 13C, 15N and 77Se NMR) and structural character-
isation (X-ray diﬀraction) of the novel compounds, and
evaluated their antiproliferative activity in two human can-
cer cell lines (41M and SK-BR-3).
2. Experimental section
2.1. Materials and methods
All solvents and reagents were obtained from commercial
suppliers and used without further puriﬁcation. Ga(NO3)3 Æ
8.15H2O was purchased from Sigma–Aldrich. The amount
of water was determined by thermogravimetric analysis.
N,N-dimethylsemicarbazide, [10] [(DMSO)2H][trans-
RuCl4(DMSO)2], [11] and [Ga(L
2)2][PF6] [9] (5) have been
prepared as described in the literature. CHN elemental anal-
yses were carried out on a Perkin–Elmer 2400 CHN elemen-
tal analyser and CHNS on a Carlo Erba EA 1108 CHNS-O
microanalyser at the Microanalytical Laboratory of the
University of Vienna. Electrospray ionisation mass spec-
trometry was carried out with a Bruker Esquire 3000 instru-
ment (Bruker Daltonic, Bremen, Germany). Electron
impact mass spectra were measured on a Finnigan MAT
8230mass spectrometer (Bremen,Germany), with an ionisa-
tion energy of 70 eV. Expected and experimental isotope
distributions were compared. Infrared spectra were
obtained from KBr pellets with a Perkin–Elmer FT-IR
2000 instrument (4000–400 cm1). Abbreviations used for
IR spectra: s, strong; m, medium. UV/visible (UV/vis) spec-
tra were recorded on a Perkin–Elmer Lambda 650 UV/vis
spectrophotometer, using samples dissolved in methanol
(900–200 nm). For stability measurements the samples were
dissolved inDMSOanddilutedwithwater such that the ﬁnal
DMSO content was 1%. Thermogravimetric analysis (TGA)
and diﬀerential thermal analysis (DTA) measurements were
carried out simultaneously with a Mettler Toledo TGA/
SDTA851e apparatus, with a 3 C/min heating rate under
an air or nitrogen atmosphere. 1H, 13C, 15N and 77Se one-
and two-dimensional NMR spectra were recorded in
DMSO-d6 with a 500 MHz Bruker FT-NMR spectrometer
Avance III. The residual 1H and 13C present in DMSO-d6
were used as internal references. 15N and 77Se chemical shifts
were referenced relative to external ammonium chloride and
diphenyl diselenide, respectively. Abbreviations used for
NMR spectra: py = pyridine and Cq,py = quaternary pyri-
dine carbon, s, singlet, m, multiplet, d, doublet, br, broad.
2.2. Synthesis of the ligands
2.2.1. 2-Acetylpyridine N,N-dimethylsemicarbazone (1)
To N,N-dimethylsemicarbazide (1.00 g, 9.70 mmol) in 2-
propanol (10 mL) was added 2-acetylpyridine (1.10 mL,
9.82 mmol), and the mixture was stirred at 0 C for 20 h.
Then the solution was evaporated to dryness under reduced
pressure. To the remaining oily residue was added hexane
(60 mL), and the mixture was stirred at 0 C until a precip-
itate appeared. After 30 min the white solid was ﬁltered oﬀ,
washed with hexane and dried in vacuo. The bulk product
was found to be a mixture of E- and Z-isomers. Yield:
1.79 g (90%). Anal. Calc. for C10H14N4O (206.25): C,
58.24; H, 6.84; N, 27.17. Found: C, 57.82; H, 6.53; N,
26.80%. Re-crystallisation from 2-propanol aﬀorded the
pure E-isomer. Yield: 0.22 g (22%). Anal. Calc. for
C10H14N4O (206.25): C, 58.24; H, 6.84; N, 27.17. Found:
C, 58.52; H, 6.79; N, 27.42%. ESI MS (electrospray ionisa-
tion mass spectra) in MeOH (positive): m/z 229 [M+Na]+;
(negative): m/z 205 [M–H]. IR spectrum in KBr of the E-
isomer, cm1: 1653 (C@O) s, 1533 s, 1465 s, 1433 s, 1372 s,
N
N
N
H
N
X
HL1: X = O
HL2: X = S
HL3: X = Se
(1)
(2)
(3)
N
N
N
X
N
N
NN
X
M PF6
-
N
+
M = Ga, X = O; [Ga(L1)2][PF6] (4)
(5)
(6)
M = Ga, X = S; [Ga(L2)2][PF6]
M = Ga, X = Se; [Ga(L3)2][PF6]
M = Ru, X = S; [Ru(L2)2][PF6] (7)
Scheme 1.
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1184 s, 786 m. E-isomer: UV/vis (MeOH), kmax, nm
(e, M1 cm1): 213 (8060), 289 (14450), 388 (1380). E-iso-
mer: 1H NMR (500.10 MHz, DMSO-d6): d = 8.94 (s, 1H,
NH), 8.57 (m, 1H, py), 8.00 (m, 1H, py), 7.81 (m, 1H,
py), 7.36 (m, 1H, py), 2.97 (s, 6H, N(CH3)2), 2.32 (s, 3H,
CCH3).
13C NMR (125.81 MHz, DMSO-d6): d = 156.3
(C@O), 156.1 (Cq,py), 148.9 (Cpy), 148.6 (C@N), 136.8
(Cpy), 123.8 (Cpy), 120.2 (Cpy), 37.1 (N(CH3)2), 12.0
(CH3). Z-isomer:
1H NMR (500.10 MHz, DMSO-d6):
d = 14.57 (s, 1H, NH), 8.75 (m, 1H, py), 8.07 (m, 1H, py),
7.71 (m, 1H, py), 7.52 (m, 1H, py), 2.96 (s, 6H, N(CH3)2),
2.34 (s, 3H, CCH3).
13C NMR (125.81 MHz, DMSO-d6):
d = 155.1 (C@O), 153.3 (Cq,py), 147.8 (Cpy), 138.8 (Cpy),
137.9 (C@N), 124.4 (Cpy), 124.3 (Cpy), 36.2 (N(CH3)2),
22.3 (CH3). Single crystals suitable for X-ray diﬀraction
study were selected directly from the reaction vessel.
2.2.2. 2-Acetylpyridine N,N-dimethylthiosemicarbazone (2)
The ligand has been prepared following the literature
protocol [12]. EI MS, m/z (relative intensity): 222 (28.6),
[M]+Æ; 207 (26.5), [M–CH3]
+. E-isomer: 1H NMR
(500.10 MHz, DMSO-d6): d = 9.62 (s, 1H, NH), 8.59 (m,
1H, py), 8.06 (d, 3JH,H = 8.5 Hz, 1H, py), 7.82 (m, 1H,
py), 7.39 (m, 1H, py), 3.31 (s, 6H, N(CH3)2), 2.38 (s, 3H,
CCH3). Z-isomer:
1H NMR (500.10 MHz, DMSO-d6):
d = 15.42 (s, 1H, NH), 8.79 (m, 1H, py), 8.11 (m, 1H,
py), 7.80 (m, 1H, py), 7.58 (m, 1H, py), 3.34 or 3.30 (s,
6H, N(CH3)2), 2.39 (s, 3H, CCH3). E
0-isomer: 1H NMR
(500.10 MHz, DMSO-d6): d = 14.70 (s, 1H, NH), 8.74
(m, 1H, py), 8.00 (m, 1H, py), 7.87 (d, 3JH,H = 7.9 Hz,
1H, py), 7.53 (m, 1H, py), 3.34 or 3.30 (s, 6H, N(CH3)2),
2.64 (s, 3H, CCH3). Single crystals suitable for X-ray dif-
fraction study were selected directly from the reaction
vessel.
2.2.3. 2-Acetylpyridine N,N-dimethylselenosemicarbazone
(3)
The ligand has been prepared following the literature
protocol [13], but re-crystallised twice from dry ethanol.
Anal. Calc. for C10H14N4Se (269.21): C, 44.61; H, 5.24;
N, 20.81. Found: C, 44.38; H, 5.20; N, 20.57%. EI MS,
m/z (relative intensity): 270 (26.7), [M]+Æ; 255 (5.9),
[M–CH3]
+. IR spectrum in KBr, cm1: 1581 m, 1497 s,
1385 s, 1363 s, 1298 s, 1254 s, 1237 s, 781 s. UV/vis
(MeOH), kmax, nm (e, M
1 cm1): 250sh (6360), 305sh
(6120), 394 (11280). E-isomer: 1H NMR (500.10 MHz,
DMSO-d6): d = 9.82 (s, 1H, NH), 8.60 (m, 1H, py),
8.10 (m, 1H, py), 7.84 (m, 1H, py), 7.41 (m, 1H, py), 3.44
or 3.26 (br. s, 6H, N(CH3)2), 2.40 (s, 3H, CCH3).
13C
NMR (125.75 MHz, DMSO-d6): d = 181.6 (C=Se), 155.5
(Cq,py), 152.2 (C@N), 149.1 (Cpy), 137.1 (Cpy), 124.5
(Cpy), 120.7 (Cpy), 12.7 (CH3).
15N NMR (50.70 MHz,
DMSO-d6): d = 309.1 (C@N), 288.4 (Npy), 148.6
(1JN,H = 92 Hz, NH).
77Se NMR (95.39 MHz, DMSO-
d6): d = 127.3 ppm. Z-isomer: 1H NMR (500.10 MHz,
DMSO-d6): d = 15.61 (s, 1H, NH), 8.81 (m, 1H, py), 8.13
(m, 1H, py), 7.83 (m, 1H, py), 7.60 (m, 1H, py), 3.44 or
3.26 (br. s, 6H, N(CH3)2), 2.41 (s, 3H, CCH3).
13C NMR
(125.75 MHz, DMSO-d6): d = 180.3 (C@Se), 152.5 (Cq,py),
148.0 (Cpy), 141.7 (C@N), 139.3 (Cpy), 125.1 (Cpy), 124.9
(Cpy), 22.4 (CH3).
15N NMR (50.70 MHz, DMSO-d6):
d = 311.4 (C=N), 157.3 (NH). 77Se NMR (95.39 MHz,
DMSO-d6): d = 127.3 ppm. E 0-isomer: 1H NMR
(500.10 MHz, DMSO-d6): d = 14.60 (s, 1H, NH), 8.76
(m, 1H, py), 8.03 (m, 1H, py), 7.93 (d, 3JH,H = 7.9 Hz,
1H, py), 7.57 (m, 1H, py), 3.40 (s, 6H, N(CH3)2), 2.68 (d,
4JH,H = 1.1 Hz, 3H, CCH3).
13C NMR (125.75 MHz,
DMSO-d6): d = 183.5 (JC,Se = 202 Hz, C–Se), 150.4 (Cpy),
148.4 (Cq,py), 143.9 (C=N), 138.8 (Cpy), 126.1 (Cpy),
123.2 (Cpy), 44.5 (N(CH3)2), 14.8 (CH3).
15N NMR
(50.70 MHz, DMSO-d6): d = 276.4 (Npy), 229.4 (
1JN,H =
88 Hz, C@NH). 77Se NMR (95.39 MHz, DMSO-d6): d =
366.9 (JSe,H = 7.0 Hz) ppm. Crystals suitable for X-ray
data collection were obtained from chloroform saturated
with n-hexane.
2.3. Synthesis of the complexes
2.2.4. [Bis-(2-acetylpyridine N,N-
dimethylsemicarbazonato)-N,N,O-gallium(III)]
hexaﬂuorophosphate, [Ga(L1)2]PF6 (4)
To 2-acetylpyridine N,N-dimethylsemicarbazone (1)
(150 mg, 0.728 mmol) in ethanol (15 mL) at 0 C was
added solid Ga(NO3)3 Æ 8.15H2O (147 mg, 0.365 mmol).
The reaction mixture was stirred at 0 C for 1 h. To the
clear solution ammonium hexaﬂuorophosphate (120 mg,
0.736 mmol) in ethanol (2 mL) was added dropwise. After
15 min the yellow precipitate was ﬁltered oﬀ, washed with
cold ethanol and dried in vacuo. Yield: 0.12 g (53%). Anal.
Calc. for C20H26F6GaN8O2P (625.16): C, 38.42; H, 4.19;
N, 17.92. Found: C, 38.17; H, 4.12; N, 17.68%. ESI MS
in MeOH (positive): m/z 479, [GaL2]
+. IR spectrum in
KBr, cm1: 1603 m, 1575 s, 1550 s, 1404 s, 1230 s, 840 s
and 558 m (P–F). UV/vis (MeOH), kmax, nm (e,
M1 cm1): 220 (14990), 249 (7300), 304 (15810), 391
(41570). 1H NMR (500.10 MHz, DMSO-d6): d = 8.25 (m,
2H, py), 8.11 (d, 3JH,H = 7.9 Hz, 2H, py), 7.86 (m, 2H,
py), 7.57 (m, 2H, py), 3.13 and 2.86 (s, 12H, N(CH3)2),
2.70 (s, 6H, CCH3).
13C NMR (125.81 MHz, DMSO-d6):
d = 167.1 (C–O), 147.4 (Cq,py), 145.4 (Cpy), 143.7 (Cpy),
139.3 (C@N), 126.6 (Cpy), 123.2 (Cpy), 36.4 and 35.6
(N(CH3)2), 12.6 (CH3). Crystals suitable for X-ray data
collection were obtained from acetonitrile saturated with
diethyl ether.
2.2.5. [Bis-(2-acetylpyridine N,N-
dimethylselenosemicarbazonato)-N,N,Se-gallium(III)]
hexaﬂuorophosphate, [Ga(L3)2]PF6 (6)
To 2-acetylpyridine N,N-dimethylselenosemicarbazone
(3) (50 mg, 0.185 mmol) in ethanol (8 mL) at 50 C
Ga(NO3)3 Æ 8.15H2O (38 mg, 0.094 mmol) in ethanol
(2 mL) was added. The yellow-green solution was stirred
for 15 min and cooled to room temperature. After addition
of ammonium hexaﬂuorophosphate (60 mg, 0.368 mmol)
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in ethanol (1 mL) the reaction mixture was stirred for
15 min, and the yellow precipitate was ﬁltered oﬀ, washed
with ethanol (2 · 5 mL) and dried in vacuo. Yield: 52 mg
(75%). Anal. Calc. for C20H26F6GaN8PSe2 (751.08): C,
31.98; H, 3.49; N, 14.92. Found: C, 31.68, H, 3.51; N,
14.63%. ESI MS in MeOH (positive): m/z 607, [GaL2]
+;
ESI MS in MeOH (negative): m/z 145, [PF6]
. IR spectrum
in KBr, cm1: 1603 m, 1516 s, 1393 s, 1300 s, 1256 s,
843 s and 558 m (P–F). UV/vis (MeOH), kmax, nm (e,
M1 cm1): 225sh (20150), 250sh (11950), 311 (14870),
398 (30810). 1H NMR (500.10 MHz, DMSO-d6): d =
8.24–8.19 (m, 4H, py), 7.92 (d, 3JH,H = 5.0 Hz, 2H, py),
7.57 (m, 2H, py), 3.30 (br. s, 12H, N(CH3)2 partially super-
imposed with the water signal), 2.88 (s, 6H, CCH3).
13C
NMR (125.75 MHz, DMSO-d6): d = 173.8 (JC,Se = 165
Hz, C–Se), 149.0 (C@N), 145.4 (Cq,py), 144.4 (Cpy), 142.6
(Cpy), 127.7 (Cpy), 124.7 (Cpy), 42.9 and 39.3 (N(CH3)2),
15.6 (CH3).
77Se NMR (95.39 MHz, DMSO-d6): d =
371.7 ppm. Crystals suitable for X-ray data collection
were obtained from acetone saturated with n-hexane.
2.2.6. [Bis-(2-acetylpyridine N,N-
dimethylthiosemicarbazonato)-N,N,S-ruthenium(III)]
hexaﬂuorophosphate, [Ru(L2)2]PF6 (7)
To 2-acetylpyridine N,N-dimethylthiosemicarbazone (2)
(93 mg, 0.418 mmol) in methanol (5 mL) at 70 C
[(DMSO)2H][trans-RuCl4(DMSO)2] (100 mg, 0.180 mmol)
in methanol (5 mL) was added dropwise. The mixture
was stirred at 70 C for 3 h, cooled down to room temper-
ature and allowed to stand at 4 C overnight. Then
ammonium hexaﬂuorophosphate (70 mg, 0.429 mmol) in
methanol (2 mL) was added, and the reaction mixture
was stirred for 2 h. The black-green precipitate was ﬁltered
oﬀ, washed with cold methanol and dried in vacuo. Yield:
57 mg (47%). Anal. Calc. for C20H26F6N8PRuS2 (688.64):
C, 34.88; H, 3.81; N, 16.27; S, 9.31. Found: C, 34.84;
H, 3.87; N, 16.06; S, 9.14%. ESI MS in MeOH (positive):
m/z 544, [RuL2]
+. IR spectrum in KBr, cm1: 1559 s,
1550 s, 1507 s, 1399 s, 1310 s, 1251 s, 839 s and 558 m
(P–F). UV/vis (MeOH), kmax, nm (e, M
1 cm1): 245sh
(17690), 299sh (16280), 343sh (24540), 382 (29570), 460sh
(6340), 593 (1750), 771sh (600). Crystals suitable for
zX-ray data collection were obtained from chloroform sat-
urated with n-hexane.
2.4. Crystallographic structure determination
X-ray diﬀraction measurements were performed on an
X8APEX II CCD diﬀractometer at 100 K. Single crystals
were positioned at 40 mm from the detector and 1007,
1936, 4029, 1336, 1066 and 2203 frames were measured,
each for 10, 5, 10, 50, 10 and 20 s over 1 scan width for
1–4, 6 and 7, correspondingly. The data were processed
using SAINT software [14]. Crystal data, data collection
parameters, and structure reﬁnement details for 1–4, 6
and 7 are given in Table 1. The structures were solved by
direct methods and reﬁned by full-matrix least-squares
techniques. Non-hydrogen atoms were reﬁned with aniso-
tropic displacement parameters. H atoms were placed at
calculated positions and reﬁned as riding atoms in the sub-
sequent least squares model reﬁnements. The isotropic
thermal parameters were estimated to be 1.2 times the val-
ues of the equivalent isotropic thermal parameters of the
non-hydrogen atoms to which hydrogen atoms are bonded.
In complex 6 Æ 2(CH3)2CO one of the lattice acetone mole-
cules is disordered over two positions with site occupation
Table 1
Crystal data and details of data collection for 1–4, 6 and 7
Complex 1 2 3 4 Æ 0.5(C2H5)2O 6 Æ 2(CH3)2CO 7
Empirical formula C10H14N4O C10H14N4S C10H14N4Se C22H31F6GaN8O2.5P C26H38F6GaN8O2PSe2 C20H26F6N8PRuS2
Fw 206.25 222.31 269.21 662.22 867.25 688.64
Space group Pbca P1 P1 P1 P1 P21/c
a (A˚) 8.7233(6) 7.2207(2) 7.2858(2) 13.0897(7) 8.7651(8) 18.2142(4)
b (A˚) 15.4944(10) 7.9483(2) 8.0019(2) 15.6031(8) 13.3241(12) 18.5378(9)
c (A˚) 15.9332(12) 9.8302(3) 9.9160(3) 15.8977(7) 16.4686(15) 18.7028(11)
a () 86.676(2) 87.326(1) 64.375(3) 79.755(6)
b () 79.757(3) 78.797(1) 83.561(3) 74.596(6) 102.298(3)
c () 76.987(3) 76.898(2) 78.325(4) 71.971(6)
V (A˚3) 2153.6(3) 540.83(5) 552.33(3) 2865.9(2) 1753.6(3) 2782.6(3)
Z 8 2 2 2 2 4
k (A˚) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
qcalcd (g cm
3) 1.272 1.365 1.619 1.535 1.642 1.644
Crystal size (mm3) 0.75 · 0.45 · 0.30 0.36 · 0.28 · 0.28 0.40 · 0.26 · 0.24 0.20 · 0.20 · 0.05 0.40 · 0.25 · 0.15 0.57 · 0.20 · 0.20
T (K) 100 100 100 100 100 100
l (mm1) 0.087 1.365 3.372 1.535 2.975 0.837
R1
a 0.0386 0.0474 0.0177 0.0496 0.0380 0.0429
wR2
b 0.1117 0.1440 0.0479 0.1249 0.0891 0.1031
GOFc 1.024 1.116 1.005 1.010 1.002 1.192
a R1 ¼
P kF oj  jF ck=
P jF oj.
b wR2 ¼ f
P½wðF 2o  F 2cÞ2=
P½wðF 2oÞ2g1=2.
c GOF ¼ fP½wðF 2o  F 2cÞ2=ðn pÞg1=2, where n is the number of reﬂections and p is the total number of parameters reﬁned.
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factors (SOF) 0.60 and 0.40, respectively. In the asymmet-
ric unit of 4 Æ 0.5(C2H5)2O one of the two PF6 anions and
the lattice diethyl ether molecule are disordered over two
positions with SOF 0.862 and 0.138, 0.561 and 0.439,
respectively. The following computer programs were used:
structure solution, SHELXS-97 [15] reﬁnement, SHELXL-97
[16] molecular diagrams, ORTEP [17] computer: Pentium
IV. Scattering factors were taken from the literature [18].
2.5. Cell lines and culture conditions
Human 41M (ovarian carcinoma) and SK-BR-3 (mam-
mary carcinoma) cells were kindly provided by Lloyd R.
Kelland (CRC Centre for Cancer Therapeutics, Institute
of Cancer Research, Sutton, UK) and Evelyn Dittrich
(General Hospital, Medical University of Vienna, Austria),
respectively. Cells were grown in 75 cm2 culture ﬂasks
(Iwaki/Asahi Technoglass, Gyouda, Japan) as adherent
monolayer cultures in complete culture medium, i.e. mini-
mal essential medium (MEM) supplemented with 10%
heat-inactivated fetal bovine serum, 1 mM sodium pyru-
vate, 4 mM L-glutamine and 1% non-essential amino acids
(100·) (all purchased from Sigma–Aldrich, Vienna, Aus-
tria). Cultures were maintained at 37 C in a humidiﬁed
atmosphere containing 5% CO2.
2.6. Cytotoxicity tests in cancer cell lines
Antiproliferative eﬀects were determined by means of
a colorimetric microculture assay (MTT assay, MTT =
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide). Cells were harvested from culture ﬂasks by tryp-
sinization and seeded into 96-well microculture plates
(Iwaki/Asahi Technoglass, Gyouda, Japan) in densities of
4 · 103 cells/well, in order to ensure exponential growth
throughout drug exposure. After a 24 h pre-incubation,
41M and SK-BR-3 cells were exposed to serial dilutions
of the test compound in 200 lL/well complete culture med-
ium for 96 h under an atmosphere containing 5% CO2.
At the end of incubation, all media were replaced by
100 lL/well RPMI 1640 medium (supplemented with
10% heat-inactivated foetal bovine serum and 2 mM L-glu-
tamine) plus 20 lL/well MTT solution in phosphate-buf-
fered saline (5 mg/ml). After incubation for 4 h, the
medium/MTT mixtures were removed, and the formazan
crystals formed by the mitochondrial dehydrogenase activ-
ity of vital cells were dissolved in 150 lL DMSO per well.
Optical densities at 550 nm were measured with a micro-
plate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm to correct for unspeciﬁc absorption.
The quantity of vital cells was expressed in terms of T/C
values by comparison to untreated control microcultures,
and 50% inhibitory concentrations (IC50) were calculated
from concentration–eﬀect curves by interpolation. Evalua-
tion is based on means from at least three independent
experiments, each comprising six microcultures per concen-
tration level.
3. Results and discussion
3.1. Synthesis of ligands and metal complexes
The ligands used in this study for the preparation of gal-
lium(III) and ruthenium(III) complexes were synthesised
by three diﬀerent methods. Condensation of N,N-dimeth-
ylsemicarbazide with 2-acetylpyridine in 2-propanol at
0 C aﬀorded HL1 as a mixture of E- and Z-isomers (see
discussion of the NMR data). Re-crystallisation from
2-propanol aﬀorded the pure E-isomer, which was fur-
ther used for complexation with gallium(III). HL2 was
synthesised by multistep reactions ended up by substitution
of the S-methyl group of methyl-3-[1-(2-pyridyl)ethyli-
dene)hydrazinecarbothioate (compound A in Scheme 2)
by dimethylamine [12]. The third ligand HL3 was prepared
by methylation of HL2 with methyl iodide in the pres-
ence of a base, followed by replacement of the thiomethyl
group by selenium using sodium hydrogen selenide [13]
(Scheme 3):
The gallium complexes [Ga(L1–3)2]PF6 (4–6) were pre-
pared as yellow microcrystalline materials in 53–91% yield
by reaction of Ga(NO3)3 Æ 8.15H2O with the corresponding
2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazone
N
N
N
H
SCH3
S
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N
N
N
H
N
S
+   HN(CH3)2 +   CH3SH
(HL2)
Scheme 2.
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in 1:2 molar ratio in ethanol, followed by addition of an
excess of NH4PF6. The ruthenium(III) compound
[Ru(L2)2]PF6 (7) was obtained as a green-black powder in
47% yield, starting from (DMSO)2H[RuCl4(DMSO)2]
and an excess of HL2 in methanol with subsequent addition
of NH4PF6.
3.2. Electronic absorption spectroscopy
The UV/vis spectra of the metal-free ligands 1–3 and the
gallium complexes 4–6 are dominated by intraligand tran-
sitions associated with the pyridine ring, azomethine and
C@X (X = O, S, Se) portions of the ligands. The coordina-
tion of the ligands to the metal caused a very large increase
of the magnitude of the lowest energy band. In the case of
the semicarbazone ligand HL1 this is especially pro-
nounced, and an intensity increase by a factor of 30
can be observed upon coordination to gallium (Fig. 1).
This is presumably due to the increased length of the chro-
mophore in the complex compared to the small extent of
the electron density delocalisation in the metal-free ligand
which was also corroborated by the non-planar conforma-
tion of HL1 found by X-ray diﬀraction (Fig. 2). The ruthe-
nium(III) complex 7 displays a strong band at 382 nm with
an extinction coeﬃcient of about 30,000 and three weak
absorptions at 460 (sh, shoulder), 593 and 771 (sh) nm,
with extinction coeﬃcients of 6340, 1750 and
600 M1 cm1, respectively.
The aqueous solution behaviour with respect to hydro-
lysis of 4–7 was studied in DMSO/H2O 1:100 (v/v) at
298 K over 20 h by UV/vis spectroscopy. The complexes
5–7 were quite stable, as can be seen from their electronic
absorption spectra (Figs. S2–S4). In contrast the semicar-
bazone complex 4 showed a 25% decrease of the intensity
of the band with an absorption maximum at 391 nm
(Fig. S1).
3.3. Thermal behaviour
The thermal properties of 4–7 have been studied by ther-
mogravimetric analysis (TGA) measurements between 25
and 500 C in air. The TG curves showed all complexes
to be non-solvated. Complexes 4–6 are all stable up to
240 C. Above this temperature begins the decomposition
of the complexes, which is not accompanied by signiﬁcant
exothermic or endothermic eﬀects. Complex 4 measured
under a nitrogen atmosphere showed a similar decomposi-
tion proﬁle with that obtained in air. The ruthenium com-
plex 7 measured in air is slightly less stable (decomposition
begins at 220 C). A large endothermic peak attributed to
the pyrolysis of the complex can be observed on the
DTA curve at about 400 C.
3.4. Mass spectrometry
The ESI mass spectrum of HL1 recorded in the positive
ion mode showed a peak at m/z 229 due to [M+Na]+, while
in the negative mode a peak at m/z 205 attributed to
[MH] was observed. For the metal-free thio- and sele-
nosemicarbazones (HL2 and HL3) the ESI mass spectra
exhibited only small peaks due to [M+Na]+ and a few
peaks also at higher m/z, which have not been identiﬁed.
However, both ligands studied by EI MS displayed molec-
ular ion peaks [M]+Æ at m/z 270 and 222 with relative inten-
sities of 28.6% and 26.7%, respectively. The positive ion
ESI mass spectra of the gallium(III) complexes 4 and 6
as well as the ruthenium complex 7 showed strong peaks
attributable to [ML2]
+ at m/z 479, 607 and 544, corre-
spondingly. The counterion PF6 is easily detectable in
the negative ion mode at m/z 145. The isotopic patterns
of all identiﬁed signals ﬁt well with the theoretical isotopic
distributions.
3.5. 1H, 13C, 15N and 77Se NMR spectroscopy
The 1H NMR spectra of the three ligands in DMSO-d6
indicate that they are all isomeric mixtures. The metal-free
thio- and selenosemicarbazones (HL2 and HL3) show each
three sets of signals. The selenosemicarbazone ligand was
Fig. 1. The electronic absorption spectra of HL1 (solid line) and
[Ga(L1)2][PF6] (dashed line) in methanol.
Fig. 2. ORTEP plot of HL1 with atom numbering scheme. The thermal
ellipsoids are drawn at 50% probability level. Selected bond lengths (A˚)
and bond angles (): C6–N2 1.2901(19), N2–N3 1.3793(17), N3–C8
1.3872(19), C8–O1 1.2426(19), C8–N4 1.358(2); N1–C5–C6–N2
154.43(14), N2–N3–C8–O1 14.3(2).
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studied in detail by one- and two-dimensional NMR spec-
troscopy to get further information about the isomers pres-
ent in solution. Besides measurements of 1H, 13C and 15N
nuclei, investigation of HL3 oﬀers the possibility of getting
chemical shift information of the 77Se nucleus (spin 1/2,
7.6% natural abundance).
The most remarkable diﬀerences caused by the presence
of diﬀerent isomeric forms were observed in the 1H NMR
spectrum of HL3 for the N–H signals at 9.82, 14.60 and
15.61 ppm, respectively, with relative intensities 0.4:1:0.1;
the strong downﬁeld shifts to 14.60 and 15.61 ppm are
accounted for by involvement of N–H in intramolecular
hydrogen bonding. Assignment of the signals to the respec-
tive E- and Z-isomers of HL3, was based on a 1H,
1H-NOESY (nuclear Overhauser and exchange spectros-
copy) spectrum, the 1H chemical shift of the NH moieties
and additionally on the remarkable shift diﬀerences of
the 13C NMR resonances of the 2-acetylpyridine methyl
group.
In the 1H, 1H NOESY spectrum, a correlation between
the N–H signal at 9.82 ppm and the methyl group protons
of the 2-acetylpyridine moiety at 2.40 ppm was detected,
being an expected feature of the E-isomer (Scheme 4). This
result is also in line with N–H chemical shifts for E-conﬁg-
ured thiosemicarbazones reported by other authors [19].
The Z-isomer displaying the N–H resonance at
15.61 ppm shows a distinctive shift of the 13C NMR signal
of the 2-acetylpyridine methyl group (22.4 ppm) in compar-
ison to the E-isomer (12.7 ppm). This diﬀerence can be
explained by the c-eﬀect [20], which implies that the change
of the chemical environment at the hydrazinic N–H has a
marked inﬂuence on the carbon atom in c-position, in
our case the 2-acetylpyridine methyl group.
Both, the E- as well as the Z-isomer gave rise to compa-
rable shift correlation signals in the two-dimensional 1H,
15N NMR spectra, which were available via one-bond
HSQC (heteronuclear single quantum coherence) and
long-range HMBC (heteronuclear multiple bond correla-
tion) experiments. The azomethine nitrogens showed reso-
nances at 311.4 and 309.1 ppm (E- and Z-isomer),
respectively, whereas signals of NH nitrogen atoms were
found at 157.3 and 148.6 ppm. For the E-species, a typical
1JN,H coupling of 92 Hz was detected. In the
77Se NMR
spectrum, a broad resonance of the E isomers was detected
at 127.3 ppm, probably superimposing with the signal of
the least abundant Z isomer. This chemical shift is in the
range of the values documented in the literature for seleno-
urea derivatives [21].
The most abundant in DMSO-d6 is the third isomer of
HL3. In the 1H NMR spectrum, a doublet at 2.68 ppm
(JH,H = 1.1 Hz) of the 2-acetylpyridine methyl group was
detected, but the coupling partner could not easily be
assigned. In a long-range 1H, 1H-COSY (correlation spec-
troscopy) experiment (optimised for very small JH,H val-
ues) coupling to the broad N–H proton signal at d 14.60
was found and additionally veriﬁed via a homonuclear
decoupling experiment. Irradiation of the N–H proton at
14.60 ppm led to disappearing of the splitting of the methyl
group protons at 2.68 ppm in accordance with the chemical
structure of isomer E 0 (Scheme 4). Further evidence for the
E 0 structure was obtained from 1H, 15N correlated NMR
spectra. The 15N chemical shift of the quaternary NH res-
onance at 229.4 ppm (typical 1JN,H coupling of 88 Hz) was
signiﬁcantly diﬀerent to those of the E- and Z-isomers
(157.3 and 148.6 ppm). In addition, a strong cross-peak
between the 2-acetylpyridine methyl group and the NH
proton at d 14.60 could be found in the long-range 1H,
15N HMBC spectrum.
The second signal at d 366.9 ppm (besides the broad
signal at 127.3 ppm for the E- and Z-isomer), observed
for HL3 in the directly measured 77Se NMR spectrum with-
out proton decoupling, was sharp (when compared to the
ﬁrst one) and splitted into a doublet with a coupling con-
stant of J = 7.0 Hz (Fig. S5). Coupling to a neighbouring
proton was proven via (i) measurement of a proton decou-
pled 77Se NMR spectrum and (ii) a 1H, 77Se COSY exper-
iment showing a correlation signal to the NH proton at
14.60 ppm and indicating that the splitting is due to a
NHÆÆÆSe interaction (Fig. S6). These ﬁndings are in good
agreement with 77Se–1H coupling constants for NHÆÆÆSe
hydrogen bonds (J = 5.4–13.1 Hz) reported by other
authors [22,23], providing strong evidence that the set of
signals with the N–H proton at 14.60 ppm can be attrib-
uted to the E 0-isomer (Scheme 4).
It is known that the thiosemicarbazone ligand HL2
exists in CDCl3 solution in three isomeric forms [24]. We
found three sets of signals with relative intensities
1:0.6:0.3 for E, E 0 and Z isomers in DMSO-d6. In contrast,
the 1H NMR spectrum of the prepared semicarbazone
ligand HL1 in DMSO-d6 showed only two sets of signals,
with varying ratios of relative intensities (0.5–1:1). The
two N–H resonances were observed at 14.57 and
8.94 ppm, respectively. However, the sample re-crystallised
from 2-propanol showed only one set of signals with N–H
at 8.94 ppm. This set of signals was also found in the 1H
NMR spectrum of the single crystal characterised by X-
ray crystallography (vide infra) and undoubtedly attributed
to the E-isomer. The 13C NMR spectrum of the E-isomer
showed a signal of the 2-acetylpyridine methyl group at
12.0 ppm, compared to 22.3 ppm for the second set of sig-
nals. This result together with the downﬁeld shift of the N–
H signal provided evidence for Z-conﬁguration of the sec-
ond isomer. Evaporation of the mother liquor after separa-
tion of the E-isomer and addition of hexane resulted in
enrichment of the mixture by the Z-isomer (observed ratio
N
N
N
H
N
X
N
N
N
X
N
N
N
N N
XHH
E-isomer E´-isomerZ-isomer
Scheme 4.
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1.4:1). Measurements after 24 h showed the same ratio of
the species present in solution, indicating that no isomerisa-
tion occurred with time. The existence of two isomers of
the semicarbazone, not only in solution but also in the solid
state, was conﬁrmed by the two C@O stretching vibrations
at 1658 and 1653 cm1 in the IR spectra of the bulk
product. The ﬁrst one disappeared after re-crystallisation
of the mixture from 2-propanol.
In contrast to the metal-free ligands, the 1H NMR spec-
tra of complexes 4–6 showed only one set of signals due to
stabilisation of ligand conﬁguration upon coordination to
the metal and the equivalence of both ligands bound to gal-
lium(III) in solution. The most remarkable diﬀerence
between the 1H NMR spectra of the gallium(III) complexes
4–6 and those of the metal-free ligands is the absence of
any NH signal for 4–6, indicating deprotonation of the
ligands upon complexation. This is in good agreement with
the 77Se NMR spectrum of 6 with a resonance at d
371.7 ppm, well comparable with the chemical shift for
the E 0-isomer of the metal-free ligand HL3.
3.6. X-ray crystallography
The result of X-ray diﬀraction study of HL1 is shown in
Fig. 2. Selected bond distances (A˚) and angles are quoted in
the legend to Fig. 2. HL1 crystallised in the orthorhombic
space group Pbca and adopted an essentially non-planar
conformation, so that the atoms N2, N3, O1 and N4 come
out from the mean plane of the pyridine ring by 0.566,
0.604, 2.427 and 1.361 A˚, correspondingly. The C8–O1
and N2–N3 bond lengths of 1.2426(19) and 1.3793(17) A˚
are equal within 3r with those reported for acetone semi-
carbazone [25] at 1.242(2) and 1.385(2) A˚, correspondingly.
The crystal structure showed an intermolecular hydrogen
bonding interaction between the atom N3 as proton donor
and atom O1i of the neighbouring molecule as proton
acceptor with the following parameters: N3–H 0.863,
H  O1i 2.183, N3  O1 3.028 A˚ and \N3–H  O1
166.24 [symmetry code (i) x+0.5, y, –z+1]. An essentially
planar conformation of HL1 was found in HL1 Æ CH3OH,
in which a hydrogen bonding interaction between the mol-
ecule of methanol as proton donor and the C@O group of
the semicarbazone ligand as proton acceptor was found
(Fig. S1).
HL2 and HL3 crystallise in the triclinic space group P1.
The ligands adopt the E 0-isomeric form in the nomencla-
ture of the conformations of thiosemicarbazones derived
from 2-acetylpyridine [26]. This conformation is diﬀerent
from that found in 2-acetylpyridine N(4)-alkylthiosemicar-
bazone (non-hydrogen bonding isomer E), where
alkyl = methyl [27], ethyl [26]. The nitrogen atom N2 in
both HL2 and HL3 acts as proton donor to both the pyri-
dine nitrogen atom N1 and the chalcogen atom (S or Se) to
give a bifurcated arrangement. The parameters of the bifur-
cated hydrogen bond in HL2 and HL3 are as follows: N2–
H 0.88, H  N1 2.26, N2  N1 2.660(3) A˚, \N2–H  N1
107.2; H  S 2.37, N2  S 2.864(2) A˚, \N2–H  S 115.7
and N2–H 0.88, H  N1 2.26, N2  N1 2.6578(14) A˚,
\N2–H  N1 107.3; H  Se 2.44, N2  Se 2.9593(10) A˚,
\N2–H  Se 118.6. It is also worth noting that a search
in the CSD [28] revealed that HL3 is the ﬁrst metal-free
selenosemicarbazone characterised by X-ray diﬀraction
(see Fig. 4).
Fig. 4. ORTEP plot of HL3 with atom numbering scheme. The thermal
ellipsoids are drawn at 50% probability level. Selected bond lengths (A˚)
and bond angles (): C6–N2 1.3004(15), N2–N3 1.3524(14), N3–C8
1.3431(15), C8–Se 1.8788(11), C8–N4 1.3471(15); N1–C5–C6–N2 5.57(15),
N2–N3–C8–Se 2.35(14).
Fig. 5. ORTEP plot of the ﬁrst independent cation [GaIII(L1)2]
+ in 4 with
atom numbering scheme. The thermal ellipsoids are drawn at 50%
probability level. Selected bond lengths (A˚) and bond angles (): Ga1–N1
2.077(3), Ga1–N5 2.081(3), Ga1–N2 2.003(3), Ga1–N6 1.989(3), Ga1–O1
1.968(3), Ga1–O2 1.967(3), C6–N2 1.288(5), C16–N6 1.300(5), N2–N3
1.375(4), N6–N7 1.370(4), N3–C8 1.353(5), N7–C18 1.356(5), C8–O1
1.289(5), C18–O2 1.300(5), C8–N4 1.364(4), C18–N8 1.354(5) A˚; \N1–
Ga1–N2 78.27(13), \N5–Ga1–N6 78.92(13), \N2–Ga1–O1 78.74(13),
N6–Ga1–O2 78.97(13).
Fig. 3. ORTEP plot of HL2 with atom numbering scheme. The thermal
ellipsoids are drawn at 50% probability level. Selected bond lengths (A˚)
and bond angles (): C6–N2 1.299(3), N2–N3 1.354(3), N3–C8 1.350(4),
C8–S 1.723(3), C8–N4 1.351(4); N1–C5–C6–N2 6.42(36), N2–N3–C8–S
2.14(34).
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The asymmetric unit of 4 Æ (C2H5)2O comprises two
crystallographically independent enantiomeric cations
[Ga(L1)2]
+ with the same chirality at the gallium center,
two PF6 anions and one disordered diethyl ether molecule.
The structure of the ﬁrst independent cation is displayed in
Fig. 5. The gallium atom is coordinated by the two approx-
imately planar tridentate ligands, in contrast to the non-
planar conformation of the metal-free semicarbazone
HL1 (Fig. 2). The coordination polyhedron approaches
an octahedron, where the two ligands are bound to Ga
through a nitrogen atom of the pyridine ring and a nitro-
gen and an oxygen atom of the semicarbazide moiety.
The bonds C8–O1 of 1.289(5) and C18–O2 of 1.300(5) A˚
are longer compared to the analogous bond in HL1
[1.2426(19)], indicating the more pronounced single-bond
character of these bonds in 4. Note that the angles \N1–
Ga1–O1 at 156.81(12) and \N5–Ga1–O2 at 157.22(22)
deviate markedly from the ideal value of 180, whereas
\N6–Ga1–N2 at 176.86(14) is close to 180.
Complex 6 Æ 2(CH3)2CO crystallises in the triclinic space
group P1. The unit cell consists of a racemic mixture of the
two enantiomers of chiral octahedral [Ga(L3)2]
+ complex
cations, two counter anions PF6 and two lattice acetone
molecules. The structure of the complex cation is shown
in Fig. 6. Each ligand is monodeprotonated and coordi-
nates to gallium via the pyridine nitrogen atom and nitro-
gen and selen donors of the selenosemicarbazide moiety,
forming two ﬁve-membered metallocycles, correspond-
ingly. Selected bond distances and bond angles are given
in the legend to Fig. 6. The bond distances C8–Se1 of
1.914(3) and C18–Se2 of 1.907(4) A˚ are comparable to that
reported for [FeL2][FeCl4] (HL = 2-acetylpyridine-3-azabi-
cyclo[3.2.2]nonylselenosemicarbazone) [29] of 1.928(11) A˚
and are longer than that of the metal-free selenosemicar-
bazone HL3 at 1.8788(11) A˚. As for the semicarbazone
complex 4, the angles \N1–Ga–Se1 at 159.98(8) and
\N5–Ga–Se2 at 159.64(8) deviate markedly from the
ideal value of 180, in contrast to \N2–Ga–N6 at
168.79(12) which is about 8 smaller than the correspond-
ing angle in complex 4. Interestingly these values are quite
similar to those found in the analogous thiosemicarbazone
complex [Ga(L2)2][GaCl4] [30] [\N1–Ga–S1 at 158.89(9),
\N5–Ga–S2 at 160.12(7) and \N2–Ga–N6 at
171.18(9)]. Of note are the large diﬀerences between
\Ga1–O1–C8 at 111.8(3) and \Ga1–X–C8 (X = S, Se)
at 94.16(11) and 90.65(11), respectively, which are due to
large variations in C@X (X = O, S, Se) bond lengths. In
contrast the \Ga–N1–C5 diﬀers in all three structures only
within 3. The search of CSD [28] showed that this is the
ﬁrst gallium(III) selenosemicarbazonate characterised by
X-ray diﬀraction.
Compound 7 crystallises in the monoclinic space group
P21/c as a racemic mixture of the two enantiomers of the
chiral octahedral ruthenium(III) complex. The ruthe-
nium(III) ion is coordinated by the two almost planar tri-
dentate ligands, which are monodeprotonated (vide infra)
and adopt the same conformation as in the metal-free state
(Fig. 7). Each ligand is bound to ruthenium through a
nitrogen atom of the pyridine ring, a nitrogen atom and
a sulfur atom of the thiosemicarbazide moiety. The bond-
ing distances of ruthenium to the nitrogen atoms of the
pyridine rings (Ru–N1 and Ru–N5) are equal within 3r
and signiﬁcantly (P18r) longer than those of ruthenium
to nitrogen atoms in the thiosemicarbazide moieties
(Ru–N2 and Ru–N6). The interatomic distances Ru–S1
and Ru–S2 (2.2852(10) and 2.2805(11) A˚) are signiﬁcantly
longer than that found in [RuIIICl2(L)(PPh3)] at 2.2513(12)
A˚ with HL = phenanthrenquinone thiosemicarbazone, but
clearly shorter than those observed for ruthenium(II) com-
plexes [RuIICl(L)(PPh3)2] at 2.3608(14) A˚ (HL = phenan-
threnquinone thiosemicarbazone) or [RuIICl(L2)(PPh3)2] Æ
3CH2Cl2 at 2.3725(13) A˚ [31]. The bond distances C8–S1
Fig. 6. ORTEP plot of [GaIII(L3)2]
+ in 6 with atom numbering scheme.
The thermal ellipsoids are drawn at 50% probability level. Selected bond
lengths (A˚) and bond angles (): Ga–N1 2.134(3), Ga–N5 2.110(3), Ga–N2
2.080(3), Ga–N6 2.077(3), Ga–Se1 2.4908(6), Ga–Se2 2.4856(6), C6–N2
1.300(4), C16–N6 1.302(5), N2–N3 1.359(4), N6–N7 1.376(4), N3–C8
1.339(4), N7–C18 1.331(5), C8–Se1 1.914(3), C18–Se2 1.907(4), C8–N4
1.341(4), C18–N8 1.371(5) A˚; \N1–Ga–N2 77.02(11), \N5–Ga–N6
76.65(12), \N2–Ga–Se1 83.58(8), \N6–Ga–Se2 83.74(9).
Fig. 7. ORTEP plot of [RuIII(L2)2]
+ in 7 with atom numbering scheme.
The thermal ellipsoids are drawn at 40% probability level. Selected bond
lengths (A˚) and bond angles (): Ru–N1 2.077(3), Ru–N5 2.087(3), Ru–N2
2.005(3), Ru–N6 2.006(3), Ru–S1 2.2852(10), Ru–S2 2.2805(11), C6–N2
1.307(6), C16–N6 1.310(5), N2–N3 1.370(5), N6–N7 1.370(5), N3–C8
1.321(7), N7–C18 1.322(5), C8–S1 1.773(5), C18–S2 1.766(4), C8–N4
1.338(6), C18–N8 1.342(5) A˚; \N1–Ru–N2 78.10(14), \N5–Ru–N6
78.18(13), \N2–Ru–S1 83.09(11), \N6–Ru–S2 83.29(10).
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and C18–S2 (1.773(5) and 1.766(4) A˚, respectively) are
more than 8r longer than that in metal-free thiosemicarba-
zone HL2 (1.723(3) A˚), indicating an increased single-bond
character of the C–S bonds in [RuIII(L2)2]PF6. The distri-
bution of electron density over thiosemicarbazide moieties
(see legend to Fig. 3) along with the presence of the PF6
counter anion are in agreement with the monodeprotonat-
ed nature of the coordinated ligands and formal oxidation
state 3+ of ruthenium in 7. The hexaﬂuorophosphate anion
was found to be disordered over two positions with P–F
bond lengths typical for this species [32].
3.7. Antiproliferative activity in cancer cell lines
The cytotoxic potencies of the seleno- and semicarba-
zone ligands HL1 and HL3 and their gallium(III) com-
plexes as well as the ruthenium(III) complex of the
thiosemicarbazone HL2 were compared with the previously
characterised metal-free thiosemicarbazone HL2 and the
gallium(III) complex [Ga(L2)2][PF6] (5) [9] in the human
tumour cell lines 41M (ovarian carcinoma) and SK-BR-3
(mammary carcinoma) by means of the colorimetric
MTT assay. All complexes and the ligands show high cyto-
toxic potencies, with IC50 values ranging from picomolar to
low micromolar concentrations (Table 2). As for the thio-
semicarbazone compounds reported in a previous article
[9], their concentration–eﬀect curves are rather ﬂat, with
a slope extending over a range of two to three orders of
magnitude (Fig. 8).
Themain purpose of this work was to explore the eﬀect of
the chalcogen atom (O, S, Se) in (chalcogen)semicarba-
zones, and in the corresponding complexes, on their cytotox-
icity. Among the several publications concerning the
biological activity of selenosemicarbazones and semicarbaz-
ones [13,33–35], only a few focus on antineoplastic eﬀects.
The eﬀect of the chalcogen on the activity of ligands 1–3
and gallium(III) complexes 4–6 is very pronounced (Fig. 8).
The cytotoxicity increases with the atomic number of the
chalcogen. The highest cytotoxicity is observed with the
selenosemicarbazones with IC50 values in low picomolar
concentrations, followed by the thiosemicarbazones in the
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Fig. 8. Concentration–eﬀect curves of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones (1–3) (white symbols), their gallium(III) complexes
[GaL2][PF6] (4–6) (black symbols) and ruthenium(III) complexes [RuL2][PF6] (7) (grey symbols), obtained by the MTT assay in 41M cells (left panels: a, c)
and SK-BR-3 cells (right panels: b, d). Values are means ± standard deviations from at least three independent experiments.
Table 2
Antiproliferative activity of a-N-heterocyclic (chalcogen) semicarbazones,
their gallium(III) and ruthenium(III) complexes in two human cancer cell
lines
Compounds IC50
a (nM)
41M SK-BR-3
Ligands 1 5800 ±1100 8500 ±4300
2b 0.22 ±0.14 2.7 ±1.4
3 0.010 ±0.001 0.21 ±0.10
Ga complexes 4 4800 ±900 5000 ±2300
5b 0.053 ±0.018 0.56 ±0.47
6 0.0045 ±0.00002 0.069 ±0.038
Ru complex 7 910 ±170 580 ±30
a 50% inhibitory concentrations in 41M and SK-BR-3 cells after expo-
sure for 96 h in the MTT assay. Values are means ± SD obtained from at
least three independent experiments.
b Values taken from Ref. [9].
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pico- to nanomolar range and the semicarbazones in the
low micromolar range. The diﬀerence between the poten-
cies of the selenosemicarbazone HL3 and the thiosemicar-
bazone HL2 is about 13–22-fold depending on the cell
line. The IC50 values of thiosemicarbazone HL
2 and semi-
carbazone HL1 diﬀer by at least three and up to ﬁve orders
of magnitude (3100–65000) (Fig. 8).
We previously showed that the cytotoxic potency
increases when a-N-heterocyclic thiosemicarbazones are
bound to gallium(III) [9]. In the case of 2-acetylpyridine-
N,N-dimethylsemicarbazone HL1 and 2-acetylpyridine-
N,N-dimethylselenosemicarbazone HL3, this shift in
cytotoxicity is less pronounced. The selenosemicarbazone
HL3 shows a 2–3 times lower activity than its correspond-
ing gallium(III) complex (6), while the eﬀect of complexa-
tion is small in the case of the semicarbazone HL1 and its
gallium complex (4). The lower stability of 4 in water could
be a reasonable explanation, as the complex most probably
dissociates to some extent within the time period of the
experiment.
Although the eﬀect of certain metal ions on the biolog-
ical activity of thiosemicarbazones is well documented,
there are only a few publications on complexes with ruthe-
nium(III) [31,36,37]. The ruthenium(III) compound 7 that
was tested in this work shows a large shift of IC50 to 0.9
and 0.58 lM in 41M and SK-BR-3 as compared to the
ligand HL2 (0.22 and 2.7 nM, respectively). This is a 4100
times lower cytotoxicity than that of the uncomplexed
ligand and even 17000 times lower than that of the gal-
lium(III) complex 5 in 41M cells. In SK-BR-3 cells, the
eﬀect on the cytotoxicity is somewhat less pronounced,
with IC50 values diﬀering by factors of 210 and 1000 in
comparison to thiosemicarbazone 2 and gallium(III) com-
pound 5, respectively. Remarkably the ruthenium(III)
complex shows IC50 values in the same order of magnitude
as the iron(III) complex (0.126 lM in 41M cells and
0.45 lM in SK-BR-3 cells) studied previously [9]. This
result conﬁrms our assumption of the positive inﬂuence
of gallium(III) on the cytotoxicity of N,N-disubstituted a-
N-heterocyclic thiosemicarbazones in comparison to other
metal ions. The eﬀect of ruthenium(III) is comparable to
that of iron(III), which might be due to their reasonable
stability upon chelation by the thiosemicarbazones and
the similar reactivity proﬁles.
4. Conclusions
The ﬁrst gallium(III)-semicarbazone and gallium(III)-
selenosemicarbazone complexes have been synthesised
and characterised by X-ray crystallography. These prepa-
rations along with the synthesis of the ruthenium(III) com-
plex with a thiosemicarbazone ligand with the same
stoichiometry as for gallium(III) made it possible to study
the eﬀect of metal ion complexation and chalcogen donor
identity on the antiproliferative activity of 2-acetylpyri-
dine-N,N-dimethyl(chalcogen)semicarbazones. The anti-
proliferative activity of chalcogensemicarbazones was
found to be strongly dependent on the identity of the chal-
cogen atom (O, S, Se) changing in the order
HL1  HL2 < HL3 in both cancer cell lines (41M and
SK-BR-3). A similar trend was found for the correspond-
ing gallium(III) complexes: [Ga(L1)2]
+  [Ga(L2)2]+ <
[Ga(L3)2]
+. Although the antiproliferative activity of the
gallium complexes prepared is primarily determined by
that of the corresponding chalcogensemicarbazones, the
eﬀect of complexation to gallium is obvious. In all cases
enhancement of cytotoxicity is observed when going from
metal-free ligands HL1–3 to the corresponding gallium
complexes [Ga(L1–3)2]
+. The rather small enhancement of
the cytotoxicity of [Ga(L1)2]
+ as compared to HL1 is prob-
ably caused by dissociation (to certain extent) of the com-
plex in the cell culture medium, as evidenced by UV/vis
measurement of aqueous solution of this complex. The
eﬀect of complexation of HL2 to ruthenium(III) is opposite
to that of binding to gallium(III). Taking into account our
previous results on the cytotoxicity of HL2, [Ga(L2)2]
+, and
[Fe(L2)2]
+, the eﬀect of ruthenium(III) appears to be com-
parable with or even somewhat more attenuating than that
of iron(III), resulting in the following rank order:
[Ru(L2)2]
+ 6 [Fe(L2)2] HL2 < [Ga(L2)2]+.
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UV/vis stability measurements 
Figure S1. UV/vis spectroscopy data of 4 in DMSO/H2O 1 : 100. First measurement 
(black), after 5 h (red), after 10 h (green), after 15 h (blue) and after 20 h (cyan). 
Figure S2. UV/vis spectroscopy data of 5 in DMSO/H2O 1 : 100. First measurement 
(red), after 15 h (blue). 
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Figure S3. UV/vis spectroscopy data of 6 in DMSO/H2O 1 : 100. First measurement 
(red), after 20 h (blue). 
Figure S4. UV/vis spectroscopy data of 7 in DMSO/H2O 1 : 100. First measurement 
(red), after 20 h (blue). 
S3
71
1H-77Se COSY and 77Se NMR spectrum
-363 -364 -365 -366 -367 -368 -369 -370 -371 ppm
Figure S5. 77Se NMR spectrum of the E´-isomer of HL3 displaying a doublet at 366.9
ppm (J= 7 Hz) 
ppm
13.814.014.214.414.614.815.015.215.4 ppm
-330
-340
-350
-360
-370
-380
-390
-400
-410
-420
Figure S6. 1H,77Se COSY NMR spectrum of the E´-isomer of HL3.
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Crystal data and discussion of the structure of 1·CH3OH
The ligand adopts a conformation with the C5N1 bond of the pyridine ring trans to the 
azomethine bond C6N2. The N2N3 distance of 1.378(2) Å is comparable to those 
found in 2HL·[Zn(H2O)6]ClO4[ ]i  of 1.355(4) and 1.354(4) Å, where HL = 2-
formylpyridine-N-oxide semicarbazone and it is shorter than the accepted length of single 
NN bond (1.45 Å),[ ]ii  indicating some extent of electron density delocalisation over the 
semicarbazide moiety. The double bond nature of the C8O1 bond is also evident 
[1.228(2) Å]. The ligand crystallizes with a methanol molecule involved in two 
intermolecular hydrogen bonding interactions. As a proton donor O2 forms the hydrogen 
bond O2H···O1 [O2H 0.84, H···O1 1.92, O2···O1 2.726(3) Å, O2H···O1 160.0°] and 
as proton acceptor the H bond O2···HN3 (x + 2, y, z + 1) [O2···H 2.56, O2···N3 
3.149(3), HN3 0.88 Å, O2···HN3 125.3°].
Figure S7. ORTEP plot of HL1·CH3OH with atom numbering scheme. The thermal 
ellipsoids are drawn at 40% probability level. Selected bond lengths (Å) and bond angles 
(deg): C6N2 1.282(3), N2N3 1.378(2), N3C8 1.376(3), C8O1 1.228(2), C8N4
1.349(3); N1C5C6N2 167.1(2), N2N3C8O1 2.7(3)°.
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X-ray diffraction measurements were performed on an X8APEX II CCD diffractometer 
at 293 K. The single crystal of 1·CH3OH was positioned at 40 mm from the detector and 
1014 frames were measured, each for 10 s over 1° scan width. 
Table S1. Crystal data and details of data collection for 1·CH3OH.
Complex 1·CH3OH
empirical 
formula 
C11H18N4O2
Fw 238.29 
Space
group 
P21/n
a, Å 10.7324(7) 
b, Å 8.5870(5) 
c, Å 14.5715(9) 
deg 
, deg 104.488(4) 
 deg 
V, Å3 1300.19(14) 
Z 4
	, Å 0.71073 

calcd, g 
cm-3
1.217 
crystal
size,
mm3
0.30 × 0.16 
× 0.16 
T, K 293 
, mm-1 0.086 
R1a 0.0510 
wR2b 0.1682 
GOFc 1.030 
a R1 = Fo - Fc/Fo, b wR2 = {[w (Fo2 - Fc2)2] /[w(Fo2)2 ]}1/2. c GOF = {[w(Fo2 - 
Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total number of 
parameters refined. 
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An Electrochemical Study of Antineoplastic Gallium, Iron and
Ruthenium Complexes with Redox Noninnocent r-N-Heterocyclic
Chalcogensemicarbazones
Christian R. Kowol,† Erwin Reisner,*,†,‡ Ion Chiorescu,† Vladimir B. Arion,*,† Markus Galanski,†
Dirk V. Deubel,† and Bernhard K. Keppler†
Institute of Inorganic Chemistry, UniVersity of Vienna, Wa¨hringerstrasse 42,
A-1090 Vienna, Austria, and Inorganic Chemistry Laboratory, UniVersity of Oxford,
South Parks Road, Oxford OX1 3QR, U.K.
Received July 16, 2008
The electrochemical properties of a series of R-N-heterocyclic chalcogensemicarbazones (HL), namely, thiosemi-
carbazones, selenosemicarbazones, and semicarbazones, and their gallium(III), iron(III), and ruthenium(III) complexes
with the general formula [ML2][Y] (M ) Ga, Fe or Ru; Y ) PF6-, NO3-, or FeCl4-) were studied by cyclic voltammetry.
The novel compounds were characterized by elemental analysis, a number of spectroscopic methods (NMR, UV-vis,
IR), mass spectrometry and by X-ray crystallography. All complexes show several, mostly reversible, redox waves
attributable to the reduction of the noninnocent chalcogensemicarbazone ligands at lower potentials (<-0.4 V vs
NHE) than the metal-centered iron or ruthenium redox waves (>0 V vs NHE) in organic electrolyte solutions. The
cyclic voltammograms of the gallium complexes display at least two consecutive reversible one-electron reduction
waves. These reductions are shifted by ∼0.6 V to lower potentials in the corresponding iron and ruthenium complexes.
The electrochemical, chemical, and spectroscopic data indicate that the ligand-centered reduction takes place at
the CH3CdN double bond. Quantum chemical calculations on the geometric and electronic structures of
2-acetylpyridine 4N,4N-dimethylthiosemicarbazone (HLB), the corresponding metal complexes [Ga(LB)2]+ and [FeII(LB)2],
and the one-electron reduction product for each of these species support the assignment of the reduction site and
elucidate the observed order of the ligand-centered redox potentials, E1/2([FeII(L)2]) < E1/2(HL) < E1/2([Ga(L)2]+). The
inﬂuence of water on the redox potentials of the complexes is reported and the physiological relevance of the
electrochemical data for cytotoxicity as well as for ribonucleotide reductase inhibitory capacity are discussed.
Introduction
Metal-based anticancer prodrugs may be activated selec-
tively in the hypoxic tumor tissue upon reduction by
biological reducing agents.1,2 Electron-transfer can occur
either to the metal-center, or, if in the biologically accessible
range, to noninnocent ligands, resulting in reactive species
capable of attacking biologically relevant target molecules
either by ligand displacement at the low valent metal center
or by radicals formed at the ligand entity, respectively. An
actiVation-by-reduction step is thought to be important for
platinum(IV) complexes that have been evaluated in clinical
development, for example, tetraplatin ([PtCl4(1,2-(NH2)2-
C6H10)], abandoned), satraplatin ([PtCl2(OAc)2(NH3)(NH2-
C6H11)], phase III), and iproplatin ([PtCl2(OH)2(NH2iPr)2],
abandoned),3 as well as for the activation of investigational
ruthenium(III) prodrugs such as trans-[RuCl4(indazole)2]-
(KP1019) and trans-[RuCl4(imidazole)(S-DMSO)]- (NAMI-
A), both of which have already ﬁnished phase I clinical
trials.4-6 Indeed, an increasing metal-centered redox potential
was shown to correlate with higher cytotoxicity for a series
of platinum(IV)7 and azole-based ruthenium(III) com-
pounds.8 Metal-centered redox potentials can be tuned and
* To whom correspondence should be addressed. Phone: +431427752615.
Fax: +431427752680. E-mail: erwin.reisner@chem.ox.ac.uk (E.R.);
vladimir.arion@univie.ac.at (V.B.A.).
† University of Vienna.
‡ University of Oxford.
(1) Reisner, E.; Arion, V. B.; Keppler, B. K.; Pombeiro, A. J. L. Inorg.
Chim. Acta 2008, 361, 1569–1583.
(2) Clarke, M. J.; Zhu, F.; Frasca, D. R. Chem. ReV. 1999, 99, 2511–
2533. (3) Hall, M. D.; Hambley, T. W. Coord. Chem. ReV. 2002, 232, 49–67.
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predicted by application of Lever’s parametrization method,
facilitating markedly the design of bioreductive drugs.1,9,10
Although hypoxia-selective organic drugs are under intensive
investigation, for example, nitroimidazoles,11 little is known
about reductively activated metal-based compounds contain-
ing electronically noninnocent ligands with physiologically
accessible redox potentials. One such example is ferrocenyl
hydroxytamoxifen, containing a ferrocene-moiety attached
to a hydroxylated form of the estrogen receptor modulator
tamoxifen, which shows high activity on estrogen receptor
positive and negative cell lines.12,13
Thiosemicarbazones are versatile redox noninnocent ligands
with a wide range of coordination modes in metal complexes,
in particular, when their binding capacity is further increased
by condensation of the thiosemicarbazide with an aldehyde
or ketone containing an additional donor atom in a suitable
position for chelation.14 In addition to their exciting coor-
dination chemistry, thiosemicarbazones have evoked con-
siderable interest because of their broad spectrum of
pharmacological activity. In particular, R-N-heterocyclic
thiosemicarbazones were found to possess antitumor, anti-
malarial, antibacterial, antifungal, and antiviral activity,15 and
64Cu-bis(thiosemicarbazonate) complexes are under inves-
tigation as hypoxia-selective positron emission tomography
tracers.16 The enzyme ribonucleotide reductase (RR) has been
identiﬁed as the principal molecular target.17 Ribonucleotide
reductase converts ribonucleotides to deoxyribonucleotides
necessary for DNA synthesis and is highly expressed in
tumor cells making it a suitable and well established target
in cancer chemotherapy.18 Initially, the inhibition of RR was
attributed to the ability of thiosemicarbazones as strong
chelators to remove iron from the enzyme active site, but
later, it was found that preformed iron chelates of some
thiosemicarbazones with a terminal NH2 group (4NH2) show
higher RR inhibitory activity than the uncomplexed thio-
semicarbazones.19-21 This is in agreement with data on
3-aminopyridine-2-carboxaldeyde thiosemicarbazone (Tri-
apine), an investigational drug currently in phase II clinical
trials, where an increase in cytotoxicity upon coordination
to iron was found.22
We reported previously that in the presence of the
reductant dithiothreitol (DTT) iron(III) complexes with 4N-
disubstituted R-N-heterocyclic thiosemicarbazone ligands
show the fastest destruction of the R2 speciﬁc tyrosine free
radical in mouse RR followed by the metal-free ligands and
the corresponding gallium(III) complexes.23 In the absence
of DTT, no tyrosyl radical quenching was observed. The
cytotoxicity data for the same compounds tested in the cancer
cell lines 41 M (ovarian carcinoma) and SK-BR-3 (mammary
carcinoma) are in reversed order: the gallium complexes
exhibited slightly higher cytotoxicity in the low nanomolar
range in comparison to the metal-free ligand, whereas the
iron(III) complexes displayed a much lower cytotoxicity in
the micromolar range. Thus, iron is essential for the fast
quenching of the tyrosyl radical in RR, but it is not solely
responsible for the antitumor potency of the 4N-disubstituted
thiosemicarbazone derivatives suggesting the existence of
additional molecular targets. The requirement of an adequate
reductant (e.g., DTT) for successful radical quenching
indicates that the iron(III) complex is reduced to its iron(II)
form prior radical quenching.
These ﬁndings prompted us to prepare a series of gal-
lium(III), iron(III), and ruthenium(III) complexes of the
general formula [ML2][Y] (M ) Ga, Fe and Ru; Y ) PF6-,
NO3- or FeCl4-), where HL is a chalcogensemicarbazone
ligand (Charts 1 and 2), and to investigate the effect of
coordination to the metal on their metal- and ligand-centered
redox properties by carrying out detailed electrochemical
investigations and quantum chemical calculations. We were
particularly interested to clarify if the redox properties/
potentials of the prepared compounds are of physiological
relevance, that is, to elucidate whether a relation between
their electrochemical properties and antiproliferative activity
or R2 speciﬁc tyrosine free radical quenching ability can be
found.
Experimental Section
All solvents and reagents were obtained from commercial
suppliers and used without further puriﬁcation. The ligands HLA,
HLB, HLE-HLG and complexes 1A, 1B, 1E-1G, 2A, 2B,
2E-2G, 2′A-2′G,23 as well as HLJ, HLK, 1J, 1K, 3B,24 and
HLD25 were prepared as described previously. HLC was synthesized
(4) Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Top. Med.
Chem. 2004, 4, 1525–1535.
(5) Clarke, M. J. Coord. Chem. ReV. 2003, 236, 209–233.
(6) Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.;
Zorbas, H.; Keppler, B. K. J. Inorg. Biochem. 2006, 100, 891–904.
(7) Hall, M. D.; Amjadi, S.; Zhang, M.; Beale, P. J.; Hambley, T. W.
J. Inorg. Biochem. 2004, 98, 1614–1624.
(8) Jakupec, M. A.; Reisner, E.; Eichinger, A.; Pongratz, M.; Arion, V. B.;
Galanski, M.; Hartinger, C. G.; Keppler, B. K. J. Med. Chem. 2005,
48, 2831–2837.
(9) Lever, A. B. P. Inorg. Chem. 1990, 29, 1271–1285.
(10) Reisner, E.; Arion, V. B.; Eichinger, A.; Kandler, N.; Giester, G.;
Pombeiro, A. J. L.; Keppler, B. K. Inorg. Chem. 2005, 44, 6704–
6716.
(11) Brown, J. M. Cancer Res. 1999, 59, 5863–5870.
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Chem. Commun. 1996, 955–956.
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by condensation of equimolar amounts of 4N-phenylthiosemicar-
bazide and 2-acetylpyridine in boiling ethanol in 60% yield.
Acetylpyrazine hydrazone was obtained by reacting acetylpyrazine
with an excess of hydrazine hydrate as the reagent and solvent at
room temperature for 24 h.
Elemental analyses were carried out on a Carlo Erba microana-
lyzer at the Microanalytical Laboratory of the University of Vienna.
Electrospray ionization mass spectrometry was carried out with a
Bruker Esquire 3000 instrument (Bruker Daltonic, Bremen, Ger-
many). Expected and experimental isotope distributions were
compared. Infrared spectra were obtained from KBr pellets with a
Perkin-Elmer FT-IR 2000 instrument (4000-400 cm-1). UV-vis
spectra were recorded on a Perkin-Elmer Lambda 650 spectropho-
tometer using samples dissolved in methanol (900-210 nm). The
iron complexes were measured on a Hewlett-Packard 8453 UV-vis
spectrophotometer (1100-210 nm). Thermogravimetric analysis
(TGA) and differential thermal analysis (DTA) measurements were
carried out simultaneously with a Mettler Toledo TGA/SDTA851e
apparatus, with a 3 °C/min heating rate under an air atmosphere.
1H, 13C, and 15N one- and two-dimensional NMR spectra were
recorded by using DMSO-d6 as the solvent with a Bruker DPX
400 or a 500 MHz Bruker FT-NMR spectrometer Avance III. The
residual 1H and 13C present in DMSO-d6 were used as internal
references. 15N NMR chemical shifts were referenced relative to
ammonium chloride as the external standard. Abbreviations for
NMR data: py ) pyridine, pz ) pyrazine, ph ) phenyl or
p-nitrophenyl, Cq,py ) quaternary carbon of pyridine, Cq,pz )
quaternary carbon of pyrazine, Cq,ph ) quaternary carbon of phenyl
or p-nitrophenyl.
Electrochemistry. Cyclic voltammograms were measured in a
three-electrode cell using a 2.0 mm-diameter glassy carbon or
platinum disk working electrode, a platinum auxiliary electrode,
and a Ag|Ag+ reference electrode containing 0.10 M AgNO3, the
potential of which was corrected using an internal standard of
ferrocenium/ferrocene. Measurements were performed at room
temperature using an EG&G PARC 273A potentiostat/galvanostat.
Deaeration of solutions was accomplished by passing a stream of
argon through the solution for 5 min prior to the measurement and
then maintaining a blanket atmosphere of argon over the solution
during the measurement. Square wave voltammograms (SWVs)
were recorded at 2 mV step height, 25 mV pulse, and a frequency
of 100 Hz (scan rate 100 mV/s). The potentials were measured in
0.20 M [n-Bu4N][BF4]/CH3CN, using [Fe(η5-C5H5)2] (E1/2 )+0.69
V vs. NHE)26 as internal standard, and are quoted relative to the
normal hydrogen electrode (NHE). HLC, HLG, and the nitro group
containing compounds HLD, HLI, 1D, 1I, 2D, and 2I were
(26) Barette, W. C., Jr.; Johnson, H. W., Jr.; Sawyer, D. T. Anal. Chem.
1984, 56, 1890–1898.
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measured in 0.20 M [n-Bu4N][BF4]/DMF (E1/2 ) +0.72 V vs
NHE)26 because of their low solubility in CH3CN. For the cyclic
voltammetry measurement in 0.15 M [n-Bu4N][BF4] in CH3CN/
H2O or DMF/H2O (7:3 v/v), a 2.0 mm-diameter glassy carbon
working electrode, a platinum auxiliary electrode, and a Ag|Ag+
reference electrode containing 3 M NaCl were used.
Synthesis of Ligands and Metal Complexes. Acetylpyrazine
4N-Phenylthiosemicarbazone (HLH). To 4N-phenylthiosemicar-
bazide27 (500 mg, 3.0 mmol) in boiling ethanol (15 mL) acetylpyra-
zine (365 mg, 3.0 mmol) was added, and the mixture was stirred
under reﬂux for 5 h. After the reaction mixture was cooled to room
temperature, the white solid was ﬁltered off, washed with ethanol,
and dried in vacuo. Yield: 590 mg (73%). Anal. Calcd for
C13H13N5S (Mr ) 271.34 g/mol): C, 57.54; H, 4.83; N, 25.81.
Found: C, 57.45; H, 4.86; N, 25.56. ESI-MS in MeOH (positive):
m/z 294, [HLH + Na]+. ESI-MS in MeOH (negative): m/z 270,
[HLH - H]-. IR spectrum in KBr, cm-1 (selected bands): 3305 s,
3217 s, 1588 m, 1528 s, 1517 s, 1469 s, 1445 s, 1362 m, 1304 m,
1259 m, 1190 s, 1169 s, 1014 m, 854 s, 806 m, 749 s, 690 s, 590 m,
555 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1): 251 (10020),
326 (27950), 420sh (1930). 1H NMR (400.13 MHz, DMSO-d6): δ
10.84 (s, 1H, N-NH) 10.33 (s, 1H, NH), 9.79 (d, 4JH,H ) 1.0 Hz,
1H, pz), 8.65-8.63 (m, 2H, pz), 7.53 (d, 3JH,H ) 7.6 Hz, 2H, ph),
7.40 (t,3JH,H ) 7.6 Hz, 2H, ph), 7.25 (t, 3JH,H ) 7.6 Hz, 1H, ph),
2.45 (s, 3H, CH3) ppm. 13C NMR (125.81 MHz, DMSO-d6): δ
178.0 (CdS), 150.4 (Cq,pz), 147.6 (CdN), 144.6 (Cpz), 144.0 (Cpz),
143.6 (Cpz), 139.6 (Cq,ph), 128.6 (Cph), 127.0 (Cph), 126.2 (Cph),
12.7 (CH3) ppm. Single crystals suitable for X-ray data collection
were obtained from a methanolic solution of HLH saturated with
dichloromethane.
Acetylpyrazine 4N-p-Nitrophenylthiosemicarbazone (HLI). To
acetylpyrazine hydrazone (300 mg, 2.20 mmol) in acetonitrile (7
mL) p-nitrophenyl isothiocyanate (397 mg, 2.20 mmol) in aceto-
nitrile (6 mL) was added, and the reaction mixture was allowed to
stir for 2 h at room temperature. The pale-yellow solid formed was
ﬁltered off, washed with acetonitrile, and dried in vacuo. Yield:
520 mg (75%). Anal. Calcd for C13H12N6O2S (Mr ) 316.34 g/mol):
C, 49.36; H, 3.82; N, 26.57. Found: C, 49.51; H, 3.85; N, 26.44.
ESI-MS in MeOH (negative): m/z 315, [HLI - H]-. IR spectrum
in KBr, cm-1 (selected bands): 3274 m, 3209 m, 3063 m, 1598 m,
1558 s, 1492 s, 1466 m, 1330 s, 1289 m, 1013 m, 850 s, 806 s,
751 m, 698 m, 625 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1):
333 (34500), 424sh (3430). 1H NMR (500.32 MHz, DMSO-d6): δ
11.25 (s, 1H, N-NH), 10.58 (s, 1H, NH), 9.75 (d, 4JH,H ) 1.0 Hz,
1H, pz), 8.68-8.66 (m, 2H, pz), 8.27 (m, 2H, ph), 8.00 (m, 2H,
ph), 2.48 (s, 3H, CH3) ppm. 13C NMR (125.81 MHz, DMSO-d6):
δ 177.4 (CdS), 150.2 (Cq,pz), 148.9 (C)N), 145.8 (Cq,ph), 144.8
(Cpz), 144.3 (Cq, ph), 144.0 (Cpz), 143.7 (Cpz), 125.8 (Cph), 124.1
(Cph), 13.0 (CH3) ppm.
N,N-Dimethyl-2-(1-pyridin-2-ylethyl)hydrazinecarbothioam-
ide (HLM). The ligand was prepared following the literature
protocol.28 Anal. Calcd for C10H16N4S (Mr ) 224.33 g/mol): C,
53.54; H, 7.19; N, 24.98; S, 14.29. Found: C, 53.49; H, 7.35; N,
25.11; S, 14.19. ESI-MS in MeOH (negative): m/z 223, [HLM -
H]-. IR spectrum in KBr, cm-1 (selected bands): 3225 m, 3167 m,
2960 m, 1597 m, 1514 s, 1437 m, 1378 s, 1320 s, 1146 m, 1115 m,
1002 m, 963 m, 915 m, 828 m, 789 s, 662 m, 547 m. UV-vis
(MeOH), λmax, nm (ε, M-1 cm-1): 246 (15030). 1H NMR (500.10
MHz, DMSO-d6): δ 8.88 (d, 3JNH,NH ) 5.7 Hz, 1H, SdCNH), 8.50
(m, 1H, py), 7.77 (dt, 3JH,H ) 7.6 Hz, 4JH,H ) 1.9 Hz, 1H, py),
7.53 (d, 3JH,H ) 7.9 Hz, 1H, py), 7.26 (m, 1H, py), 5.69 (dd, 3JNH,NH
) 5.7 Hz, 3JNH,CH ) 3.2 Hz, 1H, CHNH), 4.11 (dq, 3JH,H ) 6.6
Hz, 3JNH,CH ) 3.2 Hz, 1H, CH), 3.08 (s, 6H, N(CH3)2), 1.30 (d,
3JH,H ) 6.6 Hz, 3H, CCH3) ppm. 13C NMR (125.81 MHz, DMSO-
d6): δ 182.8 (CdS), 163.0 (Cq,py), 149.2 (Cpy), 137.0 (Cpy), 122.7
(Cpy), 121.7 (Cpy), 61.0 (CH), 40.6 (N(CH3)2), 20.0 (CCH3) ppm.
15N NMR (50.70 MHz, DMSO-d6): δ 291.2 (Npy), 116.7 (1JN,H )
98 Hz, CHNH), 76.8 (1JN,H ) 78 Hz, NH), 72.5 (N(CH3)2) ppm.
Single crystals suitable for X-ray data collection were obtained by
slow evaporation of a methanolic solution of HLM.
[Bis(2-acetylpyridine 4N-Phenylthiosemicarbazonato)-N,N,S-
gallium(III)]hexaﬂuorophosphate Monohydrate, [Ga(LC)2]PF6 ·
H2O (1C). To 2-acetylpyridine 4N-phenylthiosemicarbazone (HLC)
(50 mg, 0.185 mmol) in dry ethanol (5 mL) at room temperature
gallium(III) nitrate nonahydrate (40 mg, 0.096 mmol) in ethanol
(2 mL) was added, and the reaction mixture was allowed to stir
for 2 h. The solution was ﬁltered to remove undissolved material,
and ammonium hexaﬂuorophosphate (60 mg, 0.37 mmol) was
added to the ﬁltrate. The yellow solid formed was ﬁltered off after
30 min, washed with ethanol, and dried in vacuo. Yield: 50 mg
(70%). Anal. Calcd for C28H26F6GaN8PS2 ·H2O (Mr ) 771.39
g/mol): C, 43.60; H, 3.66; N, 14.53. Found: C, 43.28; H, 3.53; N,
14.44. ESI-MS in MeOH (positive): m/z 607, [Ga(LC)2]+; ESI-MS
in MeOH (negative): m/z 145, [PF6]-. IR spectrum in KBr, cm-1
(selected bands): 3389 m, 1598 m, 1498 m, 1457 s, 1429 s, 848
vs, 558 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1): 230sh
(32670), 254 (31090), 263sh (29710), 300 (15850), 405 (43350).
1H NMR (400.13 MHz, DMSO-d6): δ 10.26 (s, 2H, NH), 8.36 (d,
3JH,H ) 7.8 Hz, 2H, py), 8.30 (m, 2H, py), 8.10 (d, 3JH,H ) 5.1 Hz,
2H, py), 7.79 (d, 3JH,H ) 8.1 Hz, 4H, ph), 7.67 (m, 2H, py), 7.38
(t, 3JH,H ) 8.1 Hz, 4H, ph), 7.10 (t, 3JH,H ) 7.3 Hz, 2H, ph), 2.95
(s, 6H, CH3) ppm. 13C NMR (100.63 MHz, DMSO-d6): δ 172.5
(C-S), 152.1 (CdN), 145.6 (Cq,py), 145.6 (Cpy), 143.4 (Cpy), 140.5
(Cq,ph), 129.6 (Cph), 128.8 (Cpy), 125.7 (Cpy), 124.4 (Cph), 122.2
(Cph), 16.1 (CH3) ppm.
[Bis(2-acetylpyridine 4N-p-Nitrophenylthiosemicarbazonato)-
N,N,S-gallium(III)]nitrate Monohydrate, [Ga(LD)2]NO3 ·H2O
(1D). To 2-acetylpyridine 4N-p-nitrophenylthiosemicarbazone (HLD)
(100 mg, 0.32 mmol) in boiling methanol (25 mL) gallium(III)
nitrate nonahydrate (67 mg, 0.16 mmol) in methanol (2 mL) was
added, and the reaction mixture was stirred under reﬂux for 1 h.
The yellow solid was separated from the hot solution by ﬁltration,
washed with methanol, and dried in vacuo. Yield: 50 mg (41%).
Anal. Calcd for C28H24GaN11O7S2 ·H2O (Mr ) 778.43 g/mol): C,
43.20; H, 3.37; N, 19.79. Found: C, 43.04; H, 3.40; N, 19.56. ESI-
MS in MeOH (positive): m/z 697, [Ga(LD)2]+. ESI-MS in MeOH
(negative): m/z 695, [Ga(LD)2 - 2H]-. IR spectrum in KBr, cm-1
(selected bands): 3078 w, 1574 s, 1495 s, 1437 s, 1404 m, 1324 s,
1302 s, 1260 s, 1108 s, 848 m, 750 m. UV-vis (MeOH), λmax, nm
(ε, M-1 cm-1): 251sh (24650), 296sh (19880), 330sh (26520), 396
(66330), 409sh (62220). 1H NMR (400.13 MHz, DMSO-d6): δ
10.77 (s, 2H, NH), 8.48 (d, 3JH,H ) 8.1 Hz, 2H, py), 8.35 (m, 2H,
py), 8.31 (m, 4H, ph), 8.18 (d, 3JH,H ) 4.8 Hz, 2H, py), 8.08 (m,
4H, ph), 7.73 (m, 2H, py), 3.03 (s, 6H, CH3) ppm. 13C NMR (100.63
MHz, DMSO-d6): δ 172.4 (C-S), 155.7 (CdN), 146.5 (Cq,ph), 145.9
(Cpy), 145.3 (Cq,py), 143.7 (Cpy), 142.6 (Cq,ph), 129.5 (Cpy), 126.4
(Cpy), 125.8 (Cph), 121.3 (Cph), 16.7 (CH3) ppm.
[Bis(acetylpyrazine 4N-Phenylthiosemicarbazonato)-N,N,S-
gallium(III)]nitrate Monohydrate, [Ga(LH)2]NO3 ·H2O (1H). To
acetylpyrazine 4N-phenylthiosemicarbazone (HLH) (100 mg, 0.37
mmol) in boiling methanol (5 mL) gallium(III) nitrate nonahydrate
(80 mg, 0.19 mmol) in methanol (3 mL) was added, and the
mixture was stirred under reﬂux for 4 h. The yellow solid was
(27) Pulvermacher, G. Chem. Ber. 1893, 26, 613–630.
(28) Klayman, D. L.; Scovill, J. P.; Bartosevich, J. F.; Bruce, J. J. Med.
Chem. 1983, 26, 35–39.
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separated from the hot solution by ﬁltration, washed with
methanol, and dried in vacuo. Yield: 50 mg (39%). Anal. Calcd
for C26H24GaN11O3S2 ·H2O (Mr ) 690.42 g/mol): C, 45.23; H, 3.80;
N, 22.32. Found: C, 45.22; H, 3.51; N, 22.20. ESI-MS in MeOH
(positive): m/z 609, [Ga(LH)2]+. IR spectrum in KBr, cm-1 (selected
bands): 3276 m, 1599 s, 1541 s, 1489 s, 1420 s, 1328 m, 1150 s,
1096 s, 762 s, 698 m, 592 m. UV-vis (MeOH), λmax, nm (ε, M-1
cm-1): 230sh (32850), 257 (24810), 270sh (23860), 322 (24570),
430 (31950). 1H NMR (500.32 MHz, DMSO-d6): δ 10.46 (s, 2H,
NH), 9.66 (s, 2H, pz), 8.96 (d, 3JH,H ) 2.8 Hz, 2H, pz), 8.09 (m,
2H, pz), 7.79 (d, 3JH,H ) 7.6 Hz, 4H, ph), 7.40 (t, 3JH,H ) 7.8 Hz,
4H, ph), 7.13 (t, 3JH,H ) 7.6 Hz, 2H, ph), 2.99 (s, 6H, CH3) ppm.
13C NMR (125.81 MHz, DMSO-d6): δ 172.3 (C-S), 150.8 (CdN),
150.2 (Cpz), 147.2 (Cpz), 140.3 (Cq,ph), 139.8 (Cq,py), 138.9 (Cpz),
129.6 (Cph), 124.8 (Cph), 122.5 (Cph), 16.1 (CH3) ppm. 15N NMR
(50.70 MHz, DMSO-d6): δ 244.7 (Npz,uncoordinated) ppm. Crystals
suitable for X-ray data collection were obtained from an acetone
solution of 1H saturated with diethyl ether.
[Bis(acetylpyrazine 4N-p-Nitrophenylthiosemicarbazonato)-
N,N,S-gallium(III)]nitrate Monohydrate Methanol Solvate, [Ga-
(LI)2]NO3 ·H2O ·0.5CH3OH (1I). To acetylpyrazine 4N-p-nitro-
phenylthiosemicarbazone (HLI) (50 mg, 0.158 mmol) in boiling
methanol (5 mL) triethylamine (24 μL, 0.173 mmol) and gal-
lium(III) nitrate nonahydrate (33 mg, 0.079 mmol) in methanol (1
mL) were added, and the mixture was stirred under reﬂux for 3 h.
The precipitate was separated from the hot solution by ﬁltration,
washed with methanol, and dried in vacuo. Yield: 49 mg (78%).
Anal. Calcd for C26H22GaN13O7S2 ·H2O ·0.5CH3OH (Mr ) 796.43
g/mol): C, 39.96; H, 3.29; N, 22.86; S, 8.05. Found: C, 40.01; H,
3.12; N, 22.29; S, 7.78. ESI-MS in MeOH (positive): m/z 699,
[Ga(LI)2]+. ESI-MS in MeOH (negative): m/z 697, [Ga(LI)2 - 2H]-.
IR spectrum in KBr, cm-1 (selected bands): 3072 m, 1595 m,
1571 m, 1495 s, 1442 s, 1402 m, 1324 s, 1304 s, 1151 m, 1091 s,
853 m, 750 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1): 219sh
(34850), 266 (16800), 309sh (29000), 336 (35740), 415 (42820).
1H NMR (500.32 MHz, DMSO-d6): δ 10.92 (s, 2H, NH), 9.76 (d,
4JH,H ) 1.3 Hz, 2H, pz), 9.02 (d, 3JH,H ) 2.8 Hz, 2H, pz), 8.33 (m,
4H, ph), 8.16 (dd, 3JH,H ) 2.8 Hz, 4JH,H ) 1.3 Hz, 2H, pz), 8.09
(m, 4H, ph), 3.08 (s, 6H, CH3) ppm. 13C NMR (125.81 MHz,
DMSO-d6): δ 171.8 (C-S), 154.1 (CdN), 150.6 (Cpz), 147.3 (Cpz),
145.9 (Cq,ph), 142.5 (Cq,ph), 139.1 (Cq,pz), 138.8 (Cpz), 125.5 (Cph),
121.2 (Cph), 16.3 (CH3) ppm.
[Bis(2-acetylpyridine 4N-Phenylthiosemicarbazonato)-N,N,S-
iron(III)]hexaﬂuorophosphate, [Fe(LC)2]PF6 (2C). To 2-acetylpy-
ridine 4N-phenylthiosemicarbazone (HLC) (80 mg, 0.296 mmol)
in ethanol (7 mL) iron(III) nitrate nonahydrate (67 mg, 0.166 mmol)
in ethanol (1 mL) was added, and the reaction mixture was allowed
to stir for 5 h at room temperature. Ammonium hexaﬂuorophosphate
(100 mg, 0.613 mmol) was added, and the mixture was stirred for
further 45 min. The precipitate was ﬁltered off, washed with ethanol,
and dried for one week at 50 °C. Yield: 75 mg (68%). Anal. Calcd
for C28H26F6FeN8PS2 (Mr ) 739.50 g/mol): C, 45.48; H, 3.54; N,
15.15. Found: C, 45.66; H, 3.69; N, 15.11. ESI-MS in MeOH
(positive): m/z 594, [Fe(LC)2]+; ESI-MS in MeOH (negative): m/z
145, [PF6]-. IR spectrum in KBr, cm-1 (selected bands): 3366 s,
1601 m, 1540 m, 1504 s, 1458 s, 1435 s, 1318 m, 1161 s, 842 vs,
556 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1): 256 (48440),
388 (33880), 632 (890), 836 (1060).
[Bis(2-acetylpyridine 4N-p-Nitrophenylthiosemicarbazonato)-
N,N,S-iron(III)]nitrate Monohydrate, [Fe(LD)2]NO3 ·H2O (2D).
To 2-acetylpyridine 4N-p-nitrophenylthiosemicarbazone (HLD) (150
mg, 0.476 mmol) in boiling methanol (37 mL) iron(III) nitrate
nonahydrate (97 mg, 0.240 mmol) in methanol (2 mL) was added,
and the reaction mixture allowed to stir for 1 h. The black solid
was separated from the hot solution by ﬁltration, washed with
methanol, and dried in vacuo. Yield: 115 mg (63%). Anal. Calcd
for C28H24FeN11O7S2 ·H2O (Mr ) 764.55 g/mol): C, 43.99; H, 3.43;
N, 20.15. Found: C, 44.34; H, 3.23; N, 19.83. ESI-MS in MeOH
(positive): m/z 684, [Fe(LD)2]+. ESI-MS in MeOH (negative): m/z
682, [Fe(LD)2 - 2H]-. IR spectrum in KBr, cm-1 (selected bands):
3308 m, 3060 m, 1498 s, 1452 s, 1325 s, 1303 s, 1256 s, 1157 s,
1111 s, 854 m, 751 m. UV-vis (MeOH), λmax, nm (ε, M-1 cm-1):
237sh (42530), 321sh (27470), 385 (62820), 474sh (7990), 595
(1360), 837 (1220).
[Bis(acetylpyrazine 4N-Phenylthiosemicarbazonato)-N,N,S-
iron(III)]nitrate Monohydrate, [Fe(LH)2]NO3 ·H2O (2H). To
acetylpyrazine 4N-phenylthiosemicarbazone (HLH) (80 mg, 0.295
mmol) in boiling ethanol (5 mL) iron(III) nitrate nonahydrate (60
mg, 0.149 mmol) in ethanol (2 mL) was added, and the mixture
was stirred under reﬂux for 5 h. The black solid was ﬁltered off
from the hot solution, washed with ethanol, and dried in vacuo.
Yield: 70 mg (70%). Anal. Calcd for C26H24FeN11O3S2 ·H2O (Mr
) 676.53 g/mol): C, 46.16; H, 3.87; N, 22.77. Found: C, 46.35; H,
3.74; N, 22.48. ESI-MS in MeOH (positive): m/z 596, [Fe(LH)2]+.
IR spectrum in KBr, cm-1 (selected bands): 3245 m, 1597 s,
1547 m, 1428 s, 1342 m, 1148 s, 1094 s, 763 s, 695 m, 585 m.
UV-vis (MeOH), λmax, nm (ε, M-1 cm-1): 258 (45730), 311sh
(22780), 417 (29810), 515sh (6790), 675 (1140), 875 (1010).
[Bis(acetylpyrazine 4N-p-Nitrophenylthiosemicarbazonato)-
N,N,S-iron(III)]nitrate Monohydrate, [Fe(LI)2]NO3 ·H2O (2I). To
acetylpyrazine 4N-p-nitrophenylthiosemicarbazone (HLI) (50 mg,
0.158 mmol) in boiling methanol (10 mL), iron(III) nitrate
nonahydrate (32 mg, 0.079 mmol) in methanol (2 mL) was added,
and the reaction mixture was allowed to stir under reﬂux for 2 h.
The black solid was separated from the hot solution by ﬁltration,
washed with methanol, and dried in vacuo. Yield: 37 mg (61%).
Anal. Calcd for C26H22FeN13O7S2 ·H2O (Mr ) 766.53 g/mol): C,
40.74; H, 3.16; N, 23.75. Found: C, 40.77; H, 3.13; N, 23.63. ESI-
MS in MeOH (positive): m/z 686, [Fe(LI)2]+. IR spectrum in KBr,
cm-1 (selected bands): 3054 m, 1596 m, 1564 m, 1497 s, 1439 s,
1329 s, 1302 s, 1259 m, 1147 s, 1087 s, 850 m, 750 m. UV-vis
(MeOH), λmax, nm (ε, M-1 cm-1): 226sh (42630), 330 (32320),
399 (47700), 502sh (7440), 662 (1440), 884 (1120).
Crystallographic Structure Determination. X-ray diffraction
measurements were performed on a Bruker X8 APEX II CCD-
diffractometer. A single crystal of suitable size was protected by
Parathone-N oil, attached to a glass ﬁber, and mounted on a
goniometer head at 40 mm from the detector, and 1375, 1594, and
1144 frames were measured, each for 90, 5, and 90 s over 1° scan
width. The data were processed using SAINT software.29 The
structures were solved by direct methods and reﬁned by full-matrix
least-squares techniques. Non-hydrogen atoms were reﬁned with
anisotropic displacement parameters. Hydrogen atoms were placed
at calculated positions and reﬁned as riding atoms in the subsequent
least-squares model reﬁnements. The isotropic thermal parameters
were estimated to be 1.2 times the values of the equivalent isotropic
thermal parameters of the atoms to which hydrogens were bound.
The following computer programs were used: structure solution,
SHELXS-97;30 reﬁnement, SHELXL-97;31 molecular diagrams,
(29) SAINT-Plus, version 7.06a; APEX2; Bruker-Nonius AXS Inc.: Madi-
son, WI, 2004.
(30) Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solution;
University Go¨ttingen: Go¨ttingen, Germany, 1997.
(31) Sheldrick, G. M. SHELXL-97, Program for Crystal Structure Reﬁne-
ment; University Go¨ttingen: Go¨ttingen, Germany, 1997.
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ORTEP;32 computer, Pentium IV; scattering factors.33 Crystal data,
data collection parameters and structure reﬁnement details for HLH,
HLM, and 1H are given in Table 1.
Computational Details. The geometries of the 2-acetylpyridine
4N,4N-dimethylthiosemicarbazone ligand HLB, its deprotonated form
(LB)-, the metal complexes [Ga(LB)2]+, [FeII(LB)2], and the reduced
form of each of these species were optimized using a combination
of the exchange functional of Becke34a and the correlation functional
of Perdew34b (BP86), as implemented in Gaussian 03.35 The
LANL2DZ effective core potentials (ECPs)36 and the corresponding
valence-basis sets were used for the metals, and the 6-31G(d,p)
basis sets were used for the other atoms. Vibrational frequencies
calculated at this level conﬁrm that all structures are minima on
the potential energy surfaces. Improved energies were calculated
at the BP86 level together with the same ECPs and valence-basis
set on the metal atoms but totally uncontracted and augmented with
one set of f functions on Fe,37 together with the 6-311+G(3d)
basis set on the S atoms, and the 6-311+G(d,p) basis sets on the
other atoms. Free energies in vacuo were calculated by addition of
corrections from unscaled zero-point energy (ZPE), thermal energy,
work, and entropy evaluated at the BP86 level at 298.15 K, 1 atm
to the improved energies. Standard reduction potentials (SRPs) were
calculated according to our previous approach,38 which was
carefully validated for the reduction of 61 ruthenium(III/II)
complexes (bearing formal charges from 3+/2+ to 1-/2-) in four
solvents and shall be readily transferable to other metal complexes
because the metal ion is not solvent-exposed in any of those Ru
complexes. The SRP prediction is based on a thermodynamic cycle
and involves the calculation of solvation free energies using the
Poisson-Boltzmann ﬁnite element method,39 as implemented in
Jaguar 7,40 with dielectric constant of 37.5 representing acetonitrile
as the solvent. In the present work, the only difference to our
previous SRP calculation approach38 is the use of the BP86
functional, which leads to excellent agreement with experimental
SRPs (see below) and was employed for similar purposes as well.41a
The overestimation of the contribution of exchange energy by the
B3LYP functional42 is well documented41b and may result in the
overestimation of the stability of high-multiplicity spin states in
iron complexes. A comparison of the relative energies of the
electronic states of [FeII(LB)2] and [FeII(LB)2]- and of the SRPs
calculated using the BP86 and B3LYP improved energies is given
in the Supporting Information (Tables S1 and S2) and indicates
that multireference approaches would be worth considering if
permitted by the available computational resources. Other promising
methods for this particular purpose include the spectroscopy oriented
conﬁguration interaction (SORCI) method and a ligand ﬁeld theory
(LFT)-based approach.41c Atomic partial charges at BP86 were
calculated using the Mulliken43a scheme based on basis functions
as implemented in Gaussian, the Hirshfeld43b scheme based on
electron density as implemented in ADF,44 and the ESP43c scheme
of ﬁtting atomic charges to reproduce the electrostatic potential in
Jaguar.40
Results and Discussion
Synthesis and Characterization. The ligand 2-acetylpyra-
zine 4N-phenylthiosemicarbazone (HLH) (Chart 1) was
(32) Johnson, G. K. Report ORNL-5138; Oak Ridge National Laboratory:
Oak Ridge, TN, 1976.
(33) International Tables for X-ray Crystallography; Kluwer Academic
Press: Dodrecht, The Netherlands, 1992; Vol. C, Tables 4.2.6.8 and
6.1.1.4.
(34) (a) Becke, A. D. Phys. ReV. A 1988, 38, 3098–3100. (b) Perdew, J. P.
Phys. ReV. B 1986, 33, 8822–8824.
(35) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb,
M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin,
K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone,
V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.;
Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa,
J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene,
M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.;
Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev,
O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala,
P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.;
Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas,
O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.;
Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.;
Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.;
Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.;
Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen,
W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision
D.01; Gaussian, Inc.: Wallingford, CT, 2004; www.gaussian.com.
(36) (a) Wadt, W. R.; Hay, P. J. J. Chem. Phys. 1985, 82, 284–298. (b)
Hay, P. J.; Wadt, W. R. J. Chem. Phys. 1985, 82, 299–310.
(37) Ehlers, A. W.; Bo¨hme, M.; Dapprich, S.; Gobbi, A.; Ho¨llwarth, A.;
Jonas, V.; Ko¨hler, K. F.; Stegmann, R.; Veldkamp, A.; Frenking, G.
Chem. Phys. Lett. 1993, 208, 111–114.
(38) Chiorescu, I.; Deubel, D. V.; Arion, V. B.; Keppler, B. K. J. Chem.
Theory Comput. 2008, 4, 499–506.
(39) (a) Tannor, D. J.; Marten, B.; Murphy, R. B.; Friesner, R. A.; Sitkoff,
D.; Nicholls, A.; Ringnalda, M. N.; Goddard, W. A., III.; Honig, B.
J. Am. Chem. Soc. 1994, 116, 11875–11882. (b) Marten, B.; Kim, K.;
Cortis, C.; Friesner, R. A.; Murphy, R. B.; Ringnalda, M. N.; Sitkoff,
D.; Honig, B. J. Phys. Chem. 1996, 100, 11775–11788.
(40) Jaguar, version 7.0; Schro¨dinger, LCC: New York, 2007; www.schro-
dinger.com.
(41) (a) Ketterer, N. A.; Fan, H.; Blackmore, K. J.; Yang, X.; Ziller, J. W.;
Baik, M.-H.; Heyduk, A. F. J. Am. Chem. Soc. 2008, 130, 4364–
4374. (b) Reiher, M.; Salomon, O.; Hess, B. A. Theor. Chem. Acc.
2001, 107, 48–55. (c) Fouqueau, A.; Casida, M. E.; Daku, L. M. L.;
Hauser, A.; Neese, F. J. Chem. Phys. 2005, 122, 44110/1–44110/13.
(42) (a) Becke, A. D. J. Chem. Phys. 1993, 98, 5648–5652. (b) Lee, C.;
Yang, W.; Parr, R. G. Phys. ReV. B 1988, 37, 785–789.
(43) (a) Mulliken, R. S. J. Chem. Phys. 1955, 23, 1833–1840. (b) Hirshfeld,
F. L. Theor. Chim. Acta 1977, 44, 129–138. (c) Chirlian, L. E.; Miller,
M. J. Comput. Chem. 1987, 8, 894–905.
(44) (a) Te Velde, G.; Bickelhaupt, F. M.; van Gisbergen, S. J. A.; Fonseca
Guerra, C.; Baerends, E. J.; Snijders, J. G.; Ziegler, T. J. Comput.
Chem. 2001, 22, 931–967. (b) ADF 2007.01; SCM, Theoretical
Chemistry, Vrije Universiteit: Amsterdam, The Netherlands, 2007;
http://www.scm.com.
Table 1. Crystal Data and Details of Data Collection for HLH, HLM,
and 1H
HLH HLM 1H ·H2O
empirical
formula
C13H13N5S C10H16N4S C26H26GaN11O4S2
fw 271.34 224.33 690.42
space group Pj1 P21/c Pna21
a [Å] 5.7844(14) 5.4716(2) 14.9818(5)
b [Å] 10.036(3) 18.9799(7) 22.0746(7)
c [Å] 11.314(4) 11.8689(4) 8.6006(3)
R [deg] 76.005(12)
 [deg] 87.021(9) 97.289(2)
γ [deg] 89.220(9)
V [Å3] 636.5(3) 1222.63(8) 2844.37(16)
Z 2 4 4
λ [Å] 0.71073 0.71073 0.71073
Fcalcd
[g cm-3]
1.416 1.219 1.612
cryst size
[mm3]
0.16 × 0.01 × 0.01 0.30 × 0.20 × 0.20 0.26 × 0.10 × 0.10
T [K] 100 296 100
μ [mm-1] 0.247 0.241 1.171
R1a 0.0440 0.0436 0.0267
wR2b 0.0920 0.1362 0.0721
GOFc 1.031 1.015 1.055
a R1 ) Σ|Fo| - |Fc|/Σ|Fo|. b wR2 ) (Σ[w(Fo2 - Fc2)2]/Σ[w(Fo2)2])1/2.
c GOF ) (Σ[w(Fo2 - Fc2)2]/(n - p))1/2, where n is the number of reﬂections
and p is the total number of parameters reﬁned.
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synthesized by condensation of 4N-phenylthiosemicarbazide
with acetylpyrazine in boiling ethanol in 73% yield.
2-Acetylpyrazine 4N-p-nitrophenylthiosemicarbazone (HLI)
was prepared as a pale-yellow powder by reaction of
p-nitrophenyl isothiocyanate with acetylpyrazine hydrazone
in acetonitrile in 75% yield. Acetylpyrazine hydrazone was
obtained by reacting acetylpyrazine with an excess hydrazine
hydrate as the reagent and solvent. The gallium(III) complex
1C (Chart 2) was synthesized by reaction of Ga(NO3)3 ·9H2O
with 2-acetylpyridine 4N-phenylthiosemicarbazone in 1:2
molar ratio in ethanol at room temperature, followed by
addition of excess NH4PF6. Complexes 1D, 1H, and 1I were
isolated as nitrates, which precipitated shortly after addition
of Ga(NO3)3 ·9H2O to the boiling solution of the correspond-
ing ligand. These complexes show also lower aqueous
solubility than the nitrate salts of complexes 1A-1C,
1E-1G, 1J, and 1K which because of their good solubility
in (m)ethanolic solution were isolated as hexaﬂuorophos-
phates. The difference in the solubility is also evident for
the corresponding iron(III) complexes. Complexes 2D, 2H,
and 2I were obtained as nitrate salts by reaction of
Fe(NO3)3 ·9H2O with a boiling solution of the ligand,
whereas 2C was isolated as a hexaﬂuorophosphate salt. In
contrast to the nonsolvated complexes with secondary amine
substituted ligands (1A, 1B, 1E-1G, and iron(III) analogs),
microanalytical data for the novel complexes show that they
all crystallize with one water molecule. X-ray diffraction
studies showed that this water molecule is involved in
hydrogen bonding with the NH group of the anilinyl and
nitroanilinyl moiety (see below). The presence of crystal
water was also conﬁrmed by thermogravimetric analysis
(TGA) of complex 1D, where the loss of water between 40
and 110 °C was observed. A large endothermic peak in the
differential thermal analysis (DTA) at 250 °C indicated the
pyrolysis of the complex. Taking into account the observed
thermal behavior, complex 2C was dried at 50 °C over one
week to give a nonsolvated product.
The UV-vis spectra of the metal-free ligands as well as
the gallium(III) complexes are dominated by intraligand
transitions associated with the pyridine or pyrazine ring,
azomethine, and thione portions of the ligands. The extinction
coefﬁcient of the lowest energy band increases dramatically
upon coordination of the thiosemicarbazone ligands HL to
Ga(III) to give [Ga(L2)]+ concomitant with a small shift of
the absorbance maximum (420 f 430 nm for HLH f 1H
and 424f 415 nm for HLIf 1I). The increased extinction
coefﬁcient is presumably because of the change in the ligand
conjugation caused by the deprotonation of the ligands upon
complexation.
The reduced analog of HLB, namely HLM, was prepared
by reduction of an ethanolic solution of methyl 3-[1-(2-
pyridyl)ethylidene]hydrazinecarbothioate28 with NaBH4 and
subsequent nucleophilic substitution of the S-methyl group
by dimethylamine (Chart 1) or by direct reduction of HLB
with NaBH4 in ethanol. The reduction of the CdN double
bond in HLB is accompanied by the disappearence of two
UV-vis absorption bands with the maxima at 314 and 396
nm as shown in Figure 1. The presence of these two bands
for the π-delocalized thiosemicarbazone chromophore in
HLB might be explained by the existence of at least two
isomers with different electronic structures in solution, as
conﬁrmed by 1H NMR measurements in methanol-d4. In
contrast, the ligands HLH and HLI, which adopt only one
isomeric form in solution according to 1H NMR spectra in
methanol-d4, display only one strong absorption band at 326
and 333 nm, respectively. Coordination of the thiosemicar-
bazone ligands HLH and HLI to the iron(III) leads to the
following changes in their UV-vis spectra: a large increase
of the band around 400 nm, appearance of two new bands
between 502 and 675 nm (d f π* transition), and around
880 nm the d f d band corresponding to the 2T2g f 2T1g
transition of the d5 low-spin system.45
The 1H NMR spectra of the ligands HLH and HLI recorded
in DMSO-d6 indicate that, in contrast to HLB, HLK,24 and
other thiosemicarbazones,46 they exist in solution only as E
isomers. Interestingly, the analogous pyridinyl containing
ligands HLC and HLH show small amounts (<10%) of a
second isomer with strongly downﬁeld shifted N-H signals
at 14.58 and 14.92 ppm, respectively, resulting from in-
tramolecular hydrogen bonding.25 Like for other reduced
thiosemicarbazone ligands,47 the 1H NMR spectrum of HLM
indicates the presence of only one isomeric form in solution.
Two N-H signals at 8.88 ppm and 5.69 ppm could be
observed, where the ﬁrst one is split into a doublet with a
coupling constant of 3JH,H ) 5.7 Hz and the second one into
a doublet of doublet with 3JH,H ) 5.7 Hz and 3JH,H ) 3.2
Hz. The coupling constant of 3.2 Hz is also observed for
the doublet of quartet of the CH signal at 4.11 ppm, with
the quartet splitting (3JH,H ) 6.6 Hz) originating from the
coupling with the CH3CH-N methyl group at 1.30 ppm (d,
3JH,H ) 6.6 Hz). Consequently, the signal at 8.88 ppm can
be attributed to the SdCNH proton and that at 5.69 ppm to
the CHNH proton. A 2D 1H-15N HSQC NMR spectrum
shows one resonance at 116.7 ppm associated to the proton
signal at 8.88 ppm and a second resonance at 76.8 ppm
coupled with the proton at 5.69 ppm. The long-range 1H-15N
(45) Sreekanth, A.; Fun, H.-K.; Kurup, M. R. P. J. Mol. Struct. 2005, 737,
61–67.
(46) Easmon, J.; Heinisch, G.; Holzer, W. Heterocycles 1989, 29, 1399–
1408.
(47) Easmon, J.; Heinisch, G.; Holzer, W. Sci. Pharm. 1993, 61, 3–10.
Figure 1. Electronic absorption spectra of ligand HLB (dashed line) and
its reduced form HLM (solid line) in methanol. [HLB λmax, nm (ε, M-1
cm-1), 231sh (9690), 272sh (6920), 314 (9800), 396 (5680); HLM λmax,
nm (ε, M-1 cm-1), 246 (15030)].
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HMBC spectrum shows that the two N-H groups couple
with each other and, in addition, that the signal at 116.7 ppm
(1JN,H ) 98 Hz) couples with the tertiary CH signal δ )
4.11 ppm, whereas the nitrogen resonance at 76.8 ppm (1JN,H
) 78 Hz) exhibits a cross peak with the CH3 group resonance
at 1.30 ppm. All this conﬁrms the above-mentioned assign-
ments. In addition, three pyridine protons give a cross peak
with the 15N resonance at 291.2 ppm, which can be ascribed
to the pyridine nitrogen.
In contrast to some of the metal-free ligands, the 1H NMR
spectra of the gallium complexes 1C, 1D, 1H, and 1I show
only one set of signals because of the stabilization of the
ligand conﬁguration upon coordination to the metal and the
equivalence of both ligands bound to gallium(III) in solution.
The most remarkable difference between the 1H NMR spectra
of the gallium complexes and those of the metal-free ligands
is the absence of one of the N-H signals, indicating
deprotonation of the ligands upon complexation. Because it
was difﬁcult to distinguish between the two quaternary
carbon atoms of the pyridine and pyrazine ring, respectively,
and the carbon of the adjacent CdN double bond, complex
1H was studied by multinuclear (1H, 13C, and 15N) one- and
two-dimensional NMR spectroscopy. Exact assignment of
the quaternary carbon atoms was necessary for the correlation
of the 13C NMR chemical shifts with the redox potentials
(see Figure 9). In general, the 13C NMR chemical shifts of
the CdN bond of the gallium complexes occur at lower ﬁeld
than the quaternary carbon atoms of the heterocycle (for
detailed discussion see Supporting Information).
Crystal Structures. [Ga(LH)2]NO3 ·H2O (1H) crystallized
in the orthorhombic space group Pna21, while HLH crystal-
lized in the triclinic centrosymmetric space group Pj1. The
structure of the complex cation is shown in Figure 2, and
the molecular structure of the metal-free ligand HLH is shown
in Figure 3. Selected bond distances (Å) and angles (deg)
are quoted in the legends to the Figures 2 and 3. The
asymmetric unit of 1H consists of a distorted octahedral
[Ga(LH)2]+ complex cation, a counteranion NO3-, and a
cocrystallized water molecule. Each ligand is monodepro-
tonated and coordinates to gallium via the pyrazine nitrogen
atom [Ga-N1 ) 2.142(2) Å, Ga-N6 ) 2.155(2) Å], an
azomethine nitrogen [Ga-N3 ) 2.033(2) Å, Ga-N8 )
2.044(2) Å], and a sulfur donor atom [Ga-S1 ) 2.3266(8)
Å, Ga-S2 ) 2.3249(8) Å], forming two ﬁve-membered
chelate rings, correspondingly. Both coordinated ligands are
essentially planar, with exception of the phenyl group at the
terminal nitrogen atom of the thiosemicarbazide moiety.
The deviation from planarity of the phenyl ring in each
coordinated ligand can be described by torsion angles
ΘC13-C8-N5-C7 andΘC20-N10-C21-C22 of 8.2(5)° and -21.5(4)°,
respectively. The bond distances C7-S1 of 1.734(3) Å and
C20-S2 of 1.743(3) Å are comparable to those reported for
[Ga(LG)2][PF6] (HLG ) acetylpyrazine 4N,4N-dimethylthio-
semicarbazone)23 at 1.754(2) and 1.745(2) Å and are
signiﬁcantly longer than that of the metal free ligand HLH
at 1.677(3) Å. Of note are the angles N1-Ga-S1 at
159.55(7)° and N6-Ga-S2 at 156.90(7)°, which deviate
markedly from the ideal value of 180°. The reason might be
some repulsion between S1 and S2 (S1 · · ·S2 ) 3.572 Å).
The molecules of 1H are involved into a network of
intermolecular hydrogen bonds, with the NH groups of both
thiosemicarbazone ligands and the water molecule acting as
proton donors and the oxygens of the water and the nitrate
counterion acting as proton acceptor (N10-H · · ·O3 · · ·H-
O4 · · ·H-N5).
The crystal structure of the ligand HLH has an essentially
nonplanar conformation (Figure 3), which differs markedly
from that imposed by coordination. The phenyl ring C8-C13
and the pyrazine ring form dihedral angles of 54.2 and 164.7°
with the central mean plane through N3, N4, C7, and N5
atoms of the thiosemicarbazide residue. Two rotations, one
about C4-C5 bond and another about N4-C7 bond by
∼180° in the metal-free ligand are necessary to achieve the
conformation adopted by both ligands in [Ga(LH)2]+. The
molecules of HLH are associated in centrosymmetric dimers
via hydrogen bonding interactions of the type N4-H · · ·S1
(-x + 3, -y + 1, -z + 1) [N4-H ) 0.88 Å, H · · ·S1 )
2.691 Å, N4 · · ·S1 ) 3.568 Å, N4-H · · ·S1 ) 174.08°].
Although it is weak, the intramolecular H bond N5-H · · ·N3
[N5-H ) 0.794 Å, H · · ·N3 ) 2.159 Å, N5 · · ·N3 ) 2.585
Å, N5-H · · ·N3 ) 113.90°] is also of note.
The result of X-ray diffraction study for HLM is displayed
in Figure 4. The reduction of the azomethine bond is
evidenced by the sp3-hybridized atoms C6 (tetrahedral
conﬁguration) and N2 and by the lengths of the bonds
Figure 2. ORTEP plot with thermal ellipsoids at 50% probability level
for complex cation [Ga(LH)2]+ in 1H with atom labeling scheme. Selected
bond distances (Å) and angles (deg): C5-N3 ) 1.292(3), C18-N8 )
1.297(4), N3-N4 ) 1.367(3), N8-N9 ) 1.364(3), N4-C7 ) 1.320(4),
N9-C20 ) 1.325(4), C7-S1 ) 1.734(3), C20-S2 ) 1.743(3), C7-N5 )
1.356(4), C20-N10 ) 1.346(3); N1-Ga-N3 ) 76.98(9), N6-Ga-N8 )
76.16(9), N3-Ga-S1 ) 83.34(6), N8-Ga-S2 ) 83.72(7).
Figure 3. Centrosymmetric dimeric associate of HLH, emphasizing the
intra- and intermolecular hydrogen-bonding interactions; symmetry code i:
-x + 3, -y + 1, -z + 1. Selected bond distances (Å) and angles (deg):
C4-C5 ) 1.481(4), C5-N3 ) 1.284(3), N3-N4 ) 1.367(3), N4-C7 )
1.366(3), C7-S1 ) 1.677(3), C7-N5 ) 1.335(3), N5-C8 ) 1.425(3);
ΘC3-C4-C5-N3 ) 12.3(4), ΘN3-N4-C7-S1 ) 174.06(18).
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involving these atoms. The overall conformation of the
molecule is strongly distorted. The dihedral angle between
the pyridine ring and the plane through the N3, C8, N4, and
S1 atoms of the thiosemicarbazide moiety is 85.9°. The
molecules of HLM are involved in intramolecular hydrogen
bonding interactions of the type N2-H · · ·S1 [N2-H )
0.881 Å, H · · ·S1 ) 2.529 Å, N2 · · ·S1 ) 2.950 Å, N2-H-S1
) 110.10°] and in a strong intermolecular H bond N3-H · · ·
N1 (x - 1, y, z) [N3-H ) 0.834 Å, H · · ·N3 ) 2.218 Å,
N3 · · ·N1 ) 3.041 Å, N3-H · · ·N1 ) 169.00°]. A search at
CSD48 did not show any deposited X-ray diffraction data
for reduced thiosemicarbazones.
Electrochemical Studies. Ligand-Centered Reduction.
The electrochemical data for the metal complexes and ligands
under study are summarized in Tables 2 and S3 (Supporting
Information), respectively, and their electrochemical behavior
is shown in Scheme 1. In general, the complexes show
several redox waves attributable to the reduction of the
noninnocent thiosemicarbazone ligands at lower potentials
(<-0.4 V vs NHE) than the metal-centered redox waves
for the iron and ruthenium complexes (>0 V vs NHE; see
below). The cyclic voltammograms of 0.20 M [n-Bu4N][BF4]/
CH3CN solutions of the gallium thiosemicarbazonate com-
plexes 1A-1I display two consecutive reversible one-
electron (as conﬁrmed by controlled potential electrolysis
of 1B) redox waves with oxip /redip ) 1.0 at V > 50 mV/s
with ΔEp ) 60-70 mV at 0.20 V/s (Scheme 1a, Figure 5).
The redox potential of the ﬁrst ligand reduction (wave ILred)
occurs between -0.38 and -0.96 V, and the second (wave
IILred) between -0.62 and -1.25 V vs NHE depending on
the ligand identity (Table 2). As expected, complex 1A with
the 2-pyridinyl and 4-pyrrolidinyl substituents at the thio-
semicarbazone ligands shows the most negative redox
potentials, whereas complex 1I with the more electron-
withdrawing moieties nitroanilinyl and 2-pyrazinyl (the latter
being weaker σ-donor and stronger π-acceptor than the
2-pyridinyl moiety) has the most positive redox potential for
the ligand-centered reductions.
After these two consecutive reversible reduction processes
a third irreversible redox wave IIILred is observed for the
pyridinyl complexes 1A-1C between -1.63 and -1.81 V
vs. NHE, whereas wave IIILred is a reversible one-electron
reduction process at -1.35 and -1.56 V vs NHE for the
pyrazinyl containing complexes 1E-1H and is followed by
a fourth partially quasi-reversible one-electron reduction
wave, IVLred, at approximately -1.80 V vs NHE (ΔEp )
100-150 mV) (Figure 6a). For complex 1H, this fourth
reduction wave is irreversible because it overlaps with a
further wave at approximately -1.95 V vs NHE. Waves
IIILred and IVLred were not detected for 1D and 1I, both
containing a nitro-group attached to the thiosemicarbazone
ligand, but instead a quasi-reversible (ΔEp ) 90-100 mV)
reduction of the NO2 group49 at E1/2 ) -1.04 and -1.01 V
vs NHE was observed, respectively. Complexes with nitro-
derivatives are scarcely soluble in CH3CN and were therefore
measured in 0.20 M [n-Bu4N][BF4]/DMF. However, no
variations in redox properties/potentials of the complexes
(48) Cambridge Structure Database, version 5.29; Cambridge Crystal-
lographic Data Centre: Cambridge, U.K., 2007.
(49) Geske, D. H.; Ragle, J. L.; Bambenek, M. A.; Balch, A. L. J. Am.
Chem. Soc. 1964, 86, 987–1002.
Figure 4. ORTEP plot of a fragment of the crystal structure of HLM with
thermal ellipsoids at 40% probability level, showing the intra- and
intermolecular hydrogen-bonding interactions; symmetry code i: x - 1, y,
z. Selected bond distances (Å) and angles (deg): C5-C6 ) 1.503(3), C6-N2
) 1.471(2), N2-N3 ) 1.418(2), N3-C8 ) 1.359(3), C8-S1 ) 1.685(2),
C8-N4 ) 1.340(3) Å; ΘN1-C5-C6-N2 ) -151.70(16), ΘC5-C6-N2-N3 )
-75.1(2), ΘN2-N3-C8-S1 ) -10.6(3).
Table 2. Summary of the Electrochemical Dataa for the Metal
Complexes
gallium complexes
E1/2/ILred E1/2/IILred E1/2/IIILred
1A -0.96 -1.25 -1.81c,e
1B -0.93 -1.22 -1.77c,e
1C -0.79 -1.05 -1.63c
1Db -0.70c NAf NAf
1E -0.60 -0.88 -1.56
1F -0.58 -0.84 -1.49
1G -0.58 -0.85 -1.51
1H -0.46 -0.72 -1.35
1Ib -0.38d -0.62d NAf
1J -1.03 -1.34 -2.04c
1K -0.94 -1.22 -1.73c,e
iron complexes
E1/2/CFered E1/2/AFered E1/2/ILred E1/2/IILred Ep/IIILred
2A 0.06 -1.62d -2.01c,g -2.01c,g
2B 0.08 -1.61d -1.99c,g -1.99c,g
2C 0.18 -1.44d -1.72d -2.15c,e
2Db 0.27 NAf NAf NAf
2E 0.32 -1.23 -1.65 -2.12c,e
2F 0.32 -1.21 -1.64 -2.09c,e
2G 0.34 -1.22 -1.64 -2.13c,e
2H 0.43 -1.08 -1.47 -1.97c,e
2Ib 0.51 NAf NAf NAf
2′A 0.06 0.30 -1.60c
2′B 0.08 0.30 -1.61d
2′E 0.31g 0.31g -1.20c
2′F 0.31g 0.31g -1.21d
2′G 0.32g 0.32g -1.22d
ruthenium complex
E1/2/RuIII/II E1/2/RuIV/III E1/2/ILred Ep/IILred Ep/IIILred
3B +0.21 +1.27 -1.56 -2.00c,g -2.00c,e,g
a Potentials in V ( 0.01 vs NHE in 0.20 M [n-Bu4N][BF4]/CH3CN.
b Measured in 0.20 M [n-Bu4N][BF4]/DMF. c For the irreversible wave,
the Ep values are given. d oxip/redip between 0.6 and 0.8 at 0.2 V/s. e Two-
or multielectron process (see text). f For complexes with nitro-containing
ligands, the reduction of this group at approximately -1.0 V vs NHE
prevented the detection of further ligand-centered redox waves (see text).
g Could not be detected as separate waves.
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have been observed in DMF or CH3CN electrolyte solutions
as established for complex 2D.
The inﬂuence of the chalcogen atom X of the chalcogen-
semicarbazone ligands (Chart 1) on the redox potential was
studied with complexes 1B, 1J, and 1K, which contain a
sulfur, oxygen, or selenium atom, respectively. Complex 1J
(X ) O) displays the lowest reduction potentials at -1.03
and -1.34 V vs NHE for ILred and IILred, respectively,
whereas 1K (X ) Se) and 1B (X ) S) have similar redox
potentials at -0.93 to -0.94 and -1.22 V vs NHE for the
corresponding redox waves. Thio- and selenosemicarbazone
ligands are known to have comparable NMR spectra,50 and
the gallium complexes 1B and 1K also possess similar 1H
and 13C NMR chemical shifts with the largest deviation in
the 13C NMR spectra of the C-X resonance (detected at
176.1 and 173.8 ppm, respectively).23,24 Complex 1J shows
a considerably different spectrum with the C-X resonance
at 167.1 ppm and strong upﬁeld shifts for both carbon
resonances at the CH3CdN moiety (1B 14.9, 149.0 ppm;
1K 15.6, 147.4 ppm; 1J 12.6, 139.3 ppm); in accordance
with the lower redox potential of complex 1J (see below).
The ligand-centered reduction of the iron complexes
2A-2I (for FeIIIf FeII process see below) is similar to that
for the gallium analogs, although the corresponding redox
potentials ILred and IILred are considerably more negative
between -1.08 and -1.62 V, and -1.47 and -2.01 V vs
NHE, respectively (Scheme 1b, Figure 6b, Table 2). In the
case of 2A and 2B the wave IILred at -2.01 and -1.99 V vs
NHE overlaps with IIILred resulting in two indistinguishable
redox waves. Complexes 2C-2H are reduced at IIILred
between -1.97 and -2.15, close to the solvent cutoff
potential. The lower redox potentials of the iron(II) compared
to the gallium(III) complexes are in line with the calculated
higher LUMO energy level (see below) and the neutral
charge of the iron(II) complexes (compared to the positively
charged gallium complexes). For the nitro group containing
complexes 2D and 2I only one ligand-centered irreversible
reduction wave at -0.97 and -0.93 V vs NHE was detected,
which can be attributed to the reduction of the nitro group.
This is only slightly shifted to more positive potential
compared to that in the analogous gallium complexes. The
presence of the tetrachloridoferrate counteranion in 2′A-2′G
prevented the accurate detection of the second reduction
wave IILred in these complexes, because the counteranion
reacts readily with the ligand radical formed upon reduction
at ILred.
The ruthenium complex 3B shows the ﬁrst ligand reduction
at E1/2 ) -1.56 V vs NHE (Scheme 1c, Figure 6c), whereas
IILred, like for the pyridine containing iron complexes 2A
and 2B, overlaps with IIILred resulting in an irreversible
reduction wave at -2.00 V (see Supporting Information,
Figure S1).
Increasing electron donor properties of substituents are
known to increase the effective negative net charge on the
corresponding molecules and result usually in a decrease of
(50) Castle, T. C.; Maurer, R. I.; Sowrey, F. E.; Went, M. J.; Reynolds,
C. A.; McInnes, E. J. L.; Blower, P. J. J. Am. Chem. Soc. 2003, 125,
10040–10049.
Scheme 1. Overview of the Electrochemical Behavior of the Studied Ga (a), Fe (b), and Ru (c) Complexes
Figure 5. Cyclic voltammograms of (a) 1A and (b) 1F in CH3CN
containing 0.20 M [n-Bu4N][BF4] at a scan rate of 0.20 V s-1 using a
platinum working electrode. Square wave voltammograms (SWVs); (c) of
1.0 mM 1A (black line) and 1F (gray line) electrolyte solutions were
measured with 2 mV step height, 25 mV pulse, and 100 Hz frequency. The
solid line on the bottom right refers to the current (10 μA) for a-c. For the
assignment of waves, see text.
Figure 6. Cyclic voltammograms of 1G (a), and 2E (b), and 3B (c) in CH3CN
containing 0.20 M [n-Bu4N][BF4] at a scan rate of 0.20 V s-1 using a glassy
carbon working electrode, displaying the ligand (Lred), the FeIII/FeII (CFered),
and the RuIII/RuII and RuIV/RuIII redox couples.
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their redox potentials. Plotting the pKa values of the attached
amine moieties [pyrrolidine (11.31), piperidine (11.12),
dimethylamine (10.73), aniline (4.87) and p-nitroaniline
(1.02)]51 versus E1/2 results in a linear relationship (Figure
7). The resultant linear equations (see caption of Figure 7)
and the pKa values of the attached amine moieties can be
used to predict the redox potentials of novel 2-acetylpy-
ridine(pyrazine) thiosemicarbazone gallium(III) and iron(III)
complexes in CH3CN solution. The increased redox potential
of complexes containing a pyrazine (1E-1I, 2E-2I) instead
of a pyridine (1A-1D, 2A-2D) moiety can also be
rationalized by the increased net donor properties of the latter
[EL(pyridine) ) 0.25 V, EL(pyrazine) ) 0.33]9 and the
different pKa values [pKa(pyrazine) ) 0.65, pKa(pyridine)
) 5.23], respectively.51
The metal-free thiosemicarbazone ligands HLA–HLI ex-
hibit an irreversible reduction response at -1.01 to -1.47
V vs NHE (Table S3, Supporting Information). The second
reduction wave could only be observed occasionally and was
hardly reproducible, indicating the instability of the radical
formed after the ﬁrst reduction process. For the p-nitrophenyl
ligands HLD and HLI, a quasi-reversible nitro reduction wave
was detected at -1.04 and -1.03 V vs NHE, respectively.49
In agreement with the peripheral position of the nitro group
in the ligands, their reduction potentials are only slightly
more negative than those of the corresponding ligands in
the gallium and iron complexes. In addition, an irreversible
prewave was observed at Ep ) -0.82 and -0.80 V vs NHE,
respectively, which was also reported for o-nitrotoluene and
m-nitrotoluene in aprotic solvents.52 In contrast to the ligand-
centered reduction in the metal complexes where both ligands
are forced to adopt the same conﬁguration, the metal-free
ligands are present as different isomers in solution, therefore
showing no conclusive correlation between the Ep and pKa
values of the amine moieties of the ligand. In particular, for
ligand HLB three different isomers were found in DMSO
solution,24 two of them with strong intramolecular hydrogen
bonds, whereas ligand HLH in the same solvent is present
as one isomer (see NMR data). The metal-ion stabilizes the
reduced ligand radicals preventing their decomposition on
the time-scale of cyclic voltammetry and allowing for the
observation of two or three reversible ligand-centered redox
waves upon coordination. The gallium-complexes are re-
duced at ∼0.3-0.8 V more positive redox potential than the
uncoordinated ligands, whereas the same ligand-centered
reductions in the iron(II) and ruthenium(II) complexes occur
at ∼0.0-0.4 V more negative redox potentials than in the
metal-free thiosemicarbazones. Therefore complexation to
different metal ions strongly inﬂuences the ligand-centered
redox potentials, offering the possibility to speciﬁcally shift
them into the physiologically accessible range.
Metal-Centered Redox Processes. The cyclic voltam-
mograms of the iron complexes 2A-2I (Figure 8a, Table
2) display one reversible single-electron reduction wave,
CFered, at 0.06 to 0.51 V vs NHE, which is assigned to the
FeIII f FeII process of the cationic complex (oxip /redip ) 1.0
for V > 0.05 V/s with ΔEp ) 0.60-0.70 at 0.2 V/s). As
observed for the ligand-centered redox behavior, an increas-
ing net electron-donor character of the ligands (expressed
by their basicity; pKa values of substituents) correlates with
a decrease in redox potential of the iron-centered redox
couples (Figure 7). Whereas complexes 2A-2I showed only
one reduction wave (Figure 8a), the analogous complexes
2′A-2′G displayed a second wave at 0.31 ( 0.01 V vs NHE,
which is attributed to the reduction of the tetrachloridoferrate
anion, AFered (Figure 8b). Wave AFered overlaps in 2′E-2′G
with the reduction wave of the complex cation, CFered, and
could not be resolved by cyclic or square wave voltammetry,
indicating that a set of two anionic tridentate ligands
HLE-HLG acts as a net electron-donor as strong as four
tetrahedrally coordinated chlorido ligands. The current height
of the FeIII/FeII redox couple in 2′E-2′G (same concentration
and experimental conditions) was approximately 2-fold
compared to that of 2E-2G, as conﬁrmed by cyclic and
square wave voltammetry (Figure 8). Therefore, the unre-
solved wave in 2′E-2′G arises from an overlap of the FeIII/
FeII waves of the cationic iron complex and the tetrachlo-
(51) CRC Handbook of Chemistry and Physics; Lide, D. R., Ed.; CRC
Press: Boca Raton, FL, 2004.
(52) Nunez-Vergara, L. J.; Bonta, M.; Navarrete-Encina, P. A.; Squella,
J. A. Electrochim. Acta 2001, 46, 4289–4300.
Figure 7. Plot of pKa values of attached amine moieties on thiosemicar-
bazone ligands vs ligand- and metal-centered E1/2 values for the gallium
(1A-1I, top) and iron (2A-2I, bottom) complexes. For the complexes 1D,
2D, and 2I, the reduction of the nitro group prevented the detection of ILred
and/or IILred. CFered ) FeIII/FeII redox couple of complex cation; Lred )
ligand-centered reduction; thiosemicarbazonate complexes with pyrazine
(pz) or pyridine (py) moieties are shown separately. Linear equations for
gallium complexes: ILred (pz) E1/2 (V) ) -0.359 - 0.0206 ·pKa (r ) 0.996);
IILred (pz) E1/2 (V) ) -0.600 - 0.0233 ·pKa (r ) 0.985); ILred (py) E1/2 (V)
) -0.673 - 0.0247 ·pKa (r ) 0.997); IILred (py) E1/2 (V) ) -0.902 -
0.0302 ·pKa (r ) 0.997). Linear equations for iron complexes: FeIII/FeII (pz)
E1/2 (V) ) 0.524 -0.018 ·pKa (r ) 0.995); FeIII/FeII (py) E1/2 (V) ) 0.285
- 0.0197 ·pKa (r ) 0.995); ILred (pz) E1/2 (V) ) -0.969 - 0.0227 ·pKa (r
) 0.998); ILred (py) E1/2 (V) ) -1.302 - 0.0284 ·pKa (r ) 0.999); IILred
(pz) E1/2 (V) ) -1.334 - 0.0279 ·pKa (r ) 0.997); IILred (py) E1/2 (V) )
-1.499 - 0.0455 ·pKa (r ) 0.999).
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ridoferrate anion indicating the two-electron nature of this
reduction wave (Figure 8). The presence of two overlapped
one-electron processes in 2′E-2′G was conﬁrmed by
controlled potential electrolysis of 2′F at 0.14 V vs NHE.
The ruthenium(III) complex shows two reversible metal-
centered redox waves with the ﬁrst one at +0.21 V for the
RuIII f RuII redox couple and the second at +1.27 vs NHE
attributable to the RuIII f RuIV redox process (Figure 6c).
The 1.06 V difference for the RuIIIf RuII and RuIIIf RuIV
redox couples is small compared to the commonly observed
separation of these two redox waves of ∼1.6 V for octahedral
ruthenium complexes in nonaqueous solvents.53 However,
this difference can be explained by the distortion of the
octahedral geometry resulted from coordination of the
tridentate thiosemicarbazonate ligands to ruthenium, which
makes direct comparisons with other sterically noncon-
strained complexes difﬁcult.
Location of Ligand-Centered Reduction Site. Most of
the literature dealing with electrochemical properties of R-N-
heterocyclic thiosemicarbazone complexes is exclusively
focused on the metal-centered redox reactions,54-57 neglect-
ing the ligand-centered redox processes. If reductions are
described that are associated with the ligand, the position
where reduction takes place in the thiosemicarbazone moiety
is either undeﬁned58-60 or changes between the thione
portion61 and the azomethine part,62 whereas no further
studies are reported to support these assumptions. Detailed
investigations on the reduction pathway were performed for
the metal-free 2-formylpyridine thiosemicarbazone in metha-
nol.63 The data showed that the ligand is ﬁrst protonated at
the azomethine nitrogen then cleaved at the N-N bond,
forming thiourea and the 2-pyridinemethaniminium ion,
which is then further reduced to protonated 2-picolylamine.
Two other reduction mechanisms were excluded in that
study, namely, the reduction at the pyridine ring resulting
in dihydropyridine and the formation of the thiol by reduction
of the CdS double bond. The direct reduction of the
azomethine bond was already reported for the same ligand
in water 20 years ago.64 There is only one publication dealing
with the metal ion inﬂuence on the redox potentials of a
thiosemicarbazone ligand.65 Although the reference electrode
was not speciﬁed, making a quantitative comparison impos-
sible, the reported redox potentials of the perchlorate salt of
the iron(III) complex 2B and the ligand HLB appeared at
considerably different values for all reduction waves than
observed in the present study. To the best of our knowledge,
(53) Reisner, E.; Arion, V. B.; Guedes da Silva, M. F. C.; Lichtenecker,
R.; Eichinger, A.; Keppler, B. K.; Kukushkin, V. Yu.; Pombeiro,
A. J. L. Inorg. Chem. 2004, 43, 7083–7093.
(54) Bindu, P.; Kurup, M. R. P.; Satyakeerty, T. R. Polyhedron 1998, 18,
321–331.
(55) Prabhakaran, R.; Renukadevi, S. V.; Karvembu, R.; Huang, R.; Mautz,
J.; Huttner, G.; Subashkumar, R.; Natarajan, K. Eur. J. Med. Chem.
2008, 43, 268–273.
(56) Sengupta, P.; Dinda, R.; Ghosh, S.; Sheldrick, W. S. Polyhedron 2003,
22, 447–453.
(57) Ainscough, E. W.; Brodie, A. M.; Denny, W. A.; Finlay, G. J.; Ranford,
J. D. J. Inorg. Biochem. 1998, 70, 175–185.
(58) Kovala-Demertzi, D.; Domopoulou, A.; Demertzis, M. A.; Papageor-
giou, A.; West, D. X. Polyhedron 1997, 16, 3625–3633.
(59) Costa, R. F. F.; Rebolledo, A. P.; Matencio, T.; Calado, H. D. R.;
Ardisson, J. D.; Cortes, M. E.; Rodrigues, B. L.; Beraldo, H. J. Coord.
Chem. 2005, 58, 1307–1319.
(60) Graminha, A. E.; Vilhena, F. S.; Batista, A. A.; Louro, S. R. W.; Ziolli,
R. L.; Teixeira, L. R.; Beraldo, H. Polyhedron 2008, 27, 547–551.
(61) Aguirre, M.; Borras, J.; Castineiras, A.; Garcia-Monteagudo, J. M.;
Garcia-Santos, I.; Niclos, J.; West, D. X. Eur. J. Inorg. Chem. 2006,
1231–1244.
(62) Chattopadhyay, S. K.; Chattopadhyay, D.; Banerjee, T.; Kuroda, R.;
Ghosh, S. Polyhedron 1997, 16, 1925–1930.
(63) Pessôa, M. M. B.; Andrade, G. F. S.; dos Santos, M. R.; Temperini,
M. L. A. J. Electroanal. Chem. 2003, 545, 117–122.
(64) Vire, J. C.; De Jager, R. L.; Dupont, D. G.; Patriarche, G. J.; Christian,
G. D. Fresenius J. Anal. Chem 1981, 307, 277–282.
(65) Kovala-Demertzi, D.; Domopoulou, A.; Demertzis, M. A.; Valdes-
Martinez, J.; Hernandez-Ortega, S.; Espinosa-Perez, G.; West, D. X.;
Salberg, M. M.; Bain, G. A.; Bloom, P. D. Polyhedron 1996, 15, 2587–
2596.
Figure 8. Cyclic voltammograms (top, 0.20 V s-1) and square wave
voltammograms (bottom, 2 mV step height, 25 mV pulse, 100 Hz frequency)
of (a) 2A (black), (b) 2′A (gray), (c) 2′E (black) in 0.20 M [n-Bu4N][BF4]/
CH3CN by using a platinum working electrode. CFered indicates the metal-
centered reduction of the cathodic complex, and AFered the reduction of the
[FeCl4]- counteranion.
Figure 9. Plot of δ(13CdN) of the CH3CdN moiety vs E1/2 of complexes
1A-1H (pz ) pyrazine; py ) pyridine). Linear equations: ILred (pz) E1/2
(V) ) (δ - 168.96)/39.35 (r ) 0.987); IILred (pz) E1/2 (V) ) (δ - 175.32)/
34.29 (r ) 0.972); ILred (py) E1/2 (V) ) (δ - 179.19)/33.89 (r ) 0.993);
IILred (py) E1/2 (V) ) (δ - 179.61)/26.23 (r ) 0.995).
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this is the ﬁrst detailed electrochemical study of the inﬂuence
of metal ions and the chalcogen donor identity on the redox
properties of thiosemicarbazones.
There are two locations, where the ligand-centered reduc-
tion of the complexes can take place: either at the CdN
double bond of the 2-acetylpyridine moiety (CH3CdN) or
at the CdN double bond in close proximity to the chalcogen
atom. By comparison of the 13C NMR data of the gallium
complexes 1A-1I with the E1/2 redox potentials, a good
correlation can be found for both carbon resonances of the
CH3CdN moiety (Figures 9 and S2, Supporting Informa-
tion); an increasing redox potential at ILred and IILred correlates
with enhanced electronic deshielding resulting in downﬁeld
chemical shifts for the corresponding 13C nucleus. This
allows for the prediction of the ligand-centered redox
potentials of the gallium complexes by NMR shifts, and vice
versa. In contrast, no correlation could be found for the C-S
resonance (1A 172.9 ppm; 1B 176.1 ppm; 1C 172.5 ppm;
1D 172.4 ppm).23,24 Therefore, we suppose that the one-
electron ligand-centered reduction takes place at the
CH3CdN bond. This is in agreement with quantum chemical
calculations (see below) and the chemical reduction of this
CdN bond for the metal-free and coordinated ligands. The
addition of NaBH4 to an ethanolic solution of ligand HLB
resulted in the reduction of the CdN bond and the formation
of ligand HLM, which displays its ﬁrst reduction wave only
at -2.10 V vs NHE. Similarly, reduction of the nitrate salt
of 1B (precipitated after addition of diethyl ether to the 1:2
mixture of Ga(NO3)3 and HLB) with NaBH4 yielded a
product containing the uncoordinated reduced ligand HLM
in around 50% yield.
Quantum Chemical Studies. Density functional calcula-
tions were performed to elucidate (i) why the ligand-centered
reductions of the iron(II) complexes [FeII(L)2] (formed by
reduction of the iron(III) complex [FeIII(L)2]+) have a lower
standard reduction potential (SRP) than the nonmetalated
thiosemicarbazones (HL) and (ii) to locate the site of
reduction at the thiosemicarbazone ligands. The reduction
of a compound should be strongly facilitated by forming a
complex with a cationic metal ion, which should have been
reﬂected by a considerably higher redox potential. The one-
electron-reduction events involving the species, (LB)-, HLB,
[Ga(LB)2]+ (1B), and [FeII(LB)2] (2B), yielding their reduced
forms, (LB)2-, (HLB)-, [Ga(LB)2], and [FeII(LB)2]-, respec-
tively, have been investigated and compared. Note that the
deprotonated species (LB)- shall serve as the intuitive
reference compound in our calculations, because the reduc-
tion potential of (LB)- may be controlled by either proto-
nation (HLB) or metalation ([Ga(LB)2]+ and [FeII(LB)2]).
Table 3 shows an excellent agreement of our calculated and
experimental SRPs, validating the computational approach
employed for this study (all energies and SRP values are
calculated in acetonitrile solution).
Figure 10 displays the predicted structures of the most
stable isomers of (LB)-, HLB, and their reduced forms, while
other plausible isomers of (LB)- and HLB are shown in
Supporting Information, Figure S3. Figure 10 also displays
the structure of the gallium complex [Ga(LB)2]+, while the
other metal complexes have the same overall shape but with
noticeable differences in the bond distances (see Tables 4
and S4, Supporting Information). The predicted structures
of HLB and [Ga(LB)2]+ are in good to excellent agreement
with available X-ray crystallographic structures (Supporting
Information, Table S4). The calculations reveal structural
changes in the entire compounds upon reduction. In the free
ligand (LB)- (Figure 10, top), the C-S bond is elongated
(+0.04 Å) upon reduction, the adjacent CdN bond is
shortened (-0.03 Å), the N-N bond is elongated (+0.03
Å), the acetylpyridine CdN bond is elongated (+0.03 Å),
the adjacent C-C bond is shortened (-0.02 Å), and the CdN
bond in the pyridine is elongated (+0.04 Å). Similar
structural changes occur when the protonated species HLB
is reduced (Figure 10). Upon reduction of the metal
complexes [Ga(LB)2]+ and [FeII(LB)2], the structures within
the ligands change in a similar manner, but to a lesser extent
as compared to the nonmetalated species (Supporting Infor-
mation, Table S4). The reduction of the metal complexes is
also accompanied by relatively minor changes in the
metal-ligand distances (Table 4). The Ga-N bonds are
slightly shortened (-0.02 and -0.03 Å), whereas the Ga-S
bonds are elongated (+0.04 Å). In contrast, the Fe-N
distances remain constant, while the Fe-S bonds are slightly
elongated (+0.02 Å).
Table 3 lists the electron-density-based Hirshfeld partial
charges on the ligands, the metals, and the proton in the four
initial species and their reduced forms. The calculated charges
at the H, Fe, and Ga atoms in HLB, [FeII(LB)2], and
[Ga(LB)2]+ are +0.08, +0.02, and +0.32, respectively, while
the charge on each ligand is -0.08, -0.01, and +0.34,
adding up to a total charge of 0, 0, and +1 in these
compounds. Upon reduction, the charges at H, Fe, and Ga
remain constant, while the additional electronic charge is
distributed over the ligands. Partial charges calculated using
various other approaches are given in Supporting Informa-
tion, Table S5. While the absolute values differ from the
Hirshfeld charges, the overall trend of the charges increasing
in the order Fe < H < Ga is supported by each approach.
The intuitive assumption that the reduction of a compound
Table 3. Calculated and Experimental Standard Redox Potentials (SRP,
in V vs NHE), Hirshfeld Partial Charges in the Oxidized and Reduced
Forms, and LUMO Energy Level of the Oxidized Species (ELUMO, in
eV)
partial charges
SRP (E1/2); ILred ox red
compound calcd exptl Ma L Ma L ELUMO
(LB)-/2- -1.69 -1.00 -2.00 1.12
[Fe(LB)2]0/- -1.56 -1.61 0.02 -0.01 0.02 -0.51 -2.45
(HLB)0/- -1.12 -1.21 0.08 -0.08 0.07 -1.07 -3.03
[Ga(LB)2]+/0 -0.86 -0.93 0.32 0.34 0.32 -0.16 -5.85
a H, Ga, and Fe, respectively.
Table 4. Calculated Metal-Ligand Bond Lengths in Ångstrom
metal-S metal-N(N-N) metal-N(py)
compound ox red ox red ox red
[Ga(LB)2]+/0 2.41 2.45 2.09 2.06 2.14 2.12
[Fe(LB)2]0/- 2.32 2.34 1.90 1.90 1.94 1.94
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is facilitated when it binds to a metal ion appears to be valid
only if the deprotonated free ligand (LB)- is considered as
the reference compound, whereas a proton promotes the
reduction of the thiosemicarbazone more strongly than does
the iron(II) ion with its d6 low-spin electron conﬁguration.
Figure 11 displays the semioccupied molecular orbital
(SOMO) of the four reduced species (LB)2-, (HLB)-,
[FeII(LB)2]-, and [Ga(LB)2]. This orbital corresponds in each
case to the lowest unoccupied orbital (LUMO) of the
oxidized form (Supporting Information, Figure S4). The
LUMO energy levels of the oxidized species are also listed
in Table 3 and correlate with the reduction potentials: the
lower the LUMO energy, the easier the reduction. The
SOMO of (LB)2- and its conjugate acid (HLB)- are very
similar; they are distributed over the entire π system and
have both bonding and antibonding character leading to the
bond distance changes upon reduction (see above). For
instance, as the SOMO of (HLB)- has a bonding contribution
to the CdN bond adjacent to the sulfur atom (marked with
b in Figure 11), this bond is shortened when an electron
occupies this orbital. The SOMO of (HLB)- has an anti-
bonding contribution to the CdN bond adjacent to the pyridyl
group (marked with a in Figure 11), thus elongating this bond
upon reduction. This result is consistent with the chemose-
lective hydrogenation of the latter CdN bond by NaBH4 (see
above). The SOMO of the reduced metal complexes show
the same bonding and antibonding patterns as those in the
SOMO of the free ligand. In contrast to the SOMO of the
gallium species, the SOMO of the reduced iron complex
contains a small fraction of a metal d orbital. Note that none
of the iron-ligand bond lengths shortens during reduction,
indicating an enhanced Pauli repulsion between the ligand
orbitals and the partially ﬁlled d shell in the reduced iron
complex.
Biological Relevance and Comparison of Electrochemi-
cal Data with Cytotoxicity and R2 Speciﬁc Tyrosine
Free Radical Quenching. The inﬂuence of water on the
redox potentials of the gallium, iron, and ruthenium com-
plexes was studied by measuring complexes 1B, 1C, 1G,
1H, 1I, 2B, 2C, 2D, 2G, 2H, 2I, and 3B in CH3CN/H2O
(7:3 v/v) or DMF/H2O (7:3 v/v) mixtures. The low solubility
of the complexes prevented the measurement in pure aqueous
electrolyte solutions. The metal-centered redox waves for
the MIIIfMII process for the iron and ruthenium complexes
remained reversible (involving net 1+/0 net charged com-
plexes) in the aqueous organic electrolyte solutions and are
slightly shifted to more negative values with a maximum
(66) Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.;
Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. J. Med. Chem. 2006,
49, 6510–6521.
Figure 10. Calculated structures of (LB)-, (LB)2-, HLB, (HLB)-, and [Ga(LB)2]+. Bond lengths in Å.
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shift of -70 mV for 2D. Iron dipyridinyl thiosemicarbazone
complexes measured in CH3CN/H2O (7:3 v/v) were reported
to give reversible FeIII/FeII redox potentials of +0.153 to
+0.225 V vs NHE.66 The direct dipyridinyl analogs of
complex 2B and 2C exhibit redox potentials of +0.166 and
+0.225 V vs NHE, respectively, implying a more positive
potential of the phenyl substituted complex in comparison
to the 4N-dimethyl-substituted one in line with our results.
In general, higher potentials are observed for dipyridinyl
complexes due to the electron withdrawing properties of the
pyridinyl group. Furthermore, a series of 5-substituted 2-for-
mylpyridine thiosemicarbazone complexes measured in water
possess reversible iron redox potentials from +0.024 to
+0.386 V vs NHE.67
Because water has a smaller potential window, the ligand-
centered reductions for the iron complexes could be studied
only in the case of 2G and 2H. These turned out to be
completely irreversible indicating that the generated radicals
upon reduction can no longer be stabilized by the metal
center resulting in fast radical quenching by the water. We
can therefore assume that the generated ligand-radicals are
highly reactive under physiological conditions. In contrast
to the iron-centered redox processes, the reduction potentials
(Ep) for the ﬁrst ligand reduction (wave ILred; involving net
0/1- charged complexes) is shifted by +100 mV and for
the second ligand-centered reduction (wave IILred; involving
net 1-/2- charged complexes) by approximately +300 mV
for both complexes compared to the measurements in CH3CN
electrolyte solutions. The ﬁrst ligand-centered reduction
potential (wave ILred; involving net 1+/0 net charged
complexes) of the gallium complexes 1B, 1C, 1G, 1H, and
1I showed a slightly cathodically shifted redox potential (ca.,
-50 mV), whereas the second ligand-reduction at IILred was
anodically shifted up to +150 mV compared to the measure-
ments in pure organic electrolyte solutions. In general, redox
couples involving positive net charged species are shifted
to more negative redox potentials in aqueous solutions
(compared to organic medium) and vice versa. This behavior
has been explained previously1,10 on the basis of the Born
model of solvation. In accordance with this model, stabiliza-
tion of a more positively or more negatively charged species
occurs through the higher solvation energy of water resulting
in decreasing or increasing redox potentials, respectively. The
Born equation shows that the solvation energy is proportional
to the squared charge, what explains the larger shift for the
1-/2- charged species (wave IILred in iron(II) complexes)
compared to the 0/1- and 1+/0 net charged complexes.
The physiological accessibility of the MIII/MII redox couple
between 0.06 and 0.51 V vs NHE by biological reducing
agents was studied by UV-vis spectroscopy measurements
of complexes 2B, 2G, and 3B in 1% aqueous DMSO solution
with a 5-fold excess of ascorbic acid (E1/2 ) +0.06 vs
NHE68). Complex 2G is reduced immediately after addition
of ascorbic acid accompanied by a color change from brown
to green. For the ruthenium(III) complex, the UV-vis
spectrum changes within minutes, whereas for 2B only small
(67) Knight, J. M.; Whelan, H.; Petering, D. H. J. Inorg. Biochem. 1979,
11, 327–338.
(68) CRC Handbook of Biochemistry and Molecular Biology; Fasman,
G. D., ED.; CRC Press: Cleveland, OH, 1976; p 122.
Figure 11. SOMO of the reduced species.
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changes can be observed after hours. These results are in
accordance with the MIII/MII redox potentials of the metal
complexes. One major goal of this study was to introduce
electron-withdrawing substituents such as nitro-groups into
the thiosemicarbazone ligands to shift the ligand-centered
redox potentials in the direction of the physiologically
accessible range. Indeed, several gallium complexes have
redox potentials for ILred around -0.4 vs NHE, which is given
as a guiding value for the redox potential reachable in cells.69
Unfortunately, the low solubility in DMSO/H2O mixtures
with a maximal content of 1% DMSO prevents the cyto-
toxicity measurements of the novel synthesized compounds.
Therefore the comparison of the IC50 values and the
electrochemical data can only be done for the 4N-disubstituted
ligands and complexes. The cytotoxicity data of the 41 M
cancer cell line show the overall trend that the iron(III)
complexes exhibit the lowest cytotoxicity (13-172 nM)
followed by the metal-free ligand (0.073-1.1 nM) and the
gallium complexes (0.0045-0.27 nM).23 The same trend,
but less pronounced, can be found in the SK-BR-3 cancer
cell line.23 The direct comparison reveals that the gallium(III)
complexes are by a factor of 210 to 33000 (41M) and 150
to 4000 (SK-BR-3) more cytotoxic than the corresponding
iron complexes, respectively. Interestingly, the coordinated
thiosemicarbazone ligands are most easily reduced in the case
of the gallium complexes, followed by the metal-free ligands
and shifted to very low redox values in the case of the iron
complexes, what correlates with the previously obtained
cytotoxic data. But as mentioned above, we should be aware
that the physiologically accessible range of the redox
potential of cells is given from -0.4 to +0.8 V vs NHE.69
The order of the R2 speciﬁc tyrosine free radical destruction
in mouse ribonucleotide reductase is in contrast to the cy-
totoxicity data and the electrochemical results of the ligand-
centered reductions: fastest inhibition of the enzyme occurs
in the case of the iron complexes suggesting that the redox
properties of iron play an important role in the radical
quenching process.
Final Remarks
The syntheses of a series of gallium-, iron-, and ruthenium-
chalcogensemicarbazonate complexes are reported; the elec-
trochemical properties of these compounds are investigated
in detail, and their biological relevance is discussed. The
electrochemical behavior of these complexes can be speciﬁed
by (i) physiologically accessible metal-centered redox po-
tentials for the iron(III) and ruthenium(III) complexes, (ii)
formation of stable ligand radicals on the time-scale of cyclic
voltammetry upon reduction of the noninnocent chalcogen-
semicarbazone ligands in aprotic solvents, (iii) quenching
of these reductively induced ligand radicals by water, (iv)
shift of the ligand-centered redox potential in the physi-
ologically accessible range for some gallium complexes when
electron-withdrawing moieties are incorporated into the
ligand, and (v) ligand-reduction for the gallium complexes
occurs at the CH3CdN double bond. Quantum chemical
calculations show that reduction of the coordinated and
metal-free thiosemicarbazone ligands occurs at a π-orbital
that spreads over the entire thiosemicarbazone moiety. The
ligand-centered reductions ILred and IILred take place at
0.3-0.8 V more positive potentials for the gallium complexes
than for the uncoordinated (protonated) ligands. The latter
on the other hand are easier to reduce than the corresponding
iron(II) complexes. The redox potentials increasing in the
order [FeII(LB)2] < HLB < [Ga(LB)2]+ are consistent with
the trend of the calculated partial charges, Fe < H < Ga, in
these compounds and with the energy levels of their LUMO.
The presented results on the electrochemical behavior of
potential antitumor chalcogensemicarbazonate complexes
allow for the future design of potential drugs with predictable
and desired redox properties.
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Detailed discussion of the NMR data of 1H
The quaternary carbon atoms of the pyrazine moiety and the C=N double bond were detected via a 
long-range 1H–13C HMBC NMR experiment. Shift correlation signals of the methyl protons of C6 and 
carbon atoms C4 and C5 at 139.8 and 150.8 ppm, respectively, were found, but could not be assigned 
unequivocally on the basis of their chemical shifts. With the aim to find a long-range shift correlation 
between one of the pyrazine protons namely that of C2 and the quaternary atom C4, which would 
exclude a long-range coupling via five bonds to carbon atom C5, accurate assignment of pyrazine 
protons of C1, C2 and C3 was needed. In the 1H NMR spectrum of 1H, three multiplets at 9.66 (d, 1.1 
Hz), 8.96 (d, 2.8 Hz) and 8.09 ppm (dd, 1.1 and 2.8 Hz) of the pyrazine moiety were detected. In a 
homonuclear decoupling experiment, the proton at 9.66 was irradiated resulting in two doublets (at 
8.96 and 8.09 ppm) with vicinal coupling constants of 2.8 Hz. By using this technique, the proton of C3 
at 9.66 was assigned. The resonance of proton at C2 was allocated via a long-range 1H–15N HMBC 
NMR measurement optimized for coupling constants of 10 Hz, since both protons of C2 and C3 should 
show a correlation signal to the same 15N nucleus. 1H–15N cross peaks at 9.66/244.7 and 8.09/244.7 
ppm, respectively, were detected providing evidence that proton of C2 resonates at 8.09 ppm. In 
addition, a long-range coupling of proton at C2 (8.09 ppm) with the quaternary carbon atom C4 at 
139.8 ppm was found undoubtedly confirming the chemical shift of carbon atoms C4 and C5 (150.8 
ppm).
N
N
N
C1
C2
C3
C6
C4
C5
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Table S1. Comparison of standard reduction potentials (SRPs, in V vs. NHE) calculated at B3LYP and 
BP86. 
Compound B3LYP BP86 exp
(LB)−/2− –1.81 –1.69
(HLB)0/− –1.18 –1.12 –1.21
[Ga(LB)2]+/0 –1.35 –0.86 –0.93
[Fe(LB)2]0/− –2.00 –1.56 –1.61
Table S2. Relative energies (in kcal/mol) of plausible electronic states of [FeII(LB)2] and [FeII(LB)2]−. 
multiplicity B3LYP BP86
[FeII(LB)2] 1 10.6 0
3 5.9 15.0
5 0 20.6
[FeII(LB)2]− 2 13.5 0
4 0 6.3
Table S3. Redox potentialsa of the metal-free ligands HLA–HLM.
Ligand Ep / ILred
A –1.26
B –1.21
Cb –1.47
Db n/ac
E –1.06
F –1.02
G –1.01
Hb –1.31
Ib n/ac
J –1.83
K –1.13
M n/ad
a) Potentials in V ± 0.02 vs. NHE in 0.20 M [n-Bu4N][BF4]/CH3CN; b) measured in 0.20 M 
[n-Bu4N][BF4] / DMF; c) for the nitro-containing ligands, only the reduction of this group at ca. –1.0 V 
vs. NHE and a pre-wave at ca. 0.80 V vs. NHE can be observed (see text); d) first reduction at –2.10 V 
vs. NHE. 
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Table S5. Calculated partial charges on the ligands and on the metal or hydrogen. 
Mulliken (lb)a Mulliken (sb)b ESP (sb)c Hirshfeldd
Compound moiety ox red ox red ox red ox red
(LB)−/2− –1.00 –2.00 –1.00 –2.00 –1.00 –2.00 –1.00 –2.00
(HLB)0/− H 0.30 0.29 0.29 0.28 –0.04 –0.01 0.08 0.07
L –0.30 –1.29 –0.29 –1.28 0.04 –0.99 –0.08 –1.07
[Ga(LB)2]+/0 Ga 1.90 1.92 0.94 1.00 0.42 0.48 0.32 0.32
L –0.45 –0.96 0.03 –0.50 0.29 –0.24 0.34 –0.16
[Fe(LB)2]0/− Fe –0.82 –0.84 –0.02 –0.02 –0.16 –0.10 0.02 0.02
L 0.41 –0.08 0.01 –0.49 0.08 –0.45 –0.01 –0.51
a
 Large basis set. Totally uncontracted LANL2DZ on Ga and augmented with one set of f functions on 
Fe, together with the 6-311+G(d,p) basis sets on the other atoms, and the 6-311+G(3d) on S. 
b
 Small basis set. LANL2DZ on the metal, 6-31G(d,p) on the other atoms. 
c
 Same small basis set, denoted LACVP** in Jaguar. 
d Scalar relativistic ZORA, TZV2P basis on the metals and TZVP basis set on the other atoms. 
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Figure S1. Cyclic voltammogram of 3B in CH3CN containing 0.20 M [n-Bu4N][BF4] at a scan rate of 
0.20 V s–1 using a glassy carbon working electrode.
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Figure S2. Plot of δ(13CH3) of the CH3C=N moiety vs. E1/2 of complexes 1A–1H. Linear equations: 
ILred (pz): E1/2 (V) = (δ – 18.86)/6.41 (r = 0.95); IILred (pz): E1/2 (V) = (δ – 19.87)/5.56 (r = 0.93); ILred 
(py): E1/2 (V) = (δ – 21.67)/7.09 (r = 0.98); IILred (py): E1/2 (V) = (δ – 22.41)/6.03 (r = 0.95).
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Figure S3. Calculated relative energies (in kcal/mol) of plausible isomers of 2-acetylpyridine N,N-
dimethylthiosemicarbazone (HLB) and its deprotonated form (LB)− in acetonitrile.
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Figure S4. LUMO of the oxidized species (LB)−, HLB, [FeII(LB)2] and [Ga(LB)2]+. 
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2.4 Impact of Metal Coordination on Cytotoxicity of  
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and 
Novel Insights on Terminal Dimethylation 
 
Kowol, C. R.; Trondl, R.; Heffeter, P.; Arion, V. B.; Jakupec, M. A.; Roller, A.; 
Galanski, M.; Berger, W.; Keppler, B. K.   
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Abstract 
The first metal complexes of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) were 
synthesized. Triapine was prepared by a novel three-step procedure in 64% overall yield. In addition, a 
series of related ligands, namely, 2-formylpyridine thiosemicarbazone, 2-acetylpyridine 
thiosemicarbazone, 2-pyridineformamide thiosemicarbazone and their 4N-dimethylated derivatives 
(including the 4N-dimethylated analog of Triapine) were prepared, along with their corresponding 
gallium(III) and iron(III) complexes with the general formula [M(L)2]+, where HL is the respective 
thiosemicarbazone. The compounds were characterized by elemental analysis, 1H and 13C NMR, IR and 
UV-vis spectroscopies, mass spectrometry and cyclic voltammetry. In addition, Triapine and its iron(III) 
and gallium(III) complexes were studied by X-ray crystallography. All ligands and complexes were 
tested for their in vitro antiproliferative activity in two human cancer cell lines (41M and SK-BR-3), and 
structure-activity relationships were established. In general, the coordination to gallium(III) increased 
the cytotoxicity, while the iron(III) complexes show reduced cytotoxic activity as compared to the metal-
free thiosemicarbazones. Selected compounds were investigated for the capacity of inhibiting 
ribonucleotide reductase by incorporation of 3H-cytidine into DNA. 
 
Introduction 
Thiosemicarbazones are versatile ligands, as they adopt various binding modes with transition and 
main group metal ions.1 These can act as mono- or bidentate ligands,2 and their coordination capacity 
can be further increased, if aldehydes or ketones which contain additional functional group(s) in 
position(s) suitable for chelation are used for their preparation.3,4 Beside their exciting coordination 
chemistry, thiosemicarbazones are known to possess a wide range of pharmaceutical properties such as 
antitumor, antiviral, antifungal, antibacterial and antimalarial activity.5 In addition, 64Cu-
bis(thiosemicarbazonate) complexes are under investigation as hypoxia-selective positron emission 
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tomography tracers.6 The first thiosemicarbazone with antitumor properties, namely 2-formylpyridine 
thiosemicarbazone, was reported about 50 years ago.7 Further studies showed that a prerequisite for 
biological activity is a nitrogen heterocycle which contains a suitable functional group for condensation 
with thiosemicarbazide derivatives in α-position.8 5-Hydroxy-2-formylpyridine thiosemicarbazone (5-
HP) was the first compound of this series which entered phase I clinical trials. However, 5-HP is rapidly 
transformed in the body and eliminated as an inactive glucuronide conjugate.9,10 In addition, 5-HP 
showed severe hematological and gastrointestinal side effects which prevented its further clinical 
development. The currently most promising thiosemicarbazone as antitumor agent is 3-aminopyridine-2-
carboxaldehyde thiosemicarbazone (Triapine, 3-AP), which entered several phase I and II clinical 
trials.11,12,13,14,15  
As the principal molecular target of α-N-heterocyclic thiosemicarbazones the enzyme ribonucleotide 
reductase (RR) has been identified.16,17,18 This enzyme catalyzes the conversion of ribonucleotides into 
deoxyribonucleotides, providing the precursors required for DNA synthesis and repair. α-N-Heterocyclic 
thiosemicarbazones are the most potent inhibitors of RR known so far. They are several orders of 
magnitude more effective than hydroxyurea, the first clinically applied RR inhibitor.19 Faster 
proliferation of tumor cells as compared to normal cells and therefore higher expression of RR make this 
enzyme a suitable and well established target in cancer chemotherapy.20 The human RR consists of two 
homodimeric subunits: R1 and R2. The first subunit harbors the nucleotide binding site and the second 
subunit a diiron center and a tyrosyl radical. Transfer of the radical electron from tyrosine (Y122) of R2 
occurs by a proton-coupled mechanism via a chain of hydrogen-bonded amino acids over a distance of 
35 Å to cysteine (C439) of R1 subunit, where it generates a thiyl radical essential for reduction of the 
substrates.21 Recently, a second R2 subunit, called p53R2, has been identified in human cells with ~80% 
sequence homology with R2, but with p53-dependent expression.22 The p53 protein actively suppresses 
tumor formation, and the majority of human tumors have been found to contain mutations in p53 or 
defects in the pathways responsible for its activation.23 Thus the discovery of p53R2 revealed a link 
between the most important tumor suppressor and the synthesis of deoxyribonucleotides. 
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We reported previously that the gallium(III) complexes of 4N-disubstituted α-N-heterocyclic 
thiosemicarbazones (HL), with the composition [Ga(L)2]+, exhibit enhanced cytotoxicity in the low 
nanomolar range, in human cancer cell lines. In contrast, the corresponding iron(III) complexes 
displayed a much lower cytotoxicity (in the micromolar range) than the metal-free ligands.24 EPR 
measurements on isolated mouse R2 subunits of RR showed that the effects of the complexation to 
gallium(III) and iron(III) on the destruction of the R2 specific tyrosine free radical in the presence of the 
reductant dithiothreitol (DTT) are in the reverse order. The iron(III) complexes show the fastest 
destruction of the tyrosyl radical in RR, followed by the metal-free ligands and the corresponding 
gallium(III) complexes.24 In the case of Triapine, iron also enhances radical quenching.25 However, in 
contrast to 4N-dimethylated α-N-heterocyclic thiosemicarbazones, addition of iron(III) to Triapine 
results only in small changes in cytotoxicity.26,27 
In order to evaluate the effect of complexation on the cytotoxicity of Triapine, the gallium(III) and 
iron(III) complexes were synthesized for the first time. For elucidation of further structure-activity 
relationships, a series of related ligands and their corresponding gallium(III) and iron(III) complexes 
were prepared (Scheme 1). In particular, the effects of the amino group and its position as well as the 
influence of 4N-disubstitution on cytotoxicity were investigated, including for the first time the Triapine 
analog 3-aminopyridine-2-carboxaldehyde 4N-dimethylthiosemicarbazone. In addition, selected 
compounds were tested for their capacity of inhibiting ribonucleotide reductase by a 3H-cytidine DNA 
incorporation assay. 
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Scheme 1. Library of the synthesized compounds; underlined species were studied by X-ray 
crystallography. 
 
Results and Discussion  
Syntheses. The first reported synthesis of Triapine (HLD) with an overall yield of 9% started from 2-
chloro-3-nitropyridine, which was treated with sodium diethylmalonate, and then by 50% sulfuric acid 
to give 2-methyl-3-nitropyridine.28 This was further oxidized with selenium dioxide to 3-nitropyridine-
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2-carboxaldehyde. Protection of the aldehyde group of the latter by conversion into the cyclic ethylene 
acetal and reduction of the nitro group by catalytic hydrogenation using Pd/C yielded 3-aminopyridine-
2-carboxaldehyde, which was finally subjected to condensation with thiosemicarbazide and deprotected 
by concentrated HCl (Scheme S1, see Supporting Information). An improved five-step synthesis starting 
from the same material, 2-chloro-3-nitropyridine, via a palladium-mediated Suzuki coupling in the first 
step, afforded 2-methyl-3-nitropyridine, which was further converted into an enamine intermediate. 
Oxidation of the latter with NaIO4 led to 3-nitropyridine-2-carboxaldehyde, which was then reacted with 
thiosemicarbazide. In the final step the nitro derivative was reduced with either SnCl2 or Na2S to yield 
Triapine in an overall yield of 55% (Scheme S2).29 The best overall yield of 64% was achieved in a 
four-step synthesis. 3-Amino-2-chloropyridine was converted via a Heck reaction using styrene, 
followed by protection of the NH2 group and then ozonolysis to the desired carboxaldehyde. The latter 
was transformed into Triapine by condensation with thiosemicarbazide and deprotection (Scheme S3).30 
In this study, we developed a novel straightforward three-step synthesis of Triapine in 64% overall yield, 
starting from the commercially available 3-amino-2-bromopyridine as shown in Scheme 2.  
N
NH2
Br
N
NH
Br
O
O
N
NH
CHO
O
O
N
NH2
N N
H
S
NH2
(i) (ii) (iii)
 
Scheme 2. Novel synthetic pathway to Triapine (HLD). Reagents and conditions: (i) sodium 
bis(trimethylsilyl)amide (~1M/THF), (Boc)2O, 82%; (ii) n-BuLi, N-formylpiperidine, 86%; (iii) 
thiosemicarbazide, conc. HCl, NaHCO3, 91%; overall yield 64%. 
 
In the first step the amino group was protected with di-tert-butyl dicarbonate in dry THF, using 
sodium bis(trimethylsilyl)amide31 as a base. Treatment of the tert-Boc protected 3-amino-2-
bromopyridine with n-BuLi in dry THF resulted in the lithiated species, which was further reacted with 
N-formylpiperidine to give the carboxaldehyde.32 Finally, the condensation reaction with 
thiosemicarbazide in ethanol in the presence of concentrated HCl afforded Triapine hydrochloride, 
which was converted into the free base (HLD) by treatment with sodium bicarbonate.29 The Triapine 
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analog 3-aminopyridine-2-carboxaldehyde 4N-dimethylthiosemicarbazone (HLH) was prepared in 84% 
yield by using the same protocol. However, the conversion into the free base was performed by 
treatment of the hydrochloride with excess N-methylmorpholine.   
The gallium(III) complexes [Ga(LA)2]+ (1A) and [Ga(LD)2]+ (1D) were prepared by reaction of 
Ga(NO3)3·9H2O with the corresponding ligand (HLA or HLD) in methanol in the presence of NaOCH3 
or triethylamine as a base in 27 and 72% yield, respectively (Scheme 1). The 1H NMR spectra of these 
two complexes showed the presence of 0.5 and 0.15 equiv of methanol, correspondingly, in accord with 
the microanalytical data. Reaction of 2-acetylpyridine thiosemicarbazone (HLB) and 2-
pyridineformamide thiosemicarbazone (HLC) with Ga(NO3)3·9H2O in 2:1 molar ratio in ethanol in the 
absence of a base produced complexes 1B and 1C in 69 and 55% yield, respectively. The gallium 
complexes of the ligands HLE–HLH were prepared in methanol or ethanol and isolated as nitrates or in 
some cases as hexafluorophosphates (HLF and HLH) by addition of excess NH4PF6 to the reaction 
mixture (60–91% yield).24 Starting from Fe(NO3)3·9H2O and the ligands HLB and HLD–HLH in 
methanol or ethanol, the iron(III) complexes were obtained in 66–76% yield (2E and 2F were isolated as 
hexafluorophosphates).24 The synthesis of the iron(III) complexes of HLA and HLC was carried out in 
the presence of N-methylmorpholine, because this was found to improve their purity.  
Characterization. The positive ion ESI-mass spectra of all complexes showed very strong peaks due 
to [M(L)2]+ ions. A peak with m/z 145, attributed to [PF6]¯ , was registered in the negative ion mode for 
the hexafluorophosphates. In line with the UV–vis spectra of gallium(III) complexes of 2-acetylpyridine 
thiosemicarbazones,24 1A–1H display a strong absorption band centered between 389–411 nm 
associated with intraligand transitions. This band is splitted and shifted to lower energies for 1D (441 
and 459sh nm) and 1H (451 and 469 nm). In the case of iron(III) complexes, charge transfer bands, 
intraligand transitions, along with a d-d band centered between 829–977 nm attributed to the 2T2g → 
2T1g transition for the d5 low-spin system were observed.33 The 1H NMR spectrum of the ligand HLH in 
DMSO-d6 indicates the presence of only one isomeric form in solution. In contrast, two and three 
isomers were found for HLE and HLF in DMSO-d6.34,35 Interestingly, a second isomer with chemical 
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shifts at 9.18 (NH), 8.58 (py), 7.86 (py), 7.45 (py), 6.78 (NH2) and 3.28 (N(CH3)2) ppm (one pyridine 
proton signal overlaps with a signal of the main species) and ~20% content relative to the main isomer 
was found for HLG in DMSO-d6, in contrast to the data reported.36 The signal intensity of the minor 
species decreases with time, implying its conversion into the main isomeric form of the ligand. In 
contrast to the metal-free ligands, the gallium(III) complexes show only one set of signals in the 1H 
NMR spectra, due to the stabilization of the ligand configuration upon coordination to the metal and the 
equivalence of both ligands bound to gallium(III) in solution. The most remarkable difference between 
the 1H NMR spectra of the metal-free ligands and those of the gallium(III) complexes is the absence of 
the N–H proton signals of the thiosemicarbazide moiety in the latter, indicating deprotonation of the 
ligands upon coordination. 
X-ray Crystallography. X-ray diffraction quality single crystals of Triapine (HLD) were obtained by 
slow evaporation of the sodium bicarbonate neutralized mother liquor. The result of the X-ray 
diffraction study of HLD is shown in Figure 1a, along with its gallium(III) (1D) and iron(III) (2D) 
complexes (Figures 1b and 1c). Selected bond distances and angels are quoted in the legend to Figure 1. 
Triapine crystallized in the orthorhombic space group Pna21 with two crystallographically independent 
molecules in the asymmetric unit. Both adopt the E-isomeric form in terms of the nomenclature used for 
the conformations of α-N-heterocyclic thiosemicarbazones,37 unlike to the X-ray crystal structure of 
HLE with a Z conformation (see Supporting Information). In the gallium(III) and iron(III) complexes of 
Triapine (1D and 2D) the coordination polyhedron approaches an octahedron, where the two ligands 
coordinate to the metal via the pyridine nitrogen atom and the nitrogen and sulfur donors of the 
thiosemicarbazide moiety. Deprotonation of both ligands is accompanied by an elongation of the 
carbon-sulfur bonds [1D: 1.735(6) and 1.743(7) Å; 2D: 1.754(5) and 1.750(5) Å] as compared to that in 
the metal-free ligand HLD at 1.697(2) Å.  
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Figure 1. ORTEP plots of the Triapine (HLD) (a), gallium(III) complex (1D) (b) and iron(III) complex 
(2D) (c) with atom numbering schemes. The thermal ellipsoids are drawn at 50 (HLD and 2D) and 30% 
(1D) probability levels, respectively. Selected bond lengths (Å) and bond angles (deg) for HLD: C6−N3 
1.283(2), N3−N4 1.384(2), N4−C7 1.344(2), C7−S1 1.697(2), C7−N5 1.325(3) Å; Θ(N2−C4−C5−C6) 0.1(3), 
Θ(C5−C6−N3−N4) 179.48(17), Θ(N3−N4−C7−S1) 178.92(14)°. 1D: Ga1–N1 2.130(4), Ga1–N6 2.110(5), Ga1–N3 
2.034(4), Ga1–N8 2.040(5), Ga1–S1 2.3722(14), Ga1–S2 2.3563(16), C6−N3 1.301(6), C13–N8 
1.279(7), N3−N4 1.362(6), N8–N9 1.379(7), N4−C7 1.339(7), N9–C14 1.332(8), C7−S1 1.735(6), C14–
S2 1.743(7) Å; N1−Ga1−N3 77.77(17), N6−Ga1−N8 77.60(19), N3−Ga1−S1 82.56(12), N8−Ga1−S2 
82.79(15)°. 2D: Fe1–N1 1.995(4), Fe1–N6 2.011(4), Fe1–N3 1.922(4), Fe1–N8 1.925(4), Fe1–S1 
2.2302(13), Fe1–S2 2.2171(14), C6−N3 1.299(6), C13–N8 1.299(6), N3−N4 1.379(5), N8–N9 1.379(5), 
N4−C7 1.318(6), N9–C14 1.323(6), C7−S1 1.754(5), C14–S2 1.750(5) Å; N1−Fe1−N3 80.85(17), 
N6−Fe1−N8 80.97(17), N3−Fe1−S1 83.92(12), N8−Fe1−S2 84.24(12)°.  
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Electrochemistry. In phase I and II clinical trials, patients treated with Triapine developed 
methemoglobinemia,15,38 a disorder characterized by the presence of a higher than normal level of 
methemoglobin (metHb) in the blood. This side effect was ascribed to the redox activity of the iron 
complex of Triapine, although its electrochemical behavior was not studied. We investigated the 
electrochemical properties of all synthesized metal complexes by cyclic voltammetry, and the results are 
summarized in Table 1.  
Table 1. Electrochemical Dataa for 1A–1H and 2A–2H   
Gallium complexes 
  E1/2 / ILred E1/2 / IILred Ep / IIILred 
1A    –0.82 –1.10 –1.63b,c 
1B   –0.93 –1.21 –1.80b,c 
1C   –1.21 –1.46 –2.02b,c 
1D   –0.94 –1.23 –1.78b,c 
1E   –0.80 –1.09 –1.67b,c 
1F   –0.92 –1.21 –1.77b,c 
1G   –1.21 –1.47 –2.02b,c 
1H   –0.93 –1.22 –1.78b,c 
 
     
Iron complexes 
 
 E1/2 / FeIII/II E1/2 / ILred E1/2 / IILred  
2A  0.15 –1.44 –1.80b  
2B  0.04 –1.58 –1.92b  
2C  –0.21 –1.63 –2.02b  
2D  0.01 –1.56 –1.92b  
2E  0.18 –1.47 –1.78  
2F  0.07 –1.60 –1.99b,c  
2G  –0.22 –1.66 –2.04b  
2H  0.03 –1.62 –1.92  
 
     
a) Potentials in V ± 0.01 vs. NHE in 0.20 M [n-Bu4N][BF4]/DMSO; b) for the irreversible waves, the Ep 
values are given; c) two electron wave. 
 
In 0.20 M [n-Bu4N][BF4]/DMSO solution all iron complexes display a reversible FeIII/FeII redox 
couple between –0.21 and +0.18 V vs. NHE (normal hydrogen electrode) depending on the ligand 
identity. A decrease of the redox potential in the order 2A > 2B > 2C is in line with an increase of the 
electron donor properties of the corresponding ligands due to the presence of different substituents at the 
azomethine group (NH2 > CH3 > H). Likewise the electron donating properties of the amino group cause 
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the redox potential shift of the iron(III) complex of Triapine (2D) at 0.01 V as compared to the iron(III) 
complex of 2-formylpyridine thiosemicarbazone 2A at +0.15 V vs. NHE. Compared to 2A–2D, the 
reduction waves for the 4N-dimethyl substituted analogs 2E–2H are shifted by 10–30 mV to more 
positive potentials, in contrast to the expected negative shift because of the stronger electron donating 
properties of dimethylamine as compared to ammonia [pKa: dimethylamine (10.73); ammonia (9.25)].39 
Beside the metal-centered reductions, the iron complexes display two ligand-centered reduction waves, 
the first (ILred) between –1.44 and –1.66 V (Figure 2) and the second (IILred) between –1.80 and –2.04 V 
vs. NHE close to the solvent cut-off. For the corresponding gallium(III) complexes 1A–1H two 
reversible reductions (ILred and IILred) from –0.80 to –1.21 and from –1.09 to –1.47 V, correspondingly, 
and an irreversible two-electron reduction (IIILred) between –1.63 and –2.02 V vs. NHE were observed. In 
comparison the ligand-centered redox couples ILred and IILred of the corresponding iron(III) complexes 
(which first are reduced to the iron(II) species) are negatively shifted by 400–700 mV. All the ligand-
centered redox processes can be attributed to the reduction of the C=N double bond(s) adjacent to the 
pyridine ring40 (supplementary data on the electrochemical behavior of the complexes in DMSO and 
CH3CN can be found in Supporting Information).  
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Figure 2. Cyclic voltammograms of complexes 1D (a) and 2D (b) in DMSO solution containing 0.20 M 
[n-Bu4N][BF4] at a scan rate of 0.20 V s–1 using a glassy carbon working electrode, displaying the ligand 
(Lred) and the FeII/FeIII redox couple. 
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The influence of water on the iron redox potentials was studied by cyclic voltammetry measurements 
in H2O/DMSO (7:3 v/v) mixtures with 0.2 M NaClO4 as the supporting electrolyte. The low aqueous 
solubility of the complexes prevented the use of pure aqueous electrolyte solutions. The FeIII/FeII redox 
couples remained reversible in H2O/DMSO solution but were shifted by 10–50 mV to lower redox 
potentials. Unlike, complexes 2D (Figure S1) and 2H showed a positive shift by 30–40 mV.  
Our data are in very good agreement with recently reported redox potentials for 2B and 2F in 
CH3CN/H2O (7:3) at 0.02 and 0.05 V vs NHE.41 In cell-free assays Triapine was reported to enhance 
ascorbate oxidation, benzoate hydroxylation and quenching of purified RR tyrosyl radical in the 
presence of iron salts.27 In addition, EPR measurements showed that the iron(II) complex of Triapine is 
capable of reducing O2 to reactive oxygen species (ROS).25 The potential range and the reversibility of 
the redox couple of the iron complex 2D in H2O/DMSO solution provide further evidence that the 
complex is able to undergo redox cycling and produce ROS under physiological conditions. This 
conclusion is also valid for the other iron complexes studied in this work, but probably to a lesser extent 
to complexes 2C and 2G with more negative potentials of the FeIII/FeII redox couples at around –0.2 V 
vs. NHE. 
Cytotoxicity. The cytotoxic potency of the thiosemicarbazones and their corresponding gallium(III) 
and iron(III) complexes was measured in the human tumor cell lines 41M (ovarian carcinoma) and SK-
BR-3 (mammary carcinoma) by means of the colorimetric MTT assay. Generally, the 41M cells were 
more sensitive to the compounds investigated in this study. The metal-free ligands and the 
corresponding metal complexes cover a broad range of activity, with IC50 values ranging from 
nanomolar to high micromolar concentrations, depending on the ligand substitutions and the metal ion 
(Table 2).  
 
Table 2. Cytotoxicity of α-N-heterocyclic thiosemicarbazones (HLA−HLH), their gallium(III) (1A−1H) 
and iron(III) complexes (2A−2H) in two human cancer cell lines. 
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 IC50 (µM)a 
Compound 41M SK-BR-3 
Ligands 
HLA   2.9 ± 0.6 3.2 ± 0.6 
HLB 2.5 ± 0.3 3.6 ± 0.2 
HLC 4.9 ± 0.04 5.6 ± 1.1 
HLD 0.45 ± 0.03 0.52 ± 0.08 
HLE 0.0040 ± 0.0009 0.0098 ± 0.0011 
HLG 0.32 ± 0.03 0.29 ± 0.01 
HLH 0.21 ± 0.13 0.29 ± 0.08 
Ga(III) Complexes 
1A 1.5 ± 0.1 1.5 ± 0.5 
1B 1.2 ± 0.1 1.0 ± 0.1 
1C 3.4 ± 1.0 4.6 ± 1.1 
1D 0.25 ± 0.05 0.35 ± 0.04 
1E 0.0029 ± 0.0001 0.0050 ± 0.0009 
1G 0.11 ± 0.05 0.12 ± 0.04 
1H 0.020 ± 0.001 0.025 ± 0.004 
Fe(III) Complexes 
2A 2.7 ± 0.5 4.9 ± 0.5 
2B 28 ± 12 >100  
2C >100  >100  
2D 1.5 ± 0.5 1.7 ± 0.4 
2E 0.11 ± 0.04 0.15 ± 0.05 
2G 1.6 ± 0.7 1.5 ± 0.4 
2H 5.2 ± 0.2 6.0 ± 0.9 
  
Ga(NO3)3b 70 ± 4 >100  
Fe(NO3)3b >100  >100  
  
a
 50% inhibitory concentrations in 41M and SK-BR-3 cells after exposure for 96 h in the MTT assay. 
Values are means ± standard deviations obtained from at least three independent experiments, b Values 
taken from reference 24. 
 
Structure-Activity Relationships of the Metal-Free Ligands. Specific structural modifications on 
the ligand were made to explore the following structure-activity relationships: 
(i) The effect of substituents at the carbon atom of the azomethine group. Substitution of the hydrogen 
atom in HLA by a methyl group does not change the antiproliferative activity. However, the substitution 
of the hydrogen atom by a NH2 group (HLC) results in about 2-fold decrease of cytotoxicity in both cell 
lines.  
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The IC50 values for the ligands HLA and HLB were documented in the literature.42 These are very 
similar, varying from 1 to 10 µM, depending on the cell line. The first 2-pyridineformamide 
thiosemicarbazones were synthesized ten years ago with the aim of increasing aqueous solubility.43 The 
first results on their cytotoxicity were reported only quite recently. In particular, HLC tested in 
glioblastoma cell lines showed cytotoxicities in micromolar concentration range (3.6–7.3 µM).44 In the 
case of Triapine (HLD) the reported IC50 values range from 0.2 to 3.0 µM.27,45 However, because of the 
use of different cell lines and conditions, the impact of the structural changes in the ligands HLA−HLD 
(all containing a terminal NH2 group) remained obscure. Our cytotoxicity data for both cell lines 41M 
and SK-BR-3 confirm that the antiproliferative activity of HLA is very similar to that of HLB, whereas 
HLC possesses a slightly lower cytotoxic potency (Table 2). Interestingly, Triapine shows IC50 values by 
a factor 10 lower than HLC, indicating that the effect of the second amino group is dependent on its 
position. 
 (ii) Dimethylation of the terminal NH2 group. Terminal dimethylation enhances the activity of the 
thiosemicarbazones. However, the magnitude of this effect is strongly dependent on the other ligand 
substitutions. The strongest enhancement was observed when comparing HLA with its dimethylated 
counterpart HLE. The 4N-dimethylation results in a 725- (41M) and 320-fold (SK-BR-3) increase of 
cytotoxicity, respectively (Table 2, Figure 3). The same trend but with distinctly smaller differences was 
observed for the two ligands containing a 2-pyridinecarboxamide moiety (HLC vs. HLG), with an 
increase of cytotoxicity by a factor of 15–20 as a result of dimethylation. The effect was found to be 
weakest for Triapine and its dimethylated derivative (HLD vs. HLH). In this case only a 2-fold increase 
of cytotoxicity was observed. 
 (iii) The effect of an amino group in terminally dimethylated thiosemicarbazones. The cytotoxicity of 
the terminally dimethylated Triapine analogue HLH is strongly diminished compared to that of HLE, in 
which the amino group in position 3 of the pyridine heterocycle is absent. Thus, the addition of a NH2 
functionality to HLE results in a 50- and 30-fold decrease of IC50 values in 41M and SK-BR-3 cells, 
respectively. Likewise the presence of the NH2 group at the carbon atom of the azomethine bond in HLG 
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results in 30- to 80-fold decrease of cytotoxicity when compared to that of HLE. Together these data 
suggest a critical role of the NH2 group on the biological activity of terminally dimethylated α-N-
heterocyclic thiosemicarbazones. 
Thus, the most striking enhancement in cytotoxic activity (by a factor of ~300 to 700) was achieved by 
dimethylation of the terminal amino group of HLA. A similar effect was observed when the terminal 
NH2 group of 2-acetylpyridine thiosemicarbazone was disubstituted.41,46 On the other hand, our results 
demonstrate that the enhancement of cytotoxic potency by 4N-dimethylation is nearly annihilated when 
another NH2 group is present (HLH, HLG). Hence, contrary to what has been assumed in the literature,46 
addition of the terminal methyl groups, while necessary, is not sufficient for the drastic enhancement in 
cytotoxic activity of this derivatives series. Removal of any NH2 functionality is also needed.    
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Figure 3. Concentration-effect curves of metal-free thiosemicarbazones (white symbols), their 
gallium(III) complexes (black symbols) and iron(III) complexes (grey symbols), obtained by the MTT 
assay in 41M cells (left panels) and SK-BR-3 cells (right panels). (A) HLA, 1A, 2A; (B) HLB, 1B, 2B; 
(C) HLC, 1C, 2C; (D) HLD, 1D, 2D and (E) HLE, 1E, 2E. Values are means ± standard deviations from 
at least three independent experiments. 
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Figure 3 (continued). Concentration-effect curves of metal-free thiosemicarbazones (white symbols), 
their gallium(III) complexes (black symbols) and iron(III) complexes (grey symbols), obtained by the 
MTT assay in 41M cells (left panels) and SK-BR-3 cells (right panels). (G) HLG, 1G, 2G and (H) HLH, 
1H, 2H. Values are means ± standard deviations from at least three independent experiments. 
 
Structure-Activity Relationships of the Metal Complexes. The effects of complexation of 
thiosemicarbazones to gallium(III) and iron(III) are divergent (Table 2, Figure 3), and have been 
established by comparison of cytotoxicities of metal complexes and metal-free ligands. Generally, the 
iron(III) complexes show reduced cytotoxicity in comparison to that of the corresponding ligands. The 
effects vary from 3-fold to >28-fold increased IC50 values. In contrast to the iron(III) complexes, 
121
  
gallium(III) thiosemicarbazonates are 1.2 to 3.6 times more cytotoxic than the corresponding metal-free 
ligands. The effect is more pronounced only in the case of the gallium complex 1H, which is 10 times 
more active than the corresponding uncomplexed ligand HLH. 
In all previous studies the effect of Triapine complexation to iron has been determined by simple 
addition of iron salt to a solution of Triapine, assuming the formation of the desired complex. However, 
the applied procedure does not guarantee its formation. Given the conditions for complexation reactions 
are provided, mixtures of complexes with different metal-to-ligand stoichiometries and various co-
ligands can be produced. This might explain why the reported effects of Triapine complexation to iron 
are divergent. On the one hand, an enhancement in cytotoxic activity was observed in murine leukemia 
cells.26 On the other hand, a slight decrease was found in neuroblastoma cells,27 whereas no difference 
was discernible in neuroephithelioma cells.47 No marked differences were found between the cytotoxic 
potencies of iron(II) and iron(III) complexes, presumably due to spontaneous oxidation of iron(II) to 
iron(III) in cell culture medium.26,47 Generally, the reported influence of the complexation of Triapine to 
iron is moderate, in contrast to classic iron chelating agents such as DFO (desferrioxamine), which result 
in iron complexes that are almost devoid of antiproliferative activity.47 It is generally assumed that the 
iron complex of Triapine is the active species. This is based on findings in cell-free assays showing that 
the iron(II) complex is able to react with dioxygen and generate reactive oxygen species (ROS) and that 
the preformed iron complex inhibits ribonucleotide reductase (RR) much more effectively than the 
metal-free ligand.25  
In this study, the isolated iron(III) complex of Triapine (2D) is 3 times less cytotoxic in both cell lines 
than metal-free Triapine (HLD). Interestingly, this decrease in activity upon complexation with iron(III) 
is smaller than in the case of HLB, HLC and HLE−HLH. Iron(III) complexes of these ligands are 5 to 30 
times less cytotoxic than the uncomplexed ligands. Only complexation of HLA to iron(III) did not result 
in a change in cytotoxicity. Taking into account the 1:2 stoichiometry of the iron-thiosemicarbazonate 
complexes, the decrease in activity is even more pronounced. However, there is no clear correlation 
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between the cytotoxic potencies of the iron(III) complexes and the uncomplexed ligands, suggesting that 
the binding strength to iron(III) or another factor has a modulating effect on cytotoxicity. 
We have previously noted an enhancement of antiproliferative activity of gallium(III) complexes in 
comparison to their corresponding ligands.24 In this study this trend is preserved, with about 2-fold 
increase of cytotoxic activity as compared to the respective metal-free ligands. One complex (1H), 
however, exhibits a ~10-fold enhancement of activity in both cell lines. These results suggest that the 
higher activity of the gallium(III) complexes is mainly due to the stoichiometric effect of the 1:2 
gallium-to-ligand complexes.  
Inhibition of Ribonucleotide Reductase. 3H-cytidine DNA incorporation assays were performed in 
HL60 cells after 4 h drug incubation for HLD, HLE, 2D and 2E in order to ascertain whether the 
differences in cytotoxicity induced by coordination to iron(III) and/or by terminal dimethylation are 
related to different capacities of inhibiting RR. As shown in Table 3, the RR inhibitory potential follows 
the same trends as observed in the cytotoxicity tests, but in detail some differences are obvious. The 
cytotoxicity data show only a small increase in the IC50 values after coordination of HLD to iron(III) 
(2D), whereas in comparison the effect of coordination to iron(III) on RR inhibition is much more 
pronounced. The magnitudes of these effects are in reversed order for HLE and 2E. While the ability of 
2E to inhibit RR is only slightly decreased, the cytotoxicity of 2E is reduced by a factor of 16 as 
compared to the metal-free ligand HLE. Concerning the terminal dimethylation, a strong increase in 
cytotoxicity on going from HLD to HLE is not supported to the same extent by their ability to inhibit 
RR. Notably, in the IC50 range even small increases in drug concentration of the metal-free ligands 
induce strong effects on RR activity (Figure 4). In contrast, the iron complexes show a gradual increase 
of RR inhibition over a broad drug concentration range.  
 
Table 3. Comparison of the RR inhibitory potency and cytotoxicity of HLD, HLE and their iron(III) 
complexes 2D and 2E in HL60 cells. 
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 IC50 (µM)a 
Compound      RR inhibition         cytotoxicity 
HLD 5.4 ± 2.4 0.27 ± 0.06 
2D 53 ± 8.8 0.84 ± 0.05 
HLE 0.80 ± 0.13 0.0068 ± 0.0022 
2E 1.5 ± 0.8 0.11 ± 0.05 
  
a
 50% inhibitory concentrations in HL60 cells. RR inhibition was determined using 3H-cytidine DNA 
incorporation assays after 4 h drug incubation.  Cytotoxicity was determined after exposure for 96 h by 
the MTT assay. Values are means ± standard deviations from at least three independent experiments. 
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Figure 4. The ability of inhibiting ribonucleotide reductase for HLD, HLE and their iron(III) complexes 
2D and 2E as determined by 3H-cytidine DNA incorporation assays in HL60 cells.  
 
It should be noted that the RR inhibitory potential of Triapine (HLD) is well documented in the 
literature. In particular, in cell-free systems short-time treatment of purified prokaryotic or mouse RR by 
Triapine resulted in reduced 3H-cytidine incorporation into DNA.25,26 In line with these data, EPR 
measurements of intact SK-M-MC neuroepithelioma cells after their treatment with 25 µM Triapine for 
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24 h showed a 39% quenching of the tyrosyl radical.27 To our knowledge the RR inhibitory activity of 
the iron(III) complex of Triapine (2D) was so far determined exclusively under reducing conditions in 
cell-free systems.25,26 Pre-complexation of Triapine to iron was found to strongly enhance RR inhibition. 
This is in line with our previous report on enhanced tyrosyl radical quenching in isolated mouse R2 
subunits by iron(III) 4N-dimethylated thiosemicarbazonates.24 In the present study, the ability of HLD, 
HLE and their iron(III) complexes to inhibit RR was determined in living cells. Here, iron(III) 
complexes show a reduced RR inhibiting activity as compared to the metal-free ligands − the difference 
being much more evident between HLD and 2D. The mechanisms underlying these effects are still not 
known. A possible explanation is the ionic nature and the reduced lipophilicity of the iron complex, 
which probably results in lower uptake into the cell. To clarify whether the differences observed 
between metal-free ligands and the respective iron complexes are based on reduced drug uptake or 
depend on other yet unknown mechanisms is a matter of ongoing investigations.  
With regard to the impact of 4N-disubstitution on the RR inhibitory potency, only some in vitro tests 
on 5-hydroxy-2-formylpyridine thiosemicarbazones using purified RR have been reported so far.48 In 
contrast to our data in living cells, those studies showed that dimethylation of the terminal amino group 
markedly decreased the RR inhibitory activity. However, taking into account that different assays for 
determination of RR inhibitory potencies were performed and the fact that in the earlier study48 no 
cytotoxicity data were reported, a direct comparison is not possible. Our data suggest that the 
enhancement in antiproliferative activity by terminal dimethylation can not be solely dependent on RR 
inhibition, and that other intracellular targets may be involved. 
 
Conclusions 
In this study we developed a novel straightforward three-step synthesis of Triapine, the most promising 
α-N-heterocyclic thiosemicarbazone for anticancer therapy today. In addition, iron(III) and gallium(III) 
complexes of Triapine were prepared for the first time. The synthesis of 2-formylpyridine, 2-
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acetylpyridine, 2-pyridineformamide thiosemicarbazones and their 4N-dimethylated analogs as well as 
the corresponding gallium(III) and iron(III) complexes permitted to establish novel structure-cytotoxicity 
relationships. In particular, they revealed an increase of cytotoxicity by complexation of Triapine and 
related ligands to gallium(III), while coordination to iron(III) reduces their activity. Terminal nitrogen 
dimethylation was found to strongly enhance the cytotoxicity of metal-free ligands as well as their 
iron(III) and gallium(III) complexes. This is, however, not the case, when a NH2 functionality is present 
anywhere at the thiosemicarbazone backbone. 3H-cytidine DNA incorporation assays showed that the 
increased cytotoxicity upon terminal dimethylation is only partly dependent on the ability of these 
compounds to inhibit RR, implying that other mechanisms are involved. Taken together, this study 
indicates the importance of detailed structure-activity-relationship analyses for the understanding of the 
molecular mechanisms underlying the anticancer activity of thiosemicarbazones and for the creation of 
more effective chemotherapeutics. 
 
Experimental Section 
All solvents and reagents were obtained from commercial suppliers and used without further 
purification. 2-Acetylpyridine 4N-dimethylthiosemicarbazone (HLF) and its gallium(III) (1F) and 
iron(III) complexes (2F) were prepared as previously reported.24 2-Formylpyridine thiosemicarbazone 
(HLA) was synthesized by refluxing 2-formylpyridine with thiosemicarbazide in EtOH/H2O 3 : 2 for 5 h, 
and 2-formylpyridine 4N-dimethylthiosemicarbazone (HLE) by refluxing 2-formylpyridine and 4N-
dimethylthiosemicarbazide49 in MeOH for 5 h (X-ray diffraction quality crystals of HLE were obtained 
by recrystallization from methanol). 2-Acetylpyridine thiosemicarbazone (HLB·0.5H2O) was obtained 
by refluxing 2-acetylypridine and thiosemicarbazide in EtOH for 5 h, followed by recrystallization in 
EtOH. The content of water was confirmed by thermogravimetric analysis. 2-Pyridineformamide 
thiosemicarbazone (HLC) was prepared following the literature protocol.50 2-Pyridineformamide 4N-
dimethylthiosemicarbazone (HLG) was synthesized in a similar manner by using 4N-
dimethylthiosemicarbazide instead of thiosemicarbazide, with a 76% yield, in comparison to 25% 
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reported in the literature.36 tert-Butyl (2-formylpyridin-3-yl)carbamate was obtained using tert-butyl (2-
bromopyridin-3-yl)carbamate (see below), n-butyllithium and N-formylpiperidine.32 The condensation 
reaction with thiosemicarbazide and deprotection were performed according to the published 
procedure.29 Elemental analyses were carried out on a Carlo Erba microanalyzer at the Microanalytical 
Laboratory of the University of Vienna. Electrospray ionization mass spectrometry was carried out with 
a Bruker Esquire 3000 instrument (Bruker Daltonic, Bremen, Germany). Expected and experimental 
isotope distributions were compared. Infrared spectra were obtained from KBr pellets with a Perkin-
Elmer FT-IR 2000 instrument (4000–400 cm–1). UV–vis spectra were recorded on a Perkin Elmer 
Lambda 650 UV–vis spectrophotometer using samples dissolved in methanol (900–210 nm). The 
iron(III) complexes were in addition measured on a Hewlett-Packard 8453 UV–vis spectrophotometer 
(1100–210 nm). The content of water in complexes 1C, 2C and 2D was verified by thermogravimetric 
analysis (TGA) with a Mettler Toledo TGA/SDTA851e apparatus, with a 3 °C/min heating rate under an 
air atmosphere. 1H and 13C one- and two-dimensional NMR spectra were recorded in DMSO-d6, with a 
Bruker Avance III 500 MHz FT-NMR spectrometer. The residual 1H and 13C present in DMSO-d6 were 
used as internal references. Abbreviations for NMR data: py = pyridine, Cq, py = quaternary carbon of 
pyridine.  
Electrochemistry. Cyclic voltammograms were measured in a three-electrode cell using a 2.0 mm-
diameter glassy carbon working electrode, a platinum auxiliary electrode, and an AgAg+ reference 
electrode containing 0.10 M AgNO3. Measurements were performed at room temperature using an EG 
& G PARC 273A potentiostat/galvanostat. Deaeration of solutions was accomplished by passing a 
stream of argon through the solution for 5 min prior to the measurement and then maintaining a blanket 
atmosphere of argon over the solution during the measurement. The potentials were measured in 0.20 M 
[n-Bu4N][BF4]/DMSO, using [Fe(η5-C5H5)2] (E½ = +0.68 V vs. NHE)51 as internal standard, and are 
quoted relative to the normal hydrogen electrode (NHE). For cyclic voltammetry measurements in 0.20 
M NaClO4 DMSO/H2O (3:7 v/v) solutions, a 2.0 mm-diameter glassy carbon working electrode, a 
platinum auxiliary electrode, and an AgAg+ reference electrode containing 3.0 M NaCl were used.  
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Synthesis of Ligands and Metal Complexes 
tert-Butyl-(2-bromopyridin-3-yl)carbamate. A solution of 3-amino-2-bromopyridine (3.0 g, 17.3 
mmol) in dry THF (20 mL) was cooled to 0 °C and treated with 1M solution of sodium 
bis(trimethylsilyl)amide in THF (35 mL, 35 mmol). After 30 min a solution of di-tert-butyl dicarbonate 
(3.95 g, 18.1 mmol) in dry THF (20 mL) was added, and the mixture was stirred for 1.5 h at room 
temperature. The reaction mixture was poured into 0.1 M HCl (400 mL) and extracted twice with ethyl 
acetate (240 mL). The combined organic layers were extracted with brine (200 mL), dried over MgSO4, 
filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica 
using ethyl acetate/hexane 1:5 as eluent. Yield: 3.9 g (82%). Anal. Calcd. for C10H13N2O2Br (Mr = 
273.13 g/mol): C, 43.98; H, 4.80; N, 10.26. Found: C, 44.01; H, 4.51; N, 10.21. 1H NMR (500.10 MHz, 
DMSO-d6): δ 8.77 (s, 1H, NH), 8.17 (dd, 3JH,H = 4.4 Hz, 4JH,H = 1.9 Hz, 1H, py), 7.92 (dd, 3JH,H = 7.9 Hz, 
4JH,H = 1.9 Hz, 1H, py), 7.43 (dd, 3JH,H = 7.9 Hz, 3JH,H = 4.4 Hz, 1H, py), 1.47 (s, 9H, C(CH3)3). 13C 
NMR (125.81 MHz, DMSO-d6): δ 153.4 (C=O), 146.3 (Cpy), 138.3 (Cq, py), 134.8 (Cq, py), 134.6 (Cpy), 
124.1 (Cpy), 80.5 (C(CH3)3), 28.5 (C(CH3)3).  
3-aminopyridine-2-carboxaldehyde 4N-dimethylthiosemicarbazone, (HLH). To tert-butyl (2-
formylpyridin-3-yl)carbamate (147 mg, 0.66 mmol) and 4N-dimethylthiosemicarbazide (79 mg, 0.66 
mmol) in ethanol (3 mL) and H2O (1 mL) was added conc. HCl (0.3 mL) and the mixture was stirred 
under reflux for 5 h. After cooling to room temperature 10% (w/w) aqueous NaHCO3 (0.8 mL) was 
added and the mixture was stirred for further 30 min. The yellow hygroscopic HLH·HCl was filtered off, 
washed with cold water, cold ethanol (–20 °C) and diethyl ether and dried in vacuo. Yield: 130 mg 
(76%). 1H NMR (500.10 MHz, DMSO-d6): δ 12.00 (s, 1H, NH), 8.88 (s, 1H, HC=N), 8.15 (br. s, 2H, 
NH2), 8.03 (m, 1H, py), 7.69 (d, 3JH,H = 8.2 Hz, 1H, py), 7.57 (m, 1H, py), 3.35 (s, 6H, N(CH3)2). The 
HLH·HCl salt (90 mg, 0.35 mmol) was dissolved in H2O (4 mL) at 70 °C and N-methylmorpholine (60 
µL, 0.55 mmol) was added. The reaction mixture was cooled to room temperature and stirred for 1 h. 
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The precipitate was filtered off, washed with H2O, cold ethanol (–20 °C) and diethyl ether, dried in 
vacuo and afterwards over P2O5. Yield: 65 mg (84%). Anal. Calcd. for C9H13N5S (Mr = 223.30 g/mol): 
C, 48.41; H, 5.87; N, 31.36; S, 14.36. Found: C, 48.30; H, 5.96; N, 31.18; S, 14.19. ESI-MS in MeOH 
(negative): m/z 222, [HLH–H]−. IR spectrum in KBr, cm−1 (selected bands): 3304 s, 3140s, 1622 s, 1546 
s, 1442 s, 1312 s, 1210 s, 1129 m, 1059 m, 910 s, 795 m, 710 m. UV–vis (MeOH), λmax, nm (ε, M−1 
cm−1): 232 (21180), 262 (16160), 369 (14020), 436 (1920). 1H NMR (500.10 MHz, DMSO-d6): δ 11.09 
(s, 1H, NH), 8.55 (s, 1H, HC=N), 7.83 (dd, 3JH,H = 4.1 Hz, 4JH,H = 1.6 Hz, 1H, py), 7.20 (br. s, 2H, NH2), 
7.09 (dd, 3JH,H = 8.2 Hz, 4JH,H = 1.6 Hz, 1H, py), 7.06 (dd, 3JH,H = 8.2 Hz, 3JH,H = 4.1 Hz, 1H, py), 3.31 
(s, 6H, N(CH3)2).13C NMR (125.81 MHz, DMSO-d6): δ 180.0 (C=S), 149.1 (HC=N), 144.1 (Cq, py), 
137.0 (Cpy), 134.4 (Cq, py), 124.3 (Cpy), 122.3 (Cpy), 41.4 (N(CH3)2).  
[Bis(2-formylpyridine thiosemicarbazonato)-N,N,S-gallium(III)] nitrate, 
[Ga(LA)2]NO3·0.5CH3OH (1A). To 2-formylpyridine thiosemicarbazone (HLA) (140 mg, 0.78 mmol) 
and NaOCH3 (63 mg, 1.17 mmol) in dry methanol (14 mL) at 70 °C under an argon atmosphere 
gallium(III) nitrate nonahydrate (162 mg, 0.39 mmol) was added and the mixture was stirred at 70 °C for 
3 h, then cooled to room temperature and filtered from undissolved impurities. The clear solution was 
allowed to stand at +4 °C for 3 days and the crystals formed were filtered off, washed with cold 
methanol (–20 °C) and dried in vacuo. Yield: 54 mg (27%). Anal. Calcd. for 
C14H14GaN9O3S2·0.5CH3OH (Mr = 506.20 g/mol): C, 34.41; H, 3.19; N, 24.90. Found: C, 34.45; H, 
3.33; N, 24.63. ESI-MS in MeOH (positive): m/z 427, [Ga(LA)2]+. IR spectrum in KBr, cm−1 (selected 
bands): 3422 w, 3280 w, 3100 br. s, 1607 s, 1429 s, 1384 m, 1314 m, 1234 m, 1174 s, 880 m, 735 m, 
628 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 318 (24390), 395 (22240). 1H NMR (500.10 MHz, 
DMSO-d6): δ 8.95 (s, 2H, HC=N), 8.26 (br. s, 4H, NH2), 8.20 (dt, 3JH,H = 7.9 Hz, 4JH,H = 1.6 Hz, 2H, 
py), 7.98 (m, 4H, py), 7.58 (m, 2H, py). 13C NMR (125.81 MHz, DMSO-d6): δ 178.6 (C–S), 145.2 (Cq, 
py), 144.9 (Cpy), 142.7 (Cpy), 137.8 (HC=N), 127.6 (Cpy), 126.5 (Cpy). 
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[Bis(2-acetylpyridine thiosemicarbazonato)-N,N,S-gallium(III)] nitrate, [Ga(LB)2]NO3 (1B). To 
2-acetylpyridine thiosemicarbazone (HLB) (200 mg, 1.03 mmol) in ethanol (5 mL) at 70 °C gallium(III) 
nitrate nonahydrate  (217 mg, 0.52 mmol) in ethanol (2 mL) was added and the solution was stirred at 50 
°C for 2 h. The reaction mixture was cooled to room temperature and allowed to stand at +4 °C for 4 h. 
The yellow precipitate was filtered off, washed with cold ethanol (–20 °C) and diethyl ether, and dried 
in vacuo. Yield: 185 mg (69%). Anal. Calcd. for C16H18GaN9O3S2 (Mr = 518.23 g/mol): C, 37.08; H, 
3.50; N, 24.33; S, 12.38. Found: C, 37.09; H, 3.42; N, 24.28; S, 12.35. ESI-MS in MeOH (positive): m/z 
455, [Ga(LB)2]+. IR spectrum in KBr, cm−1 (selected bands): 3386 w, 3260 w, 3158 m, 1601 s, 1432 s, 
1373 s, 1294 m, 1188 m, 810 m, 778 m, 720 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 295 (20200), 
392 (28740). 1H NMR (500.10 MHz, DMSO-d6): δ 8.26–8.20 (m, 4H, py), 8.01 (br. s, 4H, NH2), 7.93 
(m, 2H, py), 7.60 (m, 2H, py), 2.81 (s, 6H, CH3). 13C NMR (125.81 MHz, DMSO-d6): δ 176.8 (C–S), 
146.7 (C=N), 145.7 (Cq, py), 144.7 (Cpy), 142.7 (Cpy), 127.5 (Cpy), 124.3 (Cpy), 14.7 (CH3). 
 [Bis(2-pyridineformamide thiosemicarbazonato)-N,N,S-gallium(III)] nitrate, 
[Ga(LC)2]NO3·0.5H2O (1C). To 2-pyridineformamide thiosemicarbazone (HLC) (200 mg, 1.02 mmol) 
in ethanol (20 mL) at 70 °C gallium(III) nitrate nonahydrate  (214 mg, 0.51 mmol) in ethanol (2.5 mL) 
was added and the mixture was stirred at the same temperature for 1 h. The yellow solid was separated 
from the hot solution by filtration, washed with ethanol, dried in vacuo at 50 °C and then over P2O5. 
Yield: 148 mg (55%). Anal. Calcd. for C14H16GaN11O3S2·0.5H2O (Mr = 529.21 g/mol): C, 31.77; H, 
3.24; N, 29.11; S, 12.12. Found: C, 31.79; H, 3.17; N, 28.75; S, 12.19. ESI-MS in MeOH (positive): m/z 
457, [Ga(LC)2]+. ESI-MS in MeOH (negative): m/z 455, [Ga(LC)2 – 2H]−. IR spectrum in KBr, cm−1 
(selected bands): 3271 br. m, 3163 w, 1648 s, 1605 s, 1515 s, 1470 s, 1384 m, 787 m, 727 m. UV–vis 
(MeOH), λmax, nm (ε, M−1 cm−1): 257 (18410), 300 (10820), 389 (17600). 1H NMR (500.10 MHz, 
DMSO-d6): δ 8.43 (d, 3JH,H = 8.2 Hz, 2H, py), 8.27 (dt, 3JH,H = 7.9 Hz, 4JH,H = 1.6 Hz, 2H, py), 8.06 (v. 
br. s, 4H, N=CNH2), 7.88 (m, 2H, py), 7.71 (m, 2H, py), 6.65 (s, 4H, NH2). 13C NMR (125.81 MHz, 
DMSO-d6): δ 169.4 (C–S), 145.5 (C=N), 144.7 (Cpy), 142.4 (Cpy), 141.6 (Cq, py), 128.4 (Cpy), 122.1 
(Cpy).  
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[Bis(3-aminopyridine-2-carboxaldehyde thiosemicarbazonato)-N,N,S-gallium(III)] nitrate, 
[Ga(LD)2]NO3·0.15CH3OH (1D). To a suspension of 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (HLD) (150 mg, 0.77 mmol) in methanol (10 mL) and triethylamine (112 µL, 0.81 
mmol) at 50 °C gallium(III) nitrate nonahydrate  (166 mg, 0.40 mmol) in methanol (2.5 mL) was added 
and the mixture was stirred for 20 min at 50 °C and 2.5 h at room temperature. The bright orange 
precipitate formed was filtered off, washed with cold methanol (–20 °C), dried in vacuo and afterwards 
over P2O5. Yield: 144 mg (72%). Anal. Calcd. for C14H16GaN11O3S2·0.15CH3OH (Mr = 525.01 g/mol): 
C, 32.37; H, 3.19; N, 29.34; S, 12.22. Found: C, 32.39; H, 3.25; N, 29.13; S, 12.14. ESI-MS in MeOH 
(positive): m/z 457, [Ga(LD)2]+. ESI-MS in MeOH (negative): m/z 455, [Ga(LD)2 – 2H]−. IR spectrum in 
KBr, cm−1 (selected bands): 3336 s, 3217 s, 1600 s, 1467 s, 1429 s, 1384 m, 1252 m, 1220 m, 1146 s, 
849 m, 805 m, 630 s. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 214sh (42410), 294 (31980), 441 
(38830), 459sh (35600). 1H NMR (500.10 MHz, DMSO-d6): δ 9.14 (s, 2H, HC=N), 7.83 (br. s, 4H, 
SCNH2), 7.31–7.24 (m, 4H, py), 7.13 (d, 3JH,H = 4.7 Hz, 2H, py), 6.71 (br. s, 4H, NH2). 13C NMR 
(125.81 MHz, DMSO-d6): δ 177.1 (C–S), 145.9 (Cq, py), 135.5 (HC=N), 132.9 (Cpy), 128.1 (Cpy), 127.6 
(Cq, py), 127.3 (Cpy). Crystals suitable for X-ray data collection were obtained by slow evaporation of an 
ethanolic solution of 1D. 
 [Bis(2-formylpyridine 4N-dimethylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(LE)2]PF6 (1E). To 2-formylpyridine 4N-dimethylthiosemicarbazone (HLE) 
(87 mg, 0.42 mmol) in methanol (6 mL) at 40 °C gallium(III) nitrate nonahydrate  (87 mg, 0.21 mmol) 
in methanol (2 mL) was added and the mixture was stirred at room temperature for 3 h. Addition of 
ammonium hexafluorophosphate (100 mg, 0.61 mmol) to the reaction mixture led to the formation of a 
yellow solid which was filtered off washed with methanol and dried in vacuo. Yield: 92 mg (70%). 
Anal. Calcd. for C18H22F6GaN8PS2 (Mr = 629.24 g/mol): C, 34.36; H, 3.52; N, 17.81; S, 10.19. Found: 
C, 34.18; H, 3.49; N, 17.54; S, 10.23. ESI-MS in MeOH (positive): m/z 483, [Ga(LE)2]+. ESI-MS in 
MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr, cm−1 (selected bands): 1607 m, 1514 s, 1368 s, 
1316 m, 1249 s, 1217 m, 1138 s, 914 m, 837 vs, 557 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 252sh 
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(11190), 301 (17690), 411 (46240). 1H NMR (500.10 MHz, DMSO-d6): δ 9.04 (s, 2H, HC=N), 8.20 (dt, 
3JH,H = 7.9 Hz, 4JH,H = 1.6 Hz, 2H, py), 7.99 (m, 4H, py), 7.56 (m, 2H, py), 3.30 and 3.23 (br. s, 12H, 
N(CH3)2). 13C NMR (125.81 MHz, DMSO-d6): δ 177.4 (C–S), 145.3 (Cq, py), 145.0 (Cpy), 142.8 (Cpy), 
138.2 (HC=N), 127.6 (Cpy), 126.4 (Cpy), 41.3 and 38.8 (N(CH3)2).  
 [Bis(2-pyridineformamide 4N-dimethylthiosemicarbazonato)-N,N,S-gallium(III)] nitrate, 
[Ga(LG)2]NO3 (1G). To 2-pyridineformamide 4N-dimethylthiosemicarbazone (HLG) (400 mg, 1.79 
mmol) in ethanol (20 mL) at 70 °C gallium(III) nitrate nonahydrate  (375 mg, 0.90 mmol) in ethanol (5 
mL) was added and the mixture was stirred at the same temperature for 2 h. The yellow-orange solid 
was separated from the hot solution by filtration, washed with ethanol and dried in vacuo. Yield: 380 mg 
(74%). Anal. Calcd. for C18H24GaN11O3S2 (Mr = 576.31 g/mol): C, 37.51; H, 4.20; N, 26.73; S, 11.13. 
Found: C, 37.47; H, 4.14; N, 26.34; S, 11.19. ESI-MS in MeOH (positive): m/z 513, [Ga(LG)2]+. ESI-
MS in MeOH (negative): m/z 511, [Ga(LG)2 – 2H]−. IR spectrum in KBr, cm−1 (selected bands): 1644 s, 
1522 s, 1487 m, 1362 br. s, 913 m, 788 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 260 (21800), 324 
(11900), 409 (22640). 1H NMR (500.10 MHz, DMSO-d6): δ 8.45 (d, 3JH,H = 8.2 Hz, 2H, py), 8.27 (dt, 
3JH,H = 7.9 Hz, 4JH,H = 1.5 Hz, 2H, py), 8.15 (v. br. s, 4H, NH2), 7.84 (m, 2H, py), 7.69 (m, 2H, py), 3.15 
(s, 12H, N(CH3)2). 13C NMR (125.81 MHz, DMSO-d6): δ 169.7 (C–S), 145.6 (C=N), 144.7 (Cpy), 142.4 
(Cpy), 141.7 (Cq, py), 128.3 (Cpy), 122.1 (Cpy), 39.3 (N(CH3)2).  
[Bis(3-aminopyridine-2-carboxaldehyde 4N-dimethylthiosemicarbazonato)-N,N,S-gallium(III)] 
hexafluorophosphate, [Ga(LH)2]PF6 (1H). To a suspension of 3-aminopyridine-2-carboxaldehyde 4N-
dimethylthiosemicarbazone hydrochloride (HLH·HCl) (150 mg, 0.58 mmol) in ethanol (15 mL) 
gallium(III) nitrate nonahydrate (130 mg, 0.31 mmol) in ethanol (3 mL) was added and the mixture was 
stirred for 1.5 h at room temperature. Subsequently a solution of ammonium hexafluorophosphate (200 
mg, 1.23 mmol) in ethanol (2 mL) was added. After 2 h the orange precipitate was filtered off, washed 
with cold ethanol (–20 °C) and dried in vacuo. Yield: 114 mg (60%). Anal. Calcd. for 
C18H24F6GaN10PS2 (Mr = 659.27 g/mol): C, 32.79; H, 3.67; N, 21.25; S, 9.73. Found: C, 33.02; H, 3.83; 
N, 21.14; S, 9.70. ESI-MS in MeOH (positive): m/z 513, [Ga(LH)2]+. ESI-MS in MeOH (negative): m/z 
132
  
145, [PF6]−. IR spectrum in KBr, cm−1 (selected bands): 3488 w, 3439 w, 3400 m, 3337 w, 1645 m, 
1511 s, 1471 s, 1380 s, 1322 s, 1256 s, 1124 s, 913 m, 845 vs, 557 m. UV–vis (MeOH), λmax, nm (ε, 
M−1 cm−1): 226 (28950), 301 (24070), 349sh (6860), 451 (44050), 469 (42720). 1H NMR (500.10 MHz, 
DMSO-d6): δ 9.29 (s, 2H, HC=N), 7.29 (dd, 3JH,H = 8.5 Hz, 4JH,H = 1.3 Hz, 2H, py) 7.24 (dd, 3JH,H = 8.5 
Hz, 3JH,H = 4.7 Hz, 2H, py), 7.15 (d, 3JH,H = 4.4 Hz, 2H, py), 6.71 (br. s, 4H, NH2), 3.21 (s, 12H, 
N(CH3)2). 13C NMR (125.81 MHz, DMSO-d6): δ 176.2 (C–S), 145.9 (Cq, py), 136.1 (HC=N), 132.9 
(Cpy), 128.1 (Cpy), 127.6 (Cq, py), 127.3 (Cpy), 40.9 and 38.6 (N(CH3)2). 
[Bis(2-formylpyridine thiosemicarbazonato)-N,N,S-iron(III)] nitrate, [Fe(LA)2]NO3 (2A). To 2-
formylpyridine thiosemicarbazone (HLA) (200 mg, 1.11 mmol) and N-methylmorpholine (120 µL, 1.09 
mmol) in methanol (20 mL) at 70 °C iron(III) nitrate nonahydrate (222 mg, 0.55 mmol) in methanol (2 
mL) was added dropwise and the reaction mixture was stirred for 3 h at 70 °C. After cooling to room 
temperature ca. 1/2 of the solvent was removed under reduced pressure and the reaction mixture was 
allowed to stand at +4 °C overnight. The black crystalline product was filtered off, washed with cold 
methanol, dried in vacuo and afterwards over P2O5. Yield: 195 mg (74%). Anal. Calcd. for 
C14H14FeN9O3S2 (Mr = 476.30 g/mol): C, 35.30; H, 2.96; N, 26.47; S, 13.47. Found: C, 35.21; H, 2.91; 
N, 26.34; S, 13.38..ESI-MS in MeOH (positive): m/z 414, [Fe(LA)2]+. IR spectrum in KBr, cm−1 
(selected bands): 3295 s, 3100 br. s, 1645 m, 1616 s, 1603 s, 1456 s, 1435 s, 1384 s, 1292 m, 1154 s, 
863 m, 767 m, 725 m, 620 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 240sh (29610), 295 (20470), 
312sh (20400), 352 (19560), 417sh (11200), 462sh (7220) 585sh (540), 882 (550).  
[Bis(2-acetylpyridine thiosemicarbazonato)-N,N,S-iron(III)] nitrate, [Fe(LB)2]NO3 (2B). To 2-
acetylpyridine thiosemicarbazone (HLB) (200 mg, 1.03 mmol) in methanol (10 mL) at room temperature 
iron(III) nitrate nonahydrate (208 mg, 0.51 mmol) in methanol (2 mL) was added dropwise and the 
reaction mixture was stirred for 3 h. The black product formed was filtered off, washed with methanol, 
dried in vacuo and then over P2O5. Yield: 198 mg (74%). Anal. Calcd. for C16H18FeN9O3S2 (Mr = 504.35 
g/mol): C, 38.10; H, 3.60; N, 24.99; S, 12.72. Found: C, 38.14; H, 3.56; N, 24.82; S, 12.83..ESI-MS in 
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MeOH (positive): m/z 442, [Fe(LB)2]+. IR spectrum in KBr, cm−1 (selected bands): 3272 m, 3108 br. s, 
1638 m, 1598 s, 1497 m, 1446 s, 1384 s, 1170 m, 767 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 
242sh (31940), 299 (22870), 319 (22700), 354 (18900), 412 (11930), 456sh (8950), 578sh (540), 865 
(670). 
 [Bis(2-pyridineformamide thiosemicarbazonato)-N,N,S-iron(III)] nitrate, [Fe(LC)2]NO3·1.5H2O 
(2C). To 2-pyridineformamide thiosemicarbazone (HLC) (200 mg, 1.02 mmol) and N-
methylmorpholine (111 µL, 1.01 mmol) in methanol (10 mL) at 50 °C iron(III) nitrate nonahydrate  (205 
mg, 0.51 mmol) in methanol (2 mL) was added and the mixture was stirred at 50 °C for 2 h. After 
cooling to room temperature ca. 1/2 of the solvent was removed under reduced pressure and the reaction 
mixture was allowed to stand at +4 °C overnight. The black crystals were filtered off, washed with cold 
methanol and dried in vacuo. Yield: 213 mg (78%). Anal. Calcd. for C14H16FeN11O3S2·1.5H2O (Mr = 
533.35 g/mol): C, 31.53; H, 3.59; N, 28.89; S, 12.02. Found: C, 31.42; H, 3.35; N, 28.69; S, 11.85. ESI-
MS in MeOH (positive): m/z 444, [Fe(LC)2]+. IR spectrum in KBr, cm−1 (selected bands): 3279 s, 3161 
s, 1622 br. s, 1550 m, 1515 m, 1463 s, 1384 s, 1193 m, 784 m. UV–vis (MeOH), λmax, nm (ε, M−1 
cm−1): 245sh (33110), 299 (15250), 355sh (11730), 460 (10280), 829 (990). 
[Bis(3-aminopyridine-2-carboxaldehyde thiosemicarbazonato)-N,N,S-iron(III)] nitrate, 
[Fe(LD)2]NO3·H2O (2D). To a suspension of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 
(HLD) (150 mg, 0.77 mmol) in ethanol (24 mL) at 50 °C iron(III) nitrate nonahydrate  (157 mg, 0.39 
mmol) in ethanol (2 mL) was added dropwise and the mixture was stirred for 10 min at 50 °C and 3 h at 
room temperature. The black-green precipitate was filtered off, washed with cold ethanol (–20 °C) and 
diethyl ether, dried in vacuo and afterwards over P2O5. Yield: 132 mg (66%). Anal. Calcd. for 
C14H16FeN11O3S2·H2O (Mr = 524.34 g/mol): C, 32.07; H, 3.46; N, 29.38; S, 12.23. Found: C, 32.34; H, 
3.18; N, 29.51; S, 12.48. ESI-MS in MeOH (positive): m/z 444, [Fe(LD)2]+. IR spectrum in KBr, cm−1 
(selected bands): 3298 m, 3149 br. m, 1629 s, 1583 s, 1469 s, 1439 s, 1384 m, 1272 s, 1245 m, 1140 s, 
794 m, 631 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 267 (26320), 303 (25340), 410sh (19655), 441 
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(21530), 483sh (15960), 606 (840), 912 (490). Crystals suitable for X-ray data collection were obtained 
by slow evaporation of a methanolic solution of 2D. 
[Bis(2-formylpyridine 4N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] hexafluorophosphate, 
[Fe(LE)2]PF6 (2E). To 2-formylpyridine 4N-dimethylthiosemicarbazone (HLE) (70 mg, 0.34 mmol) 
dissolved in ethanol (7 mL) at 40 °C iron(III) nitrate nonahydrate  (68 mg, 0.17 mmol) in ethanol (2 mL) 
was added and the mixture was stirred at room temperature for 1.5 h. After addition of ammonium 
hexafluorophosphate (90 mg, 0.55 mmol) the reaction mixture was stirred further for 1 h. The solid was 
filtered off, washed three times with cold ethanol (–20 °C) and dried in vacuo and then over P2O5. 
Yield: 79 mg (76%). Anal. Calcd. for C18H22F6FeN8PS2 (Mr = 615.36 g/mol): C, 35.13; H, 3.60; N, 
18.21; S, 10.42. Found: C, 35.30; H, 3.89; N, 17.84; S, 10.20. ESI-MS in MeOH (positive): m/z 470, 
[Fe(LE)2]+. ESI-MS in MeOH (negative): m/z 145, [PF6]−. IR spectrum in KBr, cm−1 (selected bands): 
1557 s, 1500 s, 1400 s, 1372 s, 1319 m, 1252 m, 1127 s, 839 vs, 558 m. UV–vis (MeOH), λmax, nm (ε, 
M−1 cm−1): 218sh (37940), 248 (26930), 299 (17690), 319sh (25100), 382 (25820), 624 (783), 905 
(470).  
 [Bis(2-pyridineformamide 4N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] nitrate, 
[Fe(LG)2]NO3 (2G). To 2-pyridineformamide 4N-dimethylthiosemicarbazone (HLG) (400 mg, 1.79 
mmol) in methanol (30 mL) at 50 °C iron(III) nitrate nonahydrate  (362 mg, 0.90 mmol) in methanol (3 
mL) was added and the mixture was stirred at the same temperature for 2 h. After cooling to room 
temperature ca. 1/2 of the solvent was removed under reduced pressure and the reaction mixture was 
allowed to stand at +4 °C overnight. The precipitate was filtered off, washed with ethanol and dried in 
vacuo at 50 °C. Yield: 340 mg (68%). Anal. Calcd. for C18H24FeN11O3S2 (Mr = 562.43 g/mol): C, 38.44; 
H, 4.30; N, 27.39; S, 11.40. Found: C, 38.24; H, 4.52; N, 26.94; S, 11.03. ESI-MS in MeOH (positive): 
m/z 500, [Fe(LG)2]+. ESI-MS in MeOH (negative): m/z 498, [Fe(LG)2 – 2H]−. IR spectrum in KBr, cm−1 
(selected bands): 3268 w, 1619 s, 1552 s, 1532 s, 1479 s, 1385 s, 1254 m, 911 m, 780 s, 752 m. UV–vis 
(MeOH), λmax, nm (ε, M−1 cm−1): 248sh (31850), 300 (14490), 370 (13960), 464 (11730), 869 (980). 
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[Bis(3-aminopyridine-2-carboxaldehyde 4N-dimethylthiosemicarbazonato)-N,N,S-iron(III)] 
nitrate, [Fe(LH)2]NO3 (2H). To a suspension of 3-aminopyridine-2-carboxaldehyde 4N-
dimethylthiosemicarbazone hydrochloride (HLH·HCl) (120 mg, 0.46 mmol) in ethanol (12 mL) iron(III) 
nitrate nonahydrate (100 mg, 0.25 mmol) in ethanol (1 mL) was added dropwise and the mixture was 
stirred for 3 h at room temperature. The brown precipitate was filtered off, washed with cold ethanol (–
20 °C) and diethyl ether, dried in vacuo at 50 °C and then over P2O5. Yield: 95 mg (73%). Anal. Calcd. 
for C18H24FeN11O3S2 (Mr = 562.43 g/mol): C, 38.44; H, 4.30; N, 27.39; S, 11.40. Found: C, 38.54; H, 
4.27; N, 27.11; S, 11.35. ESI-MS in MeOH (positive): m/z 500, [Fe(LH)2]+. IR spectrum in KBr, cm−1 
(selected bands): 3331 w, 3207 w, 1647 m, 1582 s, 1553 s, 1500 s, 1468 s, 1384 s, 1324 m, 1256 s, 1112 
s, 913 m, 796 m, 618 m. UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 226sh (28950), 270 (27460), 308 
(27070), 438 (31030), 487sh (22370), 642 (980), 977 (510) 
Crystallographic Structure Determination. X-ray diffraction measurements were performed on a 
Bruker X8 APEX II CCD-diffractometer. Crystal data, data collection parameters, and structure 
refinement details for HLD, HLE, 1D and 2D are given in Tables S1 and S2. The structures were solved 
by direct methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms were refined 
with anisotropic displacement parameters. H atoms were placed at calculated positions and refined as 
riding atoms in the subsequent least squares model refinements. The isotropic thermal parameters were 
estimated to be 1.2 times the values of the equivalent isotropic thermal parameters of the atoms to which 
hydrogens were bonded. The following computer programs were used: structure solution, SHELXS-
97;[52] refinement, SHELXL-97;[53] molecular diagrams, ORTEP;[54] computer: Pentium IV; scattering 
factors.[55] Crystallographic data have been deposited at the Cambridge Crystallographic Data Center 
with numbers CCDC729370–729373. Copies of data can be obtained, free of charge, on application to 
CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (deposit@ccdc.com.ac.uk).  
 
136
  
Cell lines and Culture Conditions. Human 41M (ovarian carcinoma) and SK-BR-3 (mammary 
carcinoma) cells were kindly provided by Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, 
Institute of Cancer Research, Sutton, UK) and Evelyn Dittrich (Department of Medicine I, Medical 
University of Vienna, Austria), respectively. Cells were grown in 75 cm² culture flasks (Iwaki/Asahi 
Technoglass, Gyouda, Japan) as adherent monolayer cultures in Minimal Essential Medium (MEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine 
and 1% non-essential amino acids (100×) (all purchased from Sigma-Aldrich, Vienna, Austria). Cultures 
were maintained at 37 °C in a humidified atmosphere containing 5% CO2. 
Cytotoxicity Tests in Cancer Cell Lines. Antiproliferative effects were determined by means of a 
colorimetric microculture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). Cells were harvested from culture flasks by trypsinization and seeded in 100 µL 
aliquots into 96-well microculture plates (Iwaki/Asahi Technoglass, Gyouda, Japan) in densities of 
4 × 103 cells/well, in order to ensure exponential growth of untreated controls throughout the 
experiment. After a 24 h pre-incubation, dilutions of the test compounds in 100 µL/well complete 
culture medium were added. Because of low aqueous solubility, the test compounds were dissolved in 
DMSO first and then serially diluted in complete culture medium such that the effective DMSO content 
did not exceed 0.5%. After exposure for 96 h, all media were replaced by 100 µL/well RPMI 1640 
medium (supplemented with 10% heat-inactivated fetal bovine serum and 2 mM L-glutamine) plus 
20 µL/well MTT solution in phosphate-buffered saline (5 mg/ml). After incubation for 4 h, the 
medium/MTT mixtures were removed, and the formazan crystals formed by vital cells were dissolved in 
150 µL DMSO per well. Optical densities at 550 nm were measured with a microplate reader (Tecan 
Spectra Classic), using a reference wavelength of 690 nm to correct for unspecific absorption. The 
quantity of vital cells was expressed in terms of T/C values by comparison to untreated control 
microcultures, and 50% inhibitory concentrations (IC50) were calculated from concentration-effect 
curves by interpolation. Evaluation is based on means from at least three independent experiments, each 
comprising at least three microcultures per concentration level. 
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Ribonucleotide Reductase Inhibition. To compare the RR inhibitory potential of HLD and HLE with 
that of their corresponding iron complexes 2D and 2E, 3H-cytidine incorporation assays were 
performed.56 For this purpose, exponentially growing HL60 cells (5x106) were incubated with the test 
substances for 4 h. After the incubation period, the cells were pulsed with 3H-cytidine (0.3125 µCi, 5 
nM) for 1 h at 37 °C. Then cells were collected and washed with PBS. For cell lysis, the cell pellets 
were resuspended in a lysis buffer containing 10 mM EDTA, 50 mM Tris (pH 8.0), and 0.5% sodium 
lauryl sarcosine and frozen at –20 °C. For DNA extraction, the cell lysate was incubated with 20 units 
RNAse at 37 °C for 1 h followed by 24 h treatment with 150 µg proteinase K. Subsequently DNA was 
extracted using standard procedures. After precipitation with ethanol, DNA was resuspended in water, 
DNA content measured, and radioactivity was determined.57 
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Scheme S1. The original six step synthesis of Triapine (HLD) with an overall yield of 9%. 
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Scheme S2. Improved five step synthesis of Triapine (HLD) with an overall yield of 55%. 
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Scheme S3. Four step synthesis of Triapine (HLD) with an overall yield of 64%. 
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Figure S1. Cyclic voltammogram of the Triapine iron(III) complex 2D in H2O/DMSO (7:3 v/v) solution 
containing 0.20 M NaClO4 at a scan rate of 0.20 V s–1 using a glassy carbon working electrode. 
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Discussion of the electrochemical behavior of the metal complexes in DMSO and CH3CN solution 
In our previously reported study of the electrochemical behavior of 2-acetylpyridine 4N- disubstituted 
thiosemicarbazones1 (pyrrolidine, piperidine, dimethylamine, aniline and p-nitroaniline) and their 
gallium(III), iron(III) and ruthenium(III) complexes in CH3CN solution we found a perfect correlation 
between the pKa value of the terminal amine and the redox potentials of the metal and ligand centered 
redox couples. Using the resultant linear equations and the pKa value of ammonia at 9.252 the redox 
potentials of the 2-acetylpyridine thiosemicarbazone complexes 1B and 2B in CH3CN solution can be 
predicted (linear equations for the gallium complexe ILred: E1/2 (V) = –0.673 – 0.0247·pKa; IILred : E1/2 
(V) = –0.902 – 0.0302·pKa; iron complexe: FeIII/FeII: E1/2 (V) = 0.285 – 0.0197·pKa; ILred: E1/2 (V) = –
1.302 – 0.0284·pKa).  
Table S1. Predicted and experimental redox potentials of 1B and 2B in CH3CN solution. 
 1B 2B 
 
ILred IILred FeIII/FeII ILred 
E1/2 predicted (V vs NHE) –0.90 –1.18 +0.10  –1.56 
E1/2 experimental (V vs. NHE)a –0.88  –1.16 +0.11 –1.54 
a
 0.20 M [n-Bu4N][BF4]/CH3CN using a glassy carbon electrode 
 
This shows an excellent agreement between the predicted and experimental redox potentials in 
CH3CN. Interestingly compared to CH3CN, in DMSO solution the redox potentials of 1B and 2B are 
shifted 50–70 mV to lower values, whereas for the analogous 4N-dimethylated complexes 1F and 2F no 
shift between CH3CN and DMSO can be observed (≤10 mV).  
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X-Ray crystallographic data 
Table S1. Details of data collection for HLD, HLE, 1D and 2D. 
 
Compound HLD HLE 1D 2D 
Number of 
frames 
1803 1628 1489 1170 
Seconds/frame 80 40 60 30 
Scan width 1 1 1 1 
Distance from 
the detector 
40 40 40 40 
 
Table S2. Crystal Data for HLD, HLE, 1D and 2D. 
 HLD HLE 1D 2D 
Empirical 
formula 
C7H9N5S C9H12N4S C16H22GaN11O4S2 C14H23FeN11O6.5S2 
For ula weight 195.25 208.29 566.29 569.40 
Space group Pna21 P-1 P-1 C2/c 
a [Å] 18.5732(8) 7.3747(2) 9.3441(7) 9.2033(4) 
b [Å] 5.5273(2) 7.4532(2) 18.7491(10) 23.0998(11) 
c [Å] 17.2799(7) 9.6324(3) 12.9501(13) 21.2104(8) 
α [deg]   102.437(6)  
β [deg]  109.630(2) 95.239(5) 92.473(3) 
γ [deg]   96.569(5)  
V [Å3] 1773.95(12) 489.97(2) 1136.26(18) 4505.0(3) 
Z 8 2 2 8 
λ [Å] 0.71073 0.71073 0.71073 0.71073 
ρcalcd [g cm-3] 1.462 1.412 1.655 1.679 
Crystal size [mm] 0.30 × 0.15 × 0.04 0.40 × 0.30 × 0.10 0.06 × 0.05 × 0.02 0.30 × 0.20 × 0.01 
T [K] 100 100 296 100 
µ [mm-1] 0.323 0.294 1.445 0.916 
R1[a] 0.0364 0.0337 0.0577 0.0615 
wR2[b] 0.0893 0.0990 0.1526 0.1446 
GOF[c] 1.012 1.069 1.000 1.003 
a
 R1 = Σ||Fo| − |Fc||/Σ|Fo|. b wR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2. c GOF = {Σ[w(Fo2 − Fc2)2]/(n − 
p)}1/2, where n is the number of reflections and p is the total number of parameters refined.  
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ORTEP plot of HLE with atom numbering schemes. The thermal ellipsoids are drawn at 50% 
probability level. Selected bond lengths (Å) and bond angles (deg): C6−N2 = 1.2933(16), N2−N3 = 
1.3595(15), N3−C7 = 1.3726(15), C7−S1 = 1.6855(13), C7−N4 = 1.3419(16); N1−C5−C6−N2 = 
−1.2(2), C6−N2−N3−C7 = 177.67(12), N2−N3−C7−S1 = −4.94(17).  
 
 
 
                                                 
1
 Kowol, C. R.; Reisner, E.; Chiorescu, I.; Arion, V. B.; Galanski, M.; Deubel, D. V.; Keppler B. K. An 
electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox non-innocent 
α-N-heterocyclic chalcogensemicarbazones. Inorg. Chem. 2008, 47, 11032–11047. 
 
2
 CRC Handbook of Chemistry and Physics; Lide, D. R., Ed.; CRC Press: Boca Raton, FL, 2004. 
 
154
      
2.5 Fluorescence Properties and Cellular Distribution of the Investigational  
Anti-cancer Drug Triapine (3-Aminopyridine-2-carboxaldehyde 
Thiosemicarbazone) and its Zinc(II) Complex 
  
Kowol, C. R.; Trondl, R.; Arion, V. B.; Jakupec, M. A.; Lichtscheidl, I.; Keppler, B. K.   
Angew. Chem. Int. Ed., submitted. 
 
155
      
156
  
Fluorescent Anti-
cancer Drug  
DOI: 10.1002/anie.200((will be filled in by the editorial staff)) 
Fluorescence Properties and Cellular Distribution of the Investigational Anti-cancer Drug 
Triapine (3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone) and its Zinc(II) 
Complex 
Christian R. Kowol, Robert Trondl, Vladimir B. Arion,* Michael A. Jakupec, Irene Lichtscheidl, 
Bernhard K. Keppler* 
The antineoplastic activity of α-N-heterocyclic thiosemicarbazones 
was discovered several decades ago.[1] Currently the most promising 
drug candidate of this class of compounds is Triapine (3-
aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP), which 
entered several phase I and II clinical trials as an antitumor 
chemotherapeutic agent.[ 2 ] Triapine is a potent inhibitor of the 
enzyme ribonucleotide reductase, which catalyzes the reduction of 
ribonucleotides to deoxyribonucleotides and is essential for cell 
proliferation.[3] The enzyme consists of two homodimeric subunits 
R1 and R2. The latter contains a diiron center and a tyrosyl 
radical.[4]  Although the mechanism of action of Triapine is not fully 
understood, at least at the molecular level, the active species of 
Triapine is presumed to be an iron complex which is able to 
generate reactive oxygen species (ROS) and subsequently destroy 
the tyrosyl radical in the R2 subunit of ribonucleotide reductase.[5]  
It should also be noted that nothing is known about the cellular 
distribution of this investigational anti-cancer drug.  
We discovered that Triapine possesses intrinsic fluorescence 
when light-irradiated at around λ = 360 nm. This enabled us to 
monitor for the first time the uptake and intra-cellular distribution of 
an α-N-heterocyclic thiosemicarbazone in living human cancer cells 
by fluorescence microscopy. The results of this study are reported 
herein. In addition we synthesized the first zinc(II) complex of 
Triapine (Scheme 1), considering that coordination of α-N-
heterocyclic thiosemicarbazones to zinc can increase the 
antineoplastic activity both in vitro[6] and in vivo,[7]  and compared 
its properties with those of the metal-free Triapine. 
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Scheme 1.  
The yellow complex [Zn(Triapine)Cl2]·HCl was prepared by 
reaction of ZnCl2 with Triapine in 1:1 molar ratio in methanol in the 
presence of 2 equiv of 12 M HCl. In the absence of hydrochloric 
acid in ethanol, [Zn(Triapine)Cl2] precipitated with a small amount 
(<5%) of unidentified by-product. The mother liquor generated 
single crystals of [Zn(Triapine)Cl2]·EtOH. The results of an X-ray 
crystallographic study[8] of the latter are shown in Figure 1, along 
with selected bond lengths and angles. The geometry around the 
five-coordinate zinc(II) bound to the neutral tridentate Triapine via 
NNS donor atoms and two chlorido ligands is intermediate between 
square-pyramidal and trigonal-bipyramidal (τ = 0.34).[9] 
 
Figure 1. ORTEP plot of the complex [Zn(Triapine)Cl2] with thermal 
ellipsoids at 50% probability level. Selected bond distances (Å) and 
angles (deg): Zn–Cl1, 2.2657(5); Zn–Cl2, 2.3038(5); Zn–S, 2.5016(5); 
Zn–N1, 2.1486(16); Zn–N3, 2.1378(15); N1–Zn–S, 151.46(4); N3–
Zn–Cl1, 131.02(4); N3–Zn–Cl2, 113.60(4).    
The UV/vis spectrum of Triapine in H2O exhibits an absorption 
band of the lowest energy at 359 nm, which is 6 nm 
bathochromically shifted in the spectrum of the 
[Zn(Triapine)Cl2]·HCl complex (Figure 2). Both compounds show 
very similar emission spectra with a maximum at 457 nm when 
irradiated at λex = 360 nm (Figure 2). The quantum yields of 
Triapine and [Zn(Triapine)Cl2]·HCl in H2O are 0.018 and 0.021 
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(each value ± 15%), respectively, with quinine sulfate dihydrate in 
0.1 M HClO4 as the standard.  
In the literature, several intrinsically fluorescent mono-
thiosemicarbazones were documented as sensors for metal ion 
detection.[ 10 ] Zinc(II) complexes of biologically active 
bis(thiosemicarbazones) were reported with quantum yields in 
DMSO in the same range as the compounds studied herein.[11] 
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Figure 2. UV/vis (30 µM) and fluorescence (5 µM, λex = 360 nm) 
spectra of Triapine (black) and [Zn(Triapine)Cl2]·HCl (blue) in H2O 
(maximum content of DMSO = 0.5%).   
The cellular distribution of both compounds was studied by 
fluorescence microscopy in living SW480 cells (colon carcinoma, 
human). Bright-field images of SW480 cells treated with Triapine 
(0.25 mM in 0.5% DMSO/PBS) or [Zn(Triapine)Cl2]·HCl (0.50 mM 
in PBS) (Figures 3A, B) were taken prior to fluorescence imaging to 
ensure that the studied cells were morphologically intact. 
Fluorescence images (Figures 3C, D) showed that both compounds 
are taken up by cells within minutes and that cellular distribution of 
the compounds can be visualized. Both Triapine and its zinc 
complex have a striking affinity to the nuclear membrane and to a 
more diffuse structure in the cytoplasm. Fluorescence images were 
scaled in pseudocolors to highlight cellular regions with particularly 
high affinity to the substances (Figures 3E, F). Remarkably, the zinc 
complex binds to a substructure within the nucleus, suggestive of 
nucleoli. Immunostaining of the nucleolar protein fibrillarin and co-
staining with [Zn(Triapine)Cl2]·HCl unequivocally proved that these 
substructures are indeed nucleoli (Figures 3G, H). In contrast, a 
strong affinity of Triapine to the nucleoli was not discernible. 
Nevertheless, the distinct differences in the distribution of the two 
substances suggests that zinc(II) remains coordinated to Triapine 
within the cell. 
The cytotoxic potencies of Triapine and [Zn(Triapine)Cl2]·HCl  
were determined in SW480 (colon carcinoma)  and 41M (ovarian 
carcinoma) cells by means of the colorimetric MTT assay.  
Comparison of the two compounds did not reveal meaningful 
differences. The IC50 values of Triapine in SW480 and 41M cells 
are 0.55±0.2 and 0.45±0.03 µM, respectively, whereas 
[Zn(Triapine)Cl2]·HCl shows IC50 values of 0.54±0.02 and 
0.52±0.02 µM, respectively.  
In accordance with our findings, other groups suggested 
considerable uptake of zinc bis(thiosemicarbazone) complexes into 
the nucleolus.[ 12 ]  Furthermore, the affinity of nucleoli for 
exogenous zinc bound to diphenylthiocarbazone was observed in 
HeLa cells.13   In literature the presence of physiological zinc in 
nucleoli of oocytes of starfish was reported, suggesting that zinc(II) 
mediates the affinity of the complexes to nucleoli.14   
Our results demonstrate that Triapine can be visualized with 
fluorescence microscopy in living cells without any conjugation of 
fluorophores. Although the cytotoxicities of metal-free Triapine and 
its zinc(II) complex are very similar in vitro, the cellular 
distributions, especially with regard to the nucleus are distinctly 
different. 
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Figure 3. Live-cell images of SW480 colon carcinoma cells incubated 
with Triapine (A, C, E) or [Zn(Triapine)Cl2]·HCl (B, D, F).  (A, B) 
Bright-field images; (C, D) fluorescence images; (E, F) pseudocolor 
fluorescence images. Co-staining with [Zn(Triapine)Cl2]·HCl (G) and 
immunofluorescence of the nucleolar protein fibrillarin (H), confirming 
the localization of the compound in nucleoli. 
Experimental Section 
All solvents and reagents were obtained from commercial suppliers 
and used without further purification. Triapine was synthesized by a 
three-step synthesis in 64% overall yield. In the first step the amino 
group of commercially available 3-amino-2-bromopyridine was 
protected with di-tert-butyl dicarbonate using sodium 
bis(trimethylsilyl)amide as the base.[ 15 ] Treatment of the tert-Boc 
protected 3-amino-2-bromopyridine with n-BuLi in dry THF and 
subsequent reaction with N-formylpiperidine gives the 
carboxaldehyde.[ 16 ] Finally, the condensation reaction with 
thiosemicarbazide in ethanol in the presence of concentrated HCl 
afforded Triapine hydrochloride, which was converted into the free 
base by treatment with sodium bicarbonate.[17] 
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[Zn(Triapine)Cl2]·HCl: Triapine (50 mg, 0.26 mmol) dissolved in 
boiling methanol (10 mL) was slowly added to a mixture of zinc(II) 
chloride (35 mg, 0.26 mmol) and conc. HCl (43 µL) in methanol (5 
mL) at 50 °C. The mixture was stirred for 10 min at 50°C. The yellow 
precipitate was filtered off, washed with methanol, diethyl ether, dried 
in vacuo and over P2O5. Yield: 62 mg, 66%. Elemental analysis (%): 
calcd for C7H9Cl2N5SZn·HCl (Mr = 368.00 g/mol): C 22.85, H 2.74, N 
19.03, S 8.71, found: C 23.11, H 2.71, N 18.87, S 8.77. ESI-MS in 
MeOH (negative): m/z 292, [Zn(Triapine)Cl2 – H – Cl]−. IR (KBr) 
(selected bands): υ = 3439 (m), 3351 (s), 3275 (m), 3195 (m), 1640 
(s), 1619 (s), 1542 (s), 1471 (s), 1387 (m), 1269 (s), 1099 (m), 947 
(m), 919 (m), 834 (m), 782 (s), 562 (br. m), 482 (m) cm–1; UV/vis 
(H2O): λmax (ε): 365 (15440), 288 (12630), 234sh (16500), 216 
(17840); 1H NMR (500.10 MHz, [D6]DMSO): δ = 11.91 (s, 1H, NH), 
8.54 (s, 1H, NH2), 8.33 (s, 1H, HC=N), 8.30 (s, 1H, NH2), 8.04 (d, 
3J(H,H)
 
= 4.4 Hz, 1H, py), 7.68 (d, 3J(H,H)
 
= 8.5 Hz, 1H, py), 7.56 (m, 
1H, py), 7.06 (v. br. s, 2H, NH2) ppm; 13C NMR (125.81 MHz, 
[D6]DMSO): δ = 178.6 (C=S), 146.0 (Cq,py), 137.0 (HC=N), 131.3 (Cpy), 
130.2 (Cpy), 127.0 (Cq,py), 126.5 (Cpy) ppm. 
Fluorescence Microscopy. Fluorescence properties of Triapine and 
[Zn(Triapine)Cl2]·HCl were observed under UV irradiation (360–370 
nm) with an Olympus BX41 microscope equipped with 60x and 100x 
planapochromate oil-immersion objectives and a ColorViewIII camera. 
Images were taken with several concentrations and always resulted in 
the same distribution within the cells. Exposure time was adjusted so 
that almost all auto-fluorescence of cells could be excluded, and 
excitation time was kept as short as possible to minimize irradiation 
impact on cells.  
Details of analytical characterization, X-ray data collection and 
refinement, cell culture, cytotoxicity tests and immunostaining are 
provided in the Supporting Information. 
Received: ((will be filled in by the editorial staff)) 
Published online on ((will be filled in by the editorial staff)) 
Keywords: cancer · thiosemicarbazone · fluorescence · zinc · nucleoli  
 
 
[1] R. W. Brockman, J. R. Thomson, M. J. Bell, H. E. Skipper, Cancer 
Res. 1956, 16, 167–170. 
[2]  a) Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, D. R. 
Richardson, Clin. Cancer Res. 2006, 12, 6876–6883; b) B. Ma, B. C. 
Goh, E. H. Tan, K. C. Lam, R. Soo, S. S. Leong, L. Z. Wang, F. Mo, 
A. T. C. Chan, B. Zee, T. Mok, Invest. New Drugs 2008, 26, 169–173; 
c) M. J. Mackenzie, D. Saltman, H. Hirte, J. Low, C. Johnson, G. 
Pond, M. J. Moore, Invest. New Drugs 2007, 25, 553–558; d) J. J. 
Knox, S. J. Hotte, C. Kollmannsberger, E. Winquist, B. Fisher, E. A.  
Eisenhauer, Invest. New Drugs 2007, 25, 471–477; e) J. E. Karp, F. J. 
Giles, I. Gojo, L. Morris, J. Greer, B. Johnson, M. Thein, M. Sznol, J. 
Low, Leuk. Res. 2008, 32, 71–77.    
[3]  R. A. Finch, M.-C. Liu, A. H. Cory, J. G. Cory, A. C. Sartorelli, Adv. 
Enzyme Regul. 1999, 39, 3–12. 
[4]  M. Kolberg, K. R. Strand, P. Graff, K. K. Andersson, Biochim. 
Biophys. Acta 2004, 1699, 1–34. 
[5]  J. Shao, B. Zhou, A. J. Di Bilio, L. Zhu, T. Wang, C. Qi, J. Shih, Y. 
Yen, Mol. Cancer Ther. 2006, 5, 586–592.   
[6]  a) D.  Kovala-Demertzi, P. N. Yadav, J. Wiecek, S. Skoulika, T. 
Varadinova, M. A. Demertzis, J. Inorg. Biochem. 2006, 100, 1558–
1567; b) J. M. Perez, A. I. Matesanz, A. Martin-Ambite, P. Navarro, C. 
Alonso, P. Souza, J. Inorg. Biochem. 1999, 75, 255–261. 
 
[7]  a) G. Atassi, P. Dumont, J. C. E. Harteel, Eur. J. Cancer 1979, 15, 
451–459; b) D. Kovala-Demertzi, A. Alexandratos, A. Papageorgiou, 
P. N. Yadav, P. Dalezis, M. A. Demertzis, Polyhedron 2008, 27, 
2731–2738.   
[8]  Crystal data for [Zn(Triapine)Cl2]·EtOH: C9H15Cl2N5OSZn, Mr = 
377.61 g mol–1, crystal size 0.20×0.10×0.03 mm, monoclinic, space 
group P21/c, a = 11.4639(7), b = 10.2716(5), c = 12.7509(7) Ǻ, β = 
99.422(4)°, V = 1481.20(4) Ǻ3, Z = 4, ρcalcd = 1.693 g cm–3, µ = 2.158 
mm–1,  MoKα radiation λ = 0.71073 Ǻ, T = 100 K, 2θmax = 30.10, 61508 
refections measured, 4342 independent reflections, Rint = 0.0692, 
R1[(I) > 2σ(I)] = 0.0274, wR2 (all data) = 0.0642.  
CCDC 732708 contains the supplementary crystallographic data for 
this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif.  
[9]  A. W. Addison, T. N. Rao, J. Reedijk, J. Van Rijn, G. C. Verschoor, J. 
Chem. Soc., Dalton Trans. 1984, 1349–1356.   
[10]  a) Y. Yu, L.-R. Lin, K.-B. Yang, X. Zhong, R.-B. Huang, L.-S. Zheng, 
Talanta 2006, 69, 103–106; b) J. Vazquez Ruiz, A. Garcia de Torres, J. 
M. Cano-Pavon, Talanta 1984, 31, 29–32.    
[11]  J. P. Holland, F. I. Aigbirhio, H. M. Betts, P. D. Bonnitcha, P. Burke, 
M. Christlieb, G. C. Churchill, A. R. Cowley, J. R. Dilworth, P. S. 
Donnelly, J. C. Green, J. M. Peach, S. R. Vasudevan, J. E. Warren, 
Inorg. Chem. 2007, 46, 465–485.   
[12]  A. R. Cowley, J. Davis, J. R. Dilworth, P. S. Donnelly, R. Dobson, A. 
Nightingale, J. M. Peach, B. Shore, D. Kerr, L. Seymour, Chem. 
Comm. 2005, 845–847. 
[13]  G. P. Studzinski, J. Histochem. Cytochem. 1965, 13, 365–375.   
[14]  T. Fujii, Nature 1954, 174, 1108–1109. 
[15]  T. A. Kelly, D. W. McNeil, Tetrahedron Lett. 1994, 35, 9003–9006. 
[16]  M. C. Venuti, R. A. Stephenson, R. Alvarez, J. J. Bruno, A. M. 
Strosberg, J. Med. Chem. 1988, 31, 2136–2145.   
[17]  C. Niu, J. Li, T. W. Doyle, S.-H. Chen, Tetrahedron 1998, 54, 6311–
6318. 
 
 
159
  
Entry for the Table of Contents  
 
 Fluorescent Anti-cancer drug 
Christian R. Kowol, Robert Trondl, 
Vladimir B. Arion, Michael A. Jakupec, 
Irene Lichtscheidl, Bernhard K. Keppler 
__________ Page – Page 
 
Fluorescence Properties and Cellular 
Distribution of the Investigational Anti-
cancer Drug Triapine (3-Aminopyridine-
2-carboxaldehyde Thiosemicarbazone) 
and its Zinc(II) Complex 
We discovered that Triapine (3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone), which entered several phase I and II clinical trials as an 
antitumor chemotherapeutic agent, possesses intrinsic fluorescence properties (λex 
= 360 nm). This observation enabled us to monitor for the first time the uptake and 
intra-cellular distribution of an α-N-heterocyclic thiosemicarbazone in living human 
cancer cells by fluorescence microscopy.  
 
 
Triapine
λex = 360 nm
N
N
H
N
NH2
S
NH2
Fluorescence
microscopy
160
 S1 
 
Supporting Information 
Fluorescence Properties and Cellular Distribution of the 
Investigational Anti-cancer Drug Triapine (3-Aminopyridine-2-
carboxaldehyde Thiosemicarbazone) and its Zinc(II) Complex  
 
Christian R. Kowol,1 Robert Trondl,1 Vladimir B. Arion,1,* Michael A. Jakupec,1 Irene Lichtscheidl,2 
Bernhard K. Keppler1,* 
 
1University of Vienna, Institute of Inorganic Chemistry, Währingerstr. 42, A-1090 Vienna, Austria  
 
 2University of Vienna, Institution of Cell Imaging and Ultrastructure Research, Althanstr. 14, A-1090 
Vienna, Austria 
 
 
 
 
 
 
 
 
161
 S2 
Experimental Section 
Elemental analyses were carried out on a Carlo Erba microanalyzer at the Microanalytical Laboratory 
of the University of Vienna. Electrospray ionization mass spectrometry was carried out with a Bruker 
Esquire 3000 instrument (Bruker Daltonic, Bremen, Germany). Expected and experimental isotope 
distributions were compared. Infrared spectra were obtained from KBr pellets with a Perkin-Elmer FT-
IR 2000 instrument (4000–400 cm–1). UV–vis spectra were recorded on a Perkin Elmer Lambda 650 
UV–vis spectrophotometer. Fluorescence emission spectra were recorded on a Perkin-Elmer LS 55 
fluorescence spectrophotometer. Emission spectra were corrected using the published data from NIST 
for quinine sulfate dihydrate in 0.1 M HClO4.[1] The fluorescence quantum yields were determined using 
the formula: 
ref2
refref
2
ref
sample φφ
nIA
nIA
⋅⋅
⋅⋅
=  
where quinine sulfate dihydrate in 0.1 M HClO4 is the reference (φref = 0.59)1, A the integrated area 
under the emission spectrum, I the absorbance at the excitation wavelength and n the refractive index of 
the solvent. The highest concentration of the samples was 5 µM so that the absorbance at the excitation 
wavelength (360 nm) did not exceed 0.1. 1H and 13C one- and two-dimensional NMR spectra were 
recorded in DMSO-d6 with a Bruker Avance III 500 MHz FT-NMR spectrometer. The residual 1H and 
13C present in DMSO-d6 were used as internal references. Abbreviations for NMR data: py = pyridine, 
Cq, py = quaternary carbon of pyridine. 
 
Details of X-ray data collection and refinement. X-ray diffraction measurements were performed on 
a Bruker X8 APPEXII CCD diffractometer. A single crystal of suitable size was coated with Paratone-N 
oil, mounted at room temperature on the tip of a glass fiber and cooled under a stream of cold N2 
maintained by a KRYOFLEX low-temperature apparatus. The crystal was positioned at 40 mm from the 
detector, and 2667 frames were measured, each for 20 s over 1° scan width. The data were processed 
using SAINT software.[2] The structures were solved by direct methods and refined by full-matrix least-
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squares techniques. Non-hydrogen atoms were refined with anisotropic displacement parameters. H 
atoms were placed at calculated positions and refined as riding atoms in the subsequent least squares 
model refinements. The isotropic thermal parameters were estimated to be 1.2 times the values of the 
equivalent isotropic thermal parameters of the atoms to which hydrogens were bound. The following 
computer programs were used: structure solution, SHELXS-97;[3] refinement, SHELXL-97;[4] molecular 
diagrams, ORTEP;[5] computer: Pentium IV; scattering factors.[6]  
 
Cell Culture. Human 41M (ovarian carcinoma) and SW480 (colon carcinoma) cells were kindly 
provided by Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 
Sutton, UK) and Brigitte Marian (Institute of Cancer Research, Department of Medicine I, Medical 
University of Vienna, Austria), respectively. Cells were grown in 75 cm² culture flasks (Iwaki/Asahi 
Technoglass, Gyouda, Japan) as adherent monolayer cultures in complete culture medium, i. e. Minimal 
Essential Medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum, 1 mM sodium 
pyruvate, 4 mM L-glutamine and 1% non-essential amino acids (100×) (all purchased from Sigma-
Aldrich, Vienna, Austria) without antibiotics. For fluorescence microscopy, cells were grown in 6-well 
plates on sterile cover slips. Cultures were maintained at 37 °C in a humidified atmosphere containing 
5% CO2 and 95% air. 
 
Cytotoxicity Tests in Cancer Cell Lines. Antiproliferative effects were determined by means of a 
colorimetric microculture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). Cells were harvested from culture flasks by trypsinization and seeded in 100 µL 
aliquots into 96-well microculture plates (Iwaki/Asahi Technoglass, Gyouda, Japan) in densities of 
4 × 103 cells/well (41M) and 2.5 × 103 cells/well (SW480), respectively in order to ensure exponential 
growth of untreated controls throughout the experiment. After a 24 h pre-incubation, dilutions of the test 
compounds in 100 µL/well complete culture medium were added. Because of low aqueous solubility, 
the test compounds were dissolved in DMSO first and then serially diluted in complete culture medium 
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such that the effective DMSO content did not exceed 0.5%. After exposure for 96 h, all media were 
replaced by 100 µL/well RPMI 1640 medium (supplemented with 10% heat-inactivated fetal bovine 
serum and 2 mM L-glutamine) plus 20 µL/well MTT solution in phosphate-buffered saline (5 mg/ml). 
After incubation for 4 h, the medium/MTT mixtures were removed, and the formazan crystals formed by 
vital cells were dissolved in 150 µL DMSO per well. Optical densities at 550 nm were measured with a 
microplate reader (Tecan Spectra Classic), using a reference wavelength of 690 nm to correct for 
unspecific absorption. The quantity of vital cells was expressed in terms of T/C values by comparison to 
untreated control microcultures, and 50% inhibitory concentrations (IC50) were calculated from 
concentration-effect curves by interpolation. Evaluation is based on means from at least three 
independent experiments, each comprising at least three replicates per concentration level. 
 
Immunostaining. Cells were cultured on cover slides and fixed with 4% formaldehyde. After 
fixation, cells were permeabilized with 0.3% Triton X-100 solution and then treated for 1 h with 5% 
serum diluted in PBS to block non-specific binding. The primary antibody against fibrillarin (1:400, 
monoclonal Rabbit, New England Biolabs GmbH, Frankfurt am Main, Germany) bound overnight at 4 
°C. After washing with PBS, cells were incubated with the secondary fluorochrome conjugated antibody 
(1:500, Alexa Fluor 594 goat anti-rat IgG, Invitrogen, Karlsruhe, Germany) for 1 h at room temperature. 
Cells were washed, and the secondary antibody was localized by fluorescence microscopy (Olympus 
CKX41, Tokyo, Japan). 
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